Patent Abridgement 1 [3.1 MB PDF] - Intellectual Property Office of ...

INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND 

Complete Specifications Accepted 

Copies of the specification and drawings (if any) can be obtained 

from the IPONZ website www.iponz.govt.nz. 

At any time within 3 months from the date of issue of this Journal, any 

person interested may give notice of opposition to the grant of a patent on 

any of the applications relating to the accepted complete specification 

shown hereunder, by filing form 15 in duplicate accompanied by a statement 

of the case in duplicate and a fee of $300 plus GST where applicable, 

provided that if an application for extension on form 16 is made within 

the said 3 months, the Commissioner may extend the prescribed period 

for opposition to 4 months from the date of issue of this Journal. The 

grounds for giving notice of opposition are specified in section 21 of the 

Act, and prospective opponents should also refer to regulations 48 to 56 

of the Patents Regulations 1954. 

(21) 546609 (22) 23 Nov 2004 

(54) Resettable safety shield for medical needles 

(86) PCT/US2004/039400 (87) WO2005/053774 

(51) IPC2011.01:A61M5/00,32 

(71) Specialized Health Products, Inc. 

(72) Snow, Jeremy K; Ferguson, F Mark; Smith, Daniel K; Barrus, Roy L; 

Solomon, Donald D; Thorne, David L; Vanderstek, Bradley J; 

(31) 03 721526 (32) 25 Nov 2003 (33) US 

(31) 03 739868 (32) 18 Dec 2003 (33) US 

(31) 04 608565 (32) 10 Sep 2004 (33) US 

(31) 04 622392 (32) 27 Oct 2004 (33) US 

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, 

Wellington 6011, New Zealand 

(57) A medical needle shield apparatus is disclosed. The needle shield 

comprises: a needle hub (104) with a needle cannula (103) extending 

from there to a distal end; a retainer for releasable engagement with the 

needle hub (104), and at least one shield (101) which is extensible from 

a retracted position to an extended position to enclose a distal end of the 

needle. The shield (101) includes a binding member (105), which is disposed 

within the shield (101) and defines binding surfaces that form an 

aperture configured for slidable receipt of the needle between the retracted 

position and the extended position. The binding member (105) 

includes at least one drag inducing member so that the at least one drag 

inducing member engages the needle during slidable receipt of the needle 

to create a drag force with the needle. The drag force and shield 

facilitate rotation of the binding member (105) relative to a longitudinal 

axis of the needle so that the binding surfaces engage the needle to 

prevent slidable movement of the needle in the extended position of the 

shield. The binding member (105) further includes a needle communicating 

surface which extends from there so that the needle communicating 

surface can engage with the needle to prevent rotation of the binding 

member (105). The binding member (105) further includes a binding 

member reset surface (107) selectably alignable with a reset surface 

(108). 

(21) 546771 (22) 22 Oct 2004 

(54) A collet-type splice and dead end fitting for a composite core cable 

(86) PCT/US2004/035199 (87) WO2005/041358 

(51) IPC2011.01:H01R4/50,62,58 

(71) CTC CABLE CORPORATION 

(72) Bryant, David; 

(31) 03 690839 (32) 22 Oct 2003 (33) US 

(31) 04 911072 (32) 4 Aug 2004 (33) US 



(57) A fitting for a cable having a composite core 101 comprising a collet 

304 comprised of one or more sections that form a truncated conical 

shape, the shape of the collet 304 comprising an outer diameter that 

increases from a first end to a second end creating an outside slope to 

slide within a collet housing 204, the collet further comprising a concentrically 

oriented lumen 214, the lumen 214 having a generally constant 

cross section along the length of the lumen 214 to fit a cross section and 

length of composite core 101, and a collet housing 204 having a first 

open end 226 to allow the collet 304 to fit into the collet housing 204 and 

a second open end 224 having a smaller internal diameter than the first 

open end, the housing 204 having a funnel-shaped interior that mirrors 

the outside slope of the collet 304 to enable the collet 304 to slide into the 

collet housing 204 through the first opening 226 without allowing the collet 

304 to be forcibly pulled 302 through the second open end of the 

collet housing 204. 

(21) 547673 (22) 23 Dec 2004 

(54) Use of substituted 2-aminotetralines for the preventative treatment of 

parkinson’s disease 

(86) PCT/EP2004/014656 (87) WO2005/063238 

(51) IPC2011.01:A61K31/381,40,4164,404 

(71) UCB Pharma GmbH 

(72) Scheller, Dieter; Dressen, Frank; 

(31) 03 0361258 (32) 24 Dec 2003 (33) DE 

(74) DAVIES COLLISON CAVE - SYDNEY, 255 Elizabeth Street, Sydney, 

New South Wales 2000, Australia 

(57) Disclosed is the use of a tetralin tertiary amine compound of the general 

formula wherein, n = 1 to 5, R6 and R7 are independently alkyl or 

aryl, R5 is a alkyl and the further substituents are defined in the specification, 

wherein the compound of formula I is present as a racemate or as 

a pure (R)- or (S)-enantiomer as well as physiologically acceptable salts 

of these compounds, in the manufacture of a medicament or kit for the 

preventative treatment of Parkinson's disease. 

PATENT OFFICE JOURNAL 1580 25 February 2011 Page 53 |BACK TO CONTENT


(21) 547754 (22) 3 Dec 2004 

(54) Packaging bag with a detachable gusset and a reclosable opening, 

and production machine and method 

(86) PCT/FR2004/003112 (87) WO2005/056405 

(51) IPC2011.01:B65D33/00,24,25; B65B61/18; B65D30/20; B65D85/16 

(71) S2F Flexico 

(72) Doue, Philippe; 

(31) 03 0314276 (32) 4 Dec 2003 (33) FR 

(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street, 

Melbourne, Victoria 3000, Australia 

(57) A packaging bag 10 comprises at least one flap 24 formed at one end 

with the flap 24 folded back along a fold line 22 against a face of the bag 

body and held in this position by a detachable connecting element 32, 

and a recloseable closure element 50 which extends transversally to the 

fold line 22 along at least a substantial length of the bag body and along 

a full height of the flap 24. 

(21) 547841 (22) 23 Dec 2004 

(54) Use of rotigotine for the treatment or prevention of dopaminergic neurone 

loss 

(86) PCT/EP2004/014655 (87) WO2005/063237 

(51) IPC2011.01:A61K31/381 

(71) UCB Pharma GmbH 

(72) Scheller, Dieter; Dressen, Frank; 

(31) 03 0361259 (32) 24 Dec 2003 (33) DE 



(57) Provided is the use of rotigotine, or a salt or prodrug thereof, for the 

manufacture of a medicament for the treatment or prophylaxis of a disease 

involving increased dopaminergic cell destruction, wherein the disease 

is selected from Parkinson's disease, an alphasynucleo-pathy, 

Huntington's disease, a REM sleep disturbance and an olfactory disorder, 

and wherein the treatment or prophylaxis is performed on individuals 

selected from: (a) individuals without symptoms of Parkinson's disease 

but with an increased risk of developing Parkinson's disease, and 

(b) individuals with early symptoms of Parkinson's disease, in whom at 

least three of the four cardinal symptoms of Parkinson's disease (rigidity, 

resting tremors, bradykinesia, postural instability) are not yet present, 

and wherein the prodrug is selected from the group consisting of esters, 

carbamates, acetals, ketals, phosphates, phosphonates, sulphates, 

sulphonates, silyl ethers, carbonates, acyloxyalkyl ethers, thiocarbonyl 

esters, oxythiocarbonyl esters, thiocarbamates and ethers. 

(21) 548257 (22) 28 Jan 2005 

(54) Modified human growth hormone polypeptides and their uses 

(86) PCT/US2005/002724 (87) WO2005/074546 

(51) IPC2011.01:C12P21/06 

(71) Ambrx, Inc. 

(72) Cho, Ho Sung; Daniel, Thomas; Dimarchi, Richard; Hays Putnam, 

Anna-Maria A.; Wilson, Troy; Litzinger, David; Sim, Bee-Cheng; 

(31) 04 581314 (32) 18 Jun 2004 (33) US 

(31) 04 581175 (32) 18 Jun 2004 (33) US 

(31) 04 541528 (32) 2 Feb 2004 (33) US 

(31) 04 580885 (32) 18 Jun 2004 (33) US 

(31) 04 638616 (32) 22 Dec 2004 (33) US 

(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South 

Wales 2000, Australia 

(57) Disclosed is a human growth hormone (hGH) polypeptide comprising 

a non-naturally encoded amino acid (NEAA) comprising a carbonyl functional 

group, wherein said NEAA is positioned at a following position of 

hGH comprising the amino acid sequence set forth in SEQ ID NO:2: (i) 

at the N-terminus; (ii) within residues 10-31; (iii) within residues 35-74; 

(iv) within residues 86-95; (v) within residues 97-102; (vi) within residues 

111-119; (vii) within residues 134-146; (viii) within residues 155-176; and 

(ix) at the C-terminus. 

Divisional filed as 590677 

(21) 548798 (22) 10 Feb 2005 

(54) Swinging agitator for a gypsum calcining apparatus and the like 

(86) PCT/US2005/004796 (87) WO2005/092583 

(51) IPC2011.01:B28C5/12; B01F11/00; B01F15/06; B01J6/00; C01F11/ 

46; C04B11/028; F26B3/084,092 

(71) UNITED STATES GYPSUM COMPANY 

(72) Bolind, Michael L; Porter, Michael J; 

(31) 04 10788864 (32) 27 Feb 2004 (33) US 

(31) 04 10788871 (32) 27 Feb 2004 (33) US 



(57) An agitation mechanism 60 for a gypsum processing apparatus 10 

which includes a housing 12 having a bottom wall 14, at least one side 

wall 18, and a support base 23 above and adjacent the bottom wall 14, a 

fluidization mechanism for introducing fluid to the gypsum based product, 

the fluidization mechanism defining at least a portion of the support 

base 23 of the housing 12, a burner conduit 28 extending through the 

housing 12 from at least one burner 22 and terminating through the support 

base 23 such that combustion gases from the burner 22 travel through 

the burner conduit 28 in the housing 12 and through the support base 23 

including the fluidization pad 54 back through the housing 12 and the 

gypsum based product, and an agitator frame 64 having a similarly shaped 

cross section to a cross section of the housing 12, the agitator frame 64 

pivotally connected internally to the housing 12 for reciprocating movement 

between first and second positions. The housing 12 is designed 

and constructed to receive and process powdered gypsum. The agitation 

mechanism 62 prevents the gypsum products from collecting adjacent 

to the bottom wall 14 of the housing 12. 

(21) 548823 (22) 16 Mar 2005 

(54) Galenic formulations of organic compounds (oral dosage of aliskiren) 

(86) PCT/EP2005/002798 (87) WO2005/089729 

(51) IPC2011.01:A61K31/00; A61K9/20,28 



(71) Novartis AG 

(72) Rigassi-Dietrich, Petra Gisela; Schmid, Martin; 

(31) 04 553878 (32) 17 Mar 2004 (33) US 

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 

342 Lambton Quay, Wellington 6011, New Zealand 

(57) Disclosed is a solid oral dosage form comprising; i) a therapeutically 

effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, 

as active ingredient in an amount of more than 46 percent by weight 

based on the total weight of the oral dosage form, wherein the oral dosage 

form is in the form of a tablet or film-coated tablet and is not obtained 

by wet granulation with excipients using water and/or an aqueous binder 

solution. Also disclosed is the use of said oral dosage form in the treatment 

of hypertension angina and stroke and a process to prepare said 

dosage form. 

(21) 549165 (22) 7 Jun 2004 

(54) Method for seed treatment with abamectin and thiamethoxam 

(86) PCT/EP2004/006109 (87) WO2005/094585 

(51) IPC2011.01:A01N25/00; A01N43/04,90; A01N51/00 

(71) Syngenta Participations AG 

(72) Hofer, Dieter; 

(31) 04 553516 (32) 16 Mar 2004 (33) US 



(57) Disclosed is a method of protecting a plant against insects of the 

order Thysanoptera (thrips), which comprises treating plant propagation 

material thereof, with (A) a nematicidally effective amount of a nematicide 

selected from abamectin, emamectin benzoate and spinosad and 

(B) at least one insecticidally effective amount of an insecticide selected 

from imidacloprid, clothianidin and thiamethoxam. 

(21) 549413 (22) 30 Mar 2005 

(54) Portable combustion driven fastener driving tool 

(86) PCT/IB2005/000823 (87) WO2005/095063 

(51) IPC2011.01:B25C1/00,06,08,18 

(71) JPF Works Co., Ltd. 

(72) Yamakawa, Keiji; Uejima, Yasutsugu; 

(31) 04 105992 (32) 31 Mar 2004 (33) JP 

(74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Melbourne, 

Victoria, Australia 

(57) A portable type fastener driving tool comprises a main body 1 which 

houses a rod 17 which drives in the fasteners n, a rod driving out means 

24 which pushes the rod 17 forward in the axial direction, a head part 3 

which is disposed on the front end of the main body 1 and which is provided 

with a fastener guiding part, a fastener retaining means which loads 

a fastener connecting body N which is made by connecting multiple 

fasteners n using a connecting material so that they are arranged parallel 

to one another, and a power operated fastener feed means which is 

loaded on the fastener retaining means, which feeds the fastener connecting 

bodies in the direction in which the fasteners n are arranged and 

which feeds the fasteners one by one in front of the rod 17. The fastener 

drive means is provided with a rotary type feed member which latches 

onto the fastener connecting bodies and feeds them, where the rod driving 

out means 24 uses combustion gas pressure as a source of motive 

force while the fastener feed means is provided with a feed gear which 

is used as a rotary type feed member, and an electric motor which drives 

this feed gear. 

(21) 550020 (22) 28 Feb 2005 

(54) A tissue retractor for treatment of a breathing disorder comprising a 

shaft, a retractor, and an anchor 

(86) PCT/US2005/006430 (87) WO2005/082452 

(51) IPC2011.01:A61N1/05 

(71) Linguaflex, LLC 

(72) Sanders, Ira; 

(31) 04 547897 (32) 26 Feb 2004 (33) US 



(57) A tissue retractor for treatment of a breathing disorder, is disclosed. 

The tissue retractor comprises: a) a shaft sized for insertion into soft 

tissue located in a patient's oral cavity or pharynx; b) a retractor member 

connected at or near a first end of the shaft; and c) an anchor member 

connected at or near a second end of the shaft. The retractor or anchor 

member is configured to be positioned on an external surface of the soft 

tissue where the shaft, the retractor member or the anchor member is 

adapted to exert a force toward a center of the shaft between the first 

end and the second end of the shaft. 


(21) 550114 (22) 20 Apr 2005 

(54) Substituted thiazole and pyrimidine derivatives as melanocortin 

receptor modulators 

(86) PCT/US2005/013386 (87) WO2005/103022 

(51) IPC2011.01:C07D239/42; C07D277/42,46,52; C07D403/12; 

C07D409/12; C07D417/12,14; A61K31/426,427,506,505,428; A61P3/04 

(71) TRANSTECH PHARMA, INC. 

(72) Mjalli, Adnan M M; Gaddam, Bapu R; Qabaja, Ghassan; Subramanian, 

Govindan; Zhu, Jeff; Dankwardt, John; Arimilli, Murty N; Andrews, Robert 

C; Victory, Samuel; Tian, Ye E; 

(31) 04 563882 (32) 20 Apr 2004 (33) US 



(57) Disclosed is a thiazole compound of formula (Ib), or a pharmaceutically 

acceptable salt or solvate thereof, wherein A is an amide or amine and 

where the rest of the substituents are disclosed within the specification. 

Also disclosed are pharmaceutical compositions comprising the said compound 

as well as further agents such as hypoglycaemic agents, agents 

that modulate thermogenesis, lipolysis, gut lotility, fat absorption, satiey 

and other such second agents. 



(21) 550124 (22) 28 Mar 2005 

(54) In-can fuel cell metering valve with a reduced number of seals 

(86) PCT/IB2005/051045 (87) WO2005/099968 

(51) IPC2011.01:B25C1/08; B65D83/14; F17C13/04 

(71) Illinois Tool Works Inc. 

(72) Vanstaan, Valery H; Wagdy, Mohamed K; Geier, Adalberto; Dalsant, 

Giuseppe; 

(31) 04 827551 (32) 19 Apr 2004 (33) US 



(57) A fuel cell (10) for use with a combustion tool for delivery of a predetermined 

amount of fuel with each stem actuation is disclosed. The fuel 

cell (10) has a housing defining an open end enclosed by a closure (16). 

A main valve stem (26) has an outlet (28) which moves relative to the 

housing between a closed position wherein the stem (26) is extended, 

and an open position wherein the stem (26) is retracted. A fuel metering 

valve (25) is located within the housing and includes a fuel metering 

chamber (38) in close proximity to the closure (16). The fuel metering 

chamber (38) is configured so that when the stem (26) is in the open 

position, only a measured amount of fuel is dispensed through the outlet 

(28). In a preferred embodiment, the fuel cell housing includes a separate 

fuel container (22), and the fuel metering valve (25) includes a valve 

body (34) with a second end (64) opposite the fuel metering chamber 

(38) located within the container. 

(21) 550348 (22) 8 Apr 2005 

(54) Nasal assembly with vent and baffle 

(86) PCT/AU2005/000515 (87) WO2005/097247 

(51) IPC2011.01:A61M16/06; A61M15/08; A62B7/00; A61M16/08 

(71) ResMed Ltd 

(72) Gunaratnam, Michael Kassipillai; Kwok, Philip Rodney; Hitchcock, 

Robin Garth; Veliss, Lee James; Guney, Memduh; Sokolov, Richard; 

Lithgow, Perry David; Darkin, Donald; Lynch, Susan Robyn; 

Dantanarayana, Muditha; Moore, Rachel; 

(31) 04 560610 (32) 9 Apr 2004(33) US 

(31) 04 632193 (32) 2 Dec 2004 (33) US 

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, 

Hamilton, New Zealand 

(57) A nasal assembly 50 for delivering breathable gas to a patient, comprises 

a frame having a main body, a patient interface provided to the 

main body of the frame and defining a plenum chamber, the patient interface 

adapted to sealingly engage with a patient, at least one vent 52 to 

provide a vent exit for the passage of exhaled gas, and a baffle (not 

shown) provided to the frame, the baffle including at least one arm adapted 

to extend into the plenum chamber of the patient interface and at least 

partially separate the vent exit from an air inlet. 


(21) 550571 (22) 18 Apr 2005 

(54) 3-THIOCARBAMOYLPYRAZOLE DERIVATIVES AS PESTICIDES 

(86) PCT/US2005/013097 (87) WO2005/099453 

(51) IPC2011.01:A01N43/56; A61K31/415,416; C07D231/18,38,44; 

C07D403/04; C07D231/14 

(71) Merial Ltd 

(72) Soll, Mark D; Boeckh, Albert; Kumar, Krishan; Shub, Natalya; 

(31) 04 826105 (32) 16 Apr 2004 (33) US 

(74) F B RICE & CO, Level 23, 200 Queen Street, Melbourne, Victoria 

3000, Australia 

(57) A process for the control or elimination of external parasites from an 

animal is disclosed, which comprises: topically applying in a localized 

region on the back of the animal at a dose of between about 1 to 50 mg/ 

kg a spot-on formulation comprising a compound of the formula (II), and 

subjecting the applied formulation to degradation by exposing it to a sufficient 

amount of U.V. light or fluorescent light to convert the compound 

of formula (II) to the corresponding 3-cyano derivative in an amount sufficient 

to control external parasites while diffusing therefrom over the 

animal’s body and/or in the sebaceous glands of the animal and thereby 

obtaining said control or elimination of said external parasites, 

wherein R1 represents H2N"CS"; and the other variables shown in the 

structural formula (II) are as defined in the specification. A process for 

preparing the corresponding 3-cyano derivative of the compound of formula 

(II) is also disclosed, which comprises degrading a compound of 

the formula (II) in the presence of U.V. light, fluorescent light or heat. 

(21) 550894 (22) 6 May 2005 

(54) Solid dosage form of wetted heparin 

(86) PCT/US2005/016012 (87) WO2005/107773 

(51) IPC2011.01:A61K31/727; C07C229/36; C07C233/83; C08L5/10; 

A61K31/166 

(71) Emisphere Technologies, Inc. 

(72) Majuru, Shingai; Singh, Brahma; Dhoot, Nikhil; 

(31) 04 569475 (32) 6 May 2004 (33) US 

(31) 04 572679 (32) 19 May 2004 (33) US 

(31) 04 598978 (32) 4 Aug 2004 (33) US 





(57) Disclosed is a solid pharmaceutical composition comprising: (a) a 

delivery agent of formula (I) wherein; R1, R2, R3 and R4 are independently 

hydrogen, hydroxy, -NR6R7, halogen, alkyl, or alkoxy; R5 is a substituted 

or unsubstituted alkylene, a substituted or unsubstituted 

alkenylene, a substituted or unsubstituted alkyl(arylene), or a substituted 

or unsubstituted aryl(alkylene); and R6 and R7 are independently hydrogen, 

oxygen, or alkyl; and (b) wetted heparin. Also disclosed is the use 

of an anti-thrombosis effective amount of the solid pharmaceutical composition 

as defined above for the manufacture of a medicament for treating 

or preventing thrombosis in an animal. Of particular importance are 

the compositions where the delivery agent is monosodium N-[8-(2hydroxybenzoyl)amino]caprylate 

(SNAC). 

(21) 550909 (22) 10 May 2005 

(54) Glycopyrrolate for treating childhood asthma 

(86) PCT/GB2005/001791 (87) WO2005/107873 

(51) IPC2011.01:A61K31/00,352,40,439,465; A61P11/06; A61K9/14 

(71) SOSEI R&D LTD. 

(72) Snape, Susan; Bannister, Robin Mark; 

(31) 04 0410399 (32) 10 May 2004 (33) GB 



(57) Disclosed is the use of glycopyrrolate for the manufacture of a medicament 

which is a dry powder composition for pulmonary delivery, comprising 

microparticles of glycopyrrolate, for the treatment of asthma in a 

child aged 2 to 12 years, with the proviso that said treatment excludes 

the treatment of bronchospasms. 

(21) 550942 (22) 4 May 2005 

(54) Directly compressible tricalcium phosphate 

(86) PCT/US2005/015385 (87) WO2005/107722 

(51) IPC2011.01:A61K33/42,06; A61K9/14,16,20,30,32,34 

(71) Innophos, Inc. 

(72) Hendricks, Lewis Roe; Jobbins, Jill Marie; Camarco, Wayne; 

(31) 04 567926 (32) 4 May 2004 (33) US 



(57) Disclosed is a compressible tricalcium phosphate agglomerate, comprising, 

based on 100 parts by weight (pbw) of the agglomerate, from 

about 90 to about 99 pbw tricalcium phosphate particles, each having an 

outer surface, and from about 1 to about 10 pbw of a binder comprising 

a polyvinylpyrrolidone (PVP), carageenan, a guar gum, a modified guar 

gum, or a mixture of a guar gum and a modified guar gum supported on 

at least a portion of the outer surface of at least a portion of the tricalcium 

phosphate particles and made by spray drying an aqueous slurry comprising 

the tricalcium phosphate particles and the binder. Also disclosed 

is a process for making an oral dosage form of the agglomerate and the 

instance where the oral dosage form is a chewable calcium dietary supplement. 

(21) 550985 (22) 20 May 2005 

(54) Cyclic amide derivatives, and their production and use as 

antithrombotic agents 

(86) PCT/JP2005/009711 (87) WO2005/113504 

(51) IPC2011.01:A61K31/45,506,5377; A61P7/02; C07D211/76; C07D401/ 

04; C07D403/04; C07D413/04; C07D417/04 

(71) Takeda Pharmaceutical Company Limited 

(72) Kubo, Keiji; Imaeda, Yasuhiro; 

(31) 04 152000 (32) 21 May 2004 (33) JP 



(57) Disclosed is a cyclic amide derivative which inhibits activated blood 

coagulation factor X (FXa) to exhibit anticoagulant activity and 

antithrombotic activity. The compound is useful as a drug for treating 

thrombosis, and is represented by the formula (I): wherein R1 represents 

a naphthyl which may be substituted with a halogen atom, W represents 

a bond, a represents 0, 1, or 2, X1 represents a C1-6 alkylene 

which may be substituted with a hydroxy group, Y1 represents –C(O)-, A 

represents a piperazine ring or a piperidine ring, and the remaining 

substituents are as defined in the specification. 

(21) 551420 (22) 10 May 2005 

(54) Method of screening candidate compounds for susceptibility to biliary 

excretion in hepatocyte cell cultures 

(86) PCT/US2005/016240 (87) WO2005/118787 

(51) IPC2011.01:C12N5/08; C12Q1/00 

(71) The University of North Carolina at Chapel Hill 

(72) Brouwer, Kim L; Tian, Xianbin; Zhang, Peijin; 

(31) 04842404 (32) 10 May 2004 (33) US 



(57) A method of screening a candidate compound for susceptibility to 

biliary excretion by a hepatocyte transport protein, the method comprising: 

(a) providing a cell culture comprising a plurality of hepatocytes and at 

least one bile canaliculus, at least one of the hepatocytes comprising a 

transport protein; 

(b) exposing a candidate compound to the culture; and 

(c) determining an amount of the candidate compound in the at least one 

bile canaliculus to thereby screen the candidate compound for susceptibility 

to biliary excretion by the hepatocyte transport protein, comprising 

inhibiting expression of the hepatocyte transport protein and detecting 

an amount of the candidate compound present in the at least one bile 

canaliculus, wherein the presence of a reduced amount of the candidate 

compound in the at least one bile canaliculus as compared to an amount 

of the candidate compound in the at least one bile canaliculus when 

expression of the hepatocyte transport protein is not inhibited indicates 

the susceptibility of the candidate compound to biliary excretion by the 

hepatocyte transport protein. 


(21) 551448 (22) 20 May 2005 

(54) Analysis of liquid chromotography eluates 

(86) PCT/IB2005/001772 (87) WO05/114171 

(51) IPC2011.01:G01N30/64,74,78 

(71) Novartis Vaccines and Diagnostics S.r.l. 

(72) Proietti, Daniela; Bardotti, Angela; Ricci, Stefano; 

(31) 04 0411283 (32) 20 May 2004 (33) GB 

(31) 04 0420649 (32) 16 Sep 2004 (33) GB 



(57) Disclosed is a method for detecting the presence of one or more 

saccharide analytes in a sample, said method comprising applying the 

sample to an anion exchange chromatography column under conditions 

wherein one or more saccharide analytes bind to the column, applying 

an elution buffer comprising an anion selected from a nitrate, a carbonate 

and a borate to thereby elute one or more saccharide analytes from 

the column, and analysing the eluate by both amperometry and 

spectroscopy. Also disclosed is apparatus when used to analyse a sample 

comprising one or more saccharide analytes, wherein the apparatus 

comprises (i) an anion exchange chromatography column, (ii) an elution 



buffer comprising an anion selected from a nitrate, a carbonate and a 

borate, (iii) an amperometric detector and (iv) a spectroscopic detector, 

wherein the two detectors are arranged to receive an eluate comprising 

one or more saccharide analytes in the elution buffer from the column. 

(21) 551715 (22) 15 Jun 2005 

(54) Single piece, gussetted cushion for a respiratory mask assembly 

(86) PCT/AU2005/000850 (87) WO2005/123166 

(51) IPC2011.01:A61M16/06 

(71) ResMed Limited 

(72) FRATER, Robert Henry; DREW, Joanne Elizabeth; KWOK, Philip 

Rodney; MCAULIFFE, Patrick John; DAVIDSON, Aaron Samuel; 

HITCHCOCK, Robin Garth; GUNARATNAM, Michael Kassipillai; 

(31) 04 579678 (32) 16 Jun 2004 (33) US 

(31) 04 634272 (32) 9 Dec 2004 (33) US 

(31) 05 648687 (32) 2 Feb 2005 (33) US 



(57) A mask assembly 10 comprises a frame 12, an elastomeric, onepiece 

cushion provided to the frame 12 with the cushion including a breathing 

chamber forming portion and a face contacting portion with the breathing 

chamber forming portion defining a mask interior breathing chamber 

and the face contacting portion structured to engage a patient's face, 

and a tubular connector 22 supported by the frame 12 and adapted to 

connect to an air delivery conduit. Flexibility is provided to the face contacting 

portion of the cushion by a gusseted portion including one or 

more folds. 


(21) 552230 (22) 30 Jun 2005 

(54) Systems and methods for controlling spooling of linear material including 

a motor and controller 

(86) PCT/US2005/023652 (87) WO06/007582 

(51) IPC2011.01:B65H75/34 

(71) GREAT STUFF, INC. 

(72) Lee, Michael J; Tracey, James B A; Koebler, Martin; Caamano, Ramon 

Anthony; 

(31) 04 584797 (32) 1 Jul 2004 (33) US 

(31) 04 585042 (32) 2 Jul 2004 (33) US 



(57) An automatic reel for facilitating the spooling of linear material is disclosed. 

The automatic reel includes a rotatable member, a motor, and a 

motor controller. The rotatable member has a spool surface and is capable 

of winding a linear material around the spool surface as the rotatable 

member rotates in a first direction. The rotatable member is also capable 

of deploying the linear material from around the spool surface as the 

rotatable member rotates in a second direction. The motor is capable of 

interacting with the rotatable member to selectively rotate the rotatable 

member in the first direction or in the second direction. The motor controller 

is capable of sensing a parameter associated with the motor and 

indicative of a tension of the linear material. The motor controller is capable 

of outputting a control signal to cause the motor to rotate the rotatable 

member in the second direction to deploy the linear material when 

the sensed parameter indicates that the tension of the linear material 

exceeds a certain amount. 

(21) 552452 (22) 6 Jul 2005 

(54) A method for preparing an echinacea formulation from a combination 

of Echinacea angustifolia and Echinacea purpurea 

(86) PCT/AU2005/000993 (87) WO2006/002493 

(51) IPC2011.01:A61P37/04; A61K36/00 

(71) MediHerb Holdings Ltd 

(72) Lehmann, Reg; Bone, Kerry; Penman, Kerry; Matthias, Anita; 

(31) 04 903716 (32) 7 Jul 2004 (33) AU 



(57) Disclosed is a method for preparing an Echinacea formulation which 

includes a combination of Echinacea angustifolia and Echinacea 

purpurea, the method including the step of adding sufficient Echinacea 

angustifolia to the Echinacea purpurea such that the weight ratio of 2ene 

alkylamide to 2,4-diene alkylamide in the formulation is between about 

1:15 to about 2:1. 


(21) 552600 (22) 13 Jul 2005 

(54) A gas burner with two gas flow passages 

(86) PCT/NZ2005/000172 (87) WO2006/006882 

(51) IPC2011.01:F23D14/02 

(71) FISHER & PAYKEL APPLIANCES LIMITED 

(72) Graham, Lindsay George; Brown, Simon Denzil; 

(31) 04 534091 (32) 13 Jul 2004 (33) NZ 

(31) 04 621001 (32) 21 Oct 2004 (33) US 



(57) A gas burner comprises a first gases flow passage 52 with an inlet 

and an outlet, a source of oxidising gases at the inlet of the first passage 

52, a second gases flow passage with an inlet and an outlet, a source of 

oxidising gases at the inlet of the second passage, the outlet of the first 

passage 52 proximate to the outlet second passage, a fuel gas jet 46 

configured to supply fuel to the second passage, a flame locating means 

49 within the second passage 52 sheltered from the oxidising gases in 

the first passage 52, and a burner cap 3 spaced downstream from the 

outlet of the second flow passage. The burner cap 3 extends transversely 



to the outlet of the second flow passage. Oxidising gas is typically supplied 

by fan 41 and flows over baffle 54 to the first passage 52 via circumferentially 

spaced slots in the burner housing. 

(21) 552803 (22) 8 Jul 2005 

(54) (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane 

benzenesulfonate 

(86) PCT/US2005/024464 (87) WO2006/019668 

(51) IPC2011.01:C07D487/04 

(71) ABBOTT LABORATORIES 

(72) Wayne, Greg S; Mellican, Sean M; Zhang, Geoff G; Willcox, David R; 

Breting, Jeffrey M; 

(31) 04 590677 (32) 23 Jul 2004 (33) US 



(57) Disclosed is a crystalline (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6diazabicyclo[3.2.0]heptane 

benzenesulfonate demonstrating at least one 

characteristic peak in the powder X-ray diffraction pattern at values of 

two theta of 8.8 +/- 0.2, 11.8, 13.7, 15.1, 17.2, 18.5, 18.9, 20.6, 24.4, 

24.7, and 27.4 +/-0.2, 

Also disclosed is amorphous (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6 

diazabicyclo [3.2.0]heptane benzenesulfonate. 

(21) 552898 (22) 28 Jul 2005 

(54) Method of producing a composition, composition and its use 

(86) PCT/NO2005/000281 (87) WO2006/011809 

(51) IPC2011.01:A61B5/055; A61K49/06,10; C07B61/02; C07D519/00 

(71) GE HEALTHCARE AS 

(72) Thaning, Mikkel; 

(31) 04 043229 (32) 30 Jul 2004 (33) NO 



(57) The disclosure relates to a method for producing a liquid composition 

comprising hyperpolarised 13C-pyruvate said method comprising: 

(a) forming a liquid mixture comprising a radical of formula (I), 13C-pyruvic 

acid and/or 13C-pyruvate and freezing the mixture; 

(b) enhancing the 13C nuclear polarisation of pyruvic acid and/or pyruvate 

in the mixture via DNP; 

(c) adding a buffer and a base to the frozen mixture to dissolve it and to 

convert the 13C-pyruvic acid into a 13C-pyruvate to obtain a liquid composition 

or, when only 13C-pyruvate is used in step (a), adding a buffer 

to the frozen mixture to dissolve it to obtain a liquid composition; and 

(d) optionally removing the radical and/or reaction products thereof from 

the liquid composition. The comprising hyperpolarised 13C-pyruvate 

composition produced by this method is suitable for use as an imaging 

agent for in vivo MR imaging of a human or non-human animal body. 

(21) 552941 (22) 25 Jul 2005 

(54) Modification of the lignin biosynthesis gene hydroxycinnamoyl transferase 

(HCT) 

(86) PCT/US2005/026253 (87) WO2006/012594 

(51) IPC2011.01:A01H5/00,10; C12N15/82 

(71) The Samuel Roberts Noble Foundation, Inc. 

(72) Dixon, Richard A; Reddy, M S Srinivasa; Chen, Fang; 

(31) 04 590991 (32) 24 Jul 2004 (33) US 

(74) Pizzeys Patent and Trade Mark Attorneys, Level 14, ANZ Centre, 324 

Queen Street, Brisbane, Queensland 4000, Australia 

(57) Disclosed is a transgenic plant comprising a selected DNA, wherein 

the selected DNA down regulates the lignin biosynthesis gene 

hydroxycinnamoyl transferase (HCT), said selected DNA comprising at 

least 18 contiguous nucleotides of the HCT gene or its complement, and 

wherein said plant is a legume. 


(21) 552953 (22) 8 Aug 2005 

(54) Medical skin applicator apparatus with an internal fluid container, a 

penetrating member and actuated by an externally protruding member 

(86) PCT/US2005/028162 (87) WO2007/018541 

(51) IPC2011.01:A61M5/00 

(71) TYCO HEALTHCARE GROUP, LP 

(72) CABLE, Frank; TAUER, Mark; FETTERROLL, Andrew; 

(31) 60 599927 (32) 9 Aug 2004 (33) US 

(31) 60 614503 (32) 30 Sep 2004 (33) US 

(31) 60 639182 (32) 22 Dec 2004 (33) US 



(57) A medical skin applicator apparatus comprises an outer housing 534 

defining a longitudinal axis, a fluid housing 506 having a fluid chamber 

for storing a medical agent, a manually engagable member 530 connected 

to the fluid housing 506 and extending beyond the outer housing 

534, and an applicator 504 coupled to the housing 534. The manually 

engagable member can be depressed to cause longitudinal movement 

of the fluid housing 506 to the actuated position. The fluid housing 506 

has a cap 508 with a penetrable wall to permit access to the fluid chamber 

and release of the medical agent. The applicator 504 includes an 

applicator frame and an applicator surface for applying the medical agent 

to a patient. The applicator frame has an internal penetrating member 

558 adapted to penetrate the penetrable wall of the fluid housing cap 

upon achieving a predetermined coupled relation of the fluid housing 

506 and the applicator 504, to thereby permit the medical agent to be 

dispensed from the fluid chamber and applied to the patient with the 

applicator surface. 



(21) 553028 (22) 27 Jul 2005 

(54) Isoindoline compounds and methods of making and using the same 

(86) PCT/US2005/026680 (87) WO2006/025991 

(51) IPC2011.01:A61K31/4035; A61P11/00; A61P29/00; A61P35/00; 

C07D209/46,48 

(71) CELGENE CORPORATION 

(72) Muller, George W; Man, Hon-Wah; 

(31) 04 900270 (32) 28 Jul 2004 (33) US 

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand 

(57) Disclosed is a N-benzyl isoindoline derivative, or pharmaceutically 

acceptable salt, solvate, stereoisomer or prodrug thereof, as defined in 

the specification in particular, 3-(1,3-dioxobenzo[e]isoindolin-2-yl)-3-(-3ethoxy-4-methoxyphenyl)propanenitrile, 

(1S)-Furan-2-carboxylic acid {2- 

[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3dihydro-1H-isoindol-4-yl}-amide, 

(1S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)- 

2- methanesulfonyl-ethyl]-l ,3-dioxo-2,3-dihydro-lHisoindol-4-yl}-2methoxy-acetamide,(1S)-7-(cyclopropylmethyl-amino)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonyl-ethyl]-2,3-dihydro-isoindol-l-one,(1S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2methanesulfonyl-ethyl]-7isobutylamino-2,3-dihydro-isoindol-1-one,(3R)-3-[7-(2,2-simethylpropylamino)-1-oxo-1,3-dihydro-isoindol-2-yl]-3-(3-ethoxy- 

4methoxyphenyl)-N,N-dimethyl-propionamide, 3-(3-ethoxy-4-methoxyphenyl)-3-(4-isobutylamino1,3-dioxo-l,3-dihydro-isoindol-2-yl)propionitrile,N-{2-[cyano(3-ethoxy-4-methoxyphenyl)methyl]-1,3dioxoisoindolin-4-yl}acetamide,N-{2-[Cyano(3-ethoxy-4metboxyphenyl)methyl]1,3-dioxoisoindolin-4yl}(benzylamino)carboxamide,N-{2-[cyano(3-cyclopentyloxy-4methoxyphenyl)methyl]-1,3-dioxoisoindolin-4-yl}acetamide, 

amino-N-{2- 

[cyano(3-ethoxy-4-methoxyphenyl)methyl]-1,3-dioxoisoindolin-5yl}amide, 

amino-N-{2-[cyano(3-ethoxy-4methoxyphenyl)-methyl]-1,3dioxoisoindolin-4yl}amide,N-{2-[1-(3-cyclopropylmethoxy-4methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1Hisoindol-4-yl}-acetamide, 

cyclopropanecarboxylic acid {2-[1-(3cyclopropylmethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo- 

2,3-dihydro-1H-isoindol-4-yl}-amide, (3R)-3(7-(3,3-dimethyl-ureido)-1oxo-1,3-dihydro-isoindol-2-yl}-3-(3-ethoxy-4-methoxy-phenyl)-N,Ndimethylpropionamide 

and (1S)-3-{2-[1-(3-ethoxy-4-methoxy-phenyl)-2methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-1,1-dimethylurea 

wherein the pictured compounds are representative examples. Also 

disclosed is the use of the above compound for treating disorders affecting 

by PDE4 inhibition or the production of TNF-alpha e.g. cancer, depression 

and arthritis. 

(21) 553258 (22) 17 Aug 2005 

(54) 5-[3-(4-Benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and analogues 

as inhibitors of macrophage elastase 

(86) PCT/US2005/029259 (87) WO2006/023562 

(51) IPC2011.01:A61K31/4166; C07D405/04; A61P11/06; C07D233/76,78; 

C07D307/64; A61K31/341 

(71) QUEST PHARMACEUTICAL SERVICES (QPS) 

(72) Yang, Fude; 

(31) 04 602736 (32) 19 Aug 2004 (33) US 



(57) Disclosed are hydantoin derivatives of formula (IV) (such as 5-[3-(4benzyloxyphenylthio)furan-2-yl]imidazoline-2,4-dione) 

and their 

pharmaceutically acceptable salts, wherein R is selected from the group 

consisting of phenyl, 4-benzyloxyphenyl, 4-biphenyl, 4-methoxyphenyl, 

3-methoxyphenyl, 2-methoxyphenyl, 3,5-dimethoxyphenyl, 4chlorophenyl, 

3-chlorophenyl, 2-chlorophenyl, 4-methylphenyl, 3methylphenyl, 

2-methylphenyl, and 3-trifluoromethylphenyl. Also disclosed 

is the use of a compound as defined above in the manufacture of a 

medicament to treat a disease or disorder responsive to inhibition of 

MMP-12 in a patient in need thereof (and particularly conditions such as 

asthma, chronic obstructive pulmonary disease (COPD), arthritis, cancer, 

heart disease or nephritis). 

(21) 553320 (22) 26 Aug 2005 

(54) Ceramide derivatives as modulators of immunity and autoimmunity 

(86) PCT/US2005/030330 (87) WO2006/026389 

(51) IPC2011.01:A61K31/7028,715; C12N5/08 

(71) Albert Einstein College of Medicine 

(72) Porcelli, Steven A; 

(31) 04 605362 (32) 27 Aug 2004 (33) US 



(57) Disclosed are alpha-galactosylceramides and glycosylceramides 

("ceramide-like glycolipids") that modulate NK T cells. The ceramide-like 

glycolipids vary in the cytokines induced in NK T cells and vary in the 

antigen-presenting cells that are capable of efficiently presenting the 

compounds to NK T cells. Pharmaceutical compositions of the ceramidelike 

glycolipids are provided, as are pharmaceutical compositions of the 

ceramide-like glycolipids combined with dendritic cells. Methods utilizing 

the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate 

the immune system, and to treat mammals are also provided. The 

disclosure also provides methods of evaluating a compound for its ability 

to activate an NK T cell in the presence of a cell expressing a CD 1 d 

protein. 



(21) 553384 (22) 14 Sep 2005 

(54) Peptide-based diagnostic compounds useful for diagnostic imaging 

using positron emission tomography (PET) and preparations thereof 

(86) PCT/IB2005/002727 (87) WO2006/030291 

(51) IPC2011.01:A61K51/08 

(71) GE HEALTHCARE AS; GE HEALTHCARE LIMITED 

(72) Solbakken, Magne; Arbo, Bente; Cuthbertson, Alan; Gibson, Alexander; 

(31) 04 20344 (32) 14 Sep 2004 (33) GB 



(57) Disclosed herein is a method for radiofluorination comprising reaction 

of a compound of formula (I) with a compound of formula (II) to give 

a compound of formula (III), wherein the substituents are as defined 

within the specification. The peptide-based compounds are useful for 

diagnostic imaging using positron emission tomography (PET). More 

specifically said compounds are useful for targeting vectors that bind to 

receptors associated with angiogenesis, in particular integrin receptors 

(the ávâ3 integrin receptor). 

(21) 553774 (22) 17 Aug 2005 

(54) A teatcup, and a teatcup part 

(86) PCT/SE2005/001219 (87) WO06/031164 

(51) IPC2011.01:A01J5/08 

(71) DELAVAL HOLDING AB 

(72) Mehinovic, Raza; Petterson, Torbjorn; 

(31) 04 0402203 (32) 14 Sep 2004 (33) SE 


(57) A teatcup adapted to be attached to a teat of an animal to be milked is 

disclosed. The teatcup includes a teatcup part (1) and a connection part 

(2). The teatcup part is disengageably mountable to the connection part. 

The teatcup part includes a shell (3) and a teatcup liner (4) having an 

upper opening and a lower opening. The teatcup liner forms an inner 

space (12) for receiving the teat through the upper opening and being 

provided in the shell in such a way that a pulsation chamber (12) is formed 

between the teatcup liner and the shell. The connection part including a 

milk-discharging member (32) for the discharge of milk from the teatcup, 

and a milk channel arranged to extend between the lower opening of the 

inner space of the teatcup liner and the milk-discharging member when 

the teatcup part is mounted to the connection part. The connection part 

includes a pulse supplying member for the supply of a pulsating pres- 

sure to the pulsation chamber, and a pulse channel arranged to extend 

between the pulsation chamber and the pulse-supplying member when 

the teatcup part is mounted to the connection part. The pulsation chamber 

is accessible via an aperture through the shell, and the pulse channel 

connects to the aperture when the teatcup part is mounted to the 

connection part. A sealing element is provided at the connection between 

the aperture and the pulse channel. 

(21) 553810 (22) 6 Sep 2005 

(54) A nozzle which pivots between two positions for dosing of a material 

from a container 

(86) PCT/DK2005/000567 (87) WO2006/026990 

(51) IPC2011.01:B05C17/005; B65D25/46 

(71) CLAUS LEONHARDT JENSEN; FINN HOLME HJORT 

(72) Hjort, Finn Holme; 

(31) 04 01342 (32) 6 Sep 2004 (33) DK 



(57) A nozzle (1) for use in connection with the dosing of a material from a 

container is disclosed. The nozzle includes a first nozzle base part (2), a 

nozzle tip part (3), and a link (4) connecting the nozzle parts. The link has 

a first pivotal state and a second locked state when the link is under 

pressure by the material flow. The link includes a first surface and a 

second surface. The surfaces are pivotally connected to each other and 

the surfaces are angled in relation to the longitudinal centre axis of the 

nozzle. In a first position of the first nozzle base part and nozzle tip part, 

the first nozzle base part and nozzle tip part form a conical internal flow 

channel, where no part of the link protrudes into the conical internal flow 

channel. 



(21) 554057 (22) 23 Sep 2005 

(54) Compression garment with seam corresponding to muscle ridge 

(86) PCT/AU2005/001450 (87) WO2006/032096 

(51) IPC2011.01:A41D1/08; A41D13/00,05; A41D27/00,24 

(71) Skins Capital Pty Limited 

(72) Duffy, Bradley Thomas; Duffy, Susan Kathleen; 

(31) 04 905456 (32) 23 Sep 2004 (33) AU 



(57) A compression garment (50) for clothing a body part, such as a lower 

torso and the legs. The body part includes a muscle ridge, such as a 

lateral edge of the gluteus maximus (49). Compression garment has first 

and second panels of stretchable material joined by a seam (32). At least 

part of the seam is adapted to correspond to at least part of the muscle 

ridge so that in use a muscle group is substantially supported by the first 

or second panel. The garment is adapted to effect a compression of 

between 5mmHg and 40mmHg. 


(21) 554517 (22) 19 Oct 2005 

(54) Flavonoid composition for treating oral diseases 

(86) PCT/US2005/037936 (87) WO2006/045056 

(51) IPC2011.01:A61K31/35; A61K9/68,00; A61K47/00; A61K9/14; A61K8/ 

00,97; A61K36/539,48,74 

(71) Unigen Pharmaceuticals, Inc. 

(72) Jia, Qi; Zhao, Yuan; 

(31) 04 620163 (32) 19 Oct 2004 (33) US 



(57) Disclosed is a pharmaceutical composition comprising a mixture of at 

least one Free-B-Ring flavonoid and at least one flavan; wherein said 

Free-B-ring flavonoid is isolated from a plant or plants in the Scutellaria 

genus of plants and said flavan is isolated from a plant or plants in the 

Acacia or Uncaria genus of plants. The composition is useful for the 

preparation of a medicament for preventing and treating diseases and 

conditions of the mouth, gums and teeth, selected from the group consisting 

of: gingivitis; periodontitis; pulpitis; periodontal conditions caused 

by the physical implantation of oral dentures, trauma, injuries, bruxism, 

neoplastic and other degenerative processes; material alba; pellicles; 

dental plagues; calculus; and stains; or for maintaining optimum saliva 

production and pH; minimizing bacterial growth; reducing the formation 

of pellicles and plague; inhibiting tooth decalcification and tooth caries 

(decay); promoting remineralization; whitening teeth; maintaining healthy 

oral hygiene; and reducing oral malodour (halitosis). 


(21) 554561 (22) 19 Oct 2005 

(54) Permeate Tube 

(86) PCT/SE2005/001554 (87) WO06/043884 

(51) IPC2011.01:B01D63/10 

(71) ALFA LAVAL CORPORATE AB 

(72) Larsen, Knud Verner; 

(31) 04 0402542 (32) 20 Oct 2004 (33) SE 

(31) 04 0403169 (32) 22 Dec 2004 (33) SE 


(57) A permeate tube for spiral wound membrane which comprises at least 

one tubular unit (1) is disclosed. Spaced substantially along the unit's 

length are a plurality of permeate transfer means (2) enabling permeate 

transfer from an external surface region of the unit to an internal passageway 

of the unit. One or more grooves (3) in the external surface 

form flow channels connect the permeate transfer means. At least a part 

of the internal passageway of each tubular unit has a polygonal crosssection. 

(21) 554779 (22) 30 Jan 2006 

(54) Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic 

acid) and its pharmaceutically acceptable salts 

(86) PCT/IN2006/000033 (87) WO2006/095363 

(51) IPC2011.01:A61K31/196; A61K9/08; C07C229/40 

(71) Troikaa Pharmaceuticals Ltd. 

(72) Patel, Ketan Rajnibhai; Patel, Milan Rajnibhai; 

(31) 96/MUM/2005 (32) 1 Feb 2005 (33) IN 



(57) Disclosed is an injectable preparation containing about 75 mg/ml to 

about 100 mg/ml of diclofenac sodium or therapeutically equivalent 

amounts of alternative pharmaceutically acceptable water-soluble salts 

of diclofenac, said preparations having a viscosity of about 1.5 to about 

4.7 CPS and a pH of about 6-10; said preparations further comprising 

either: a) a co-solvent/solubiliser selected from a monohydric alcohol 

(such as benzyl alcohol or ethyl alcohol) present in the composition at 

about 4% to about 25% v/v, or tetrahydrofurfuryl alcohol polyethylene 

glycol ether (glycofurol) present in the composition at about 18 to about 

35% v/v; in combination with water and optional pharmaceutically acceptable 

excipient(s); or b) a solvent system comprising combinations of 

at least two or more cosolvents/solubilisers selected from differing classes, 

wherein the co-solvents/solubilisers are selected from monohydric 

alcohol(s) present in the composition up to about 15% v/v; polyhydric 

alcohol(s) (such as propylene glycol or a polyethylene glycol) present in 

the composition up to about 15% v/v; and tetrahydrofurfuryl alcohol 

polyethylene glycol ether (glycofurol) present in the composition up to 

about 25% v/v; in combination with water and optional pharmaceutically 

acceptable excipient(s). 

(21) 555075 (22) 28 Nov 2005 

(54) Compositions for combating beta-lactamase-mediated antibiotic resistance 

using ceftriaxone, sulbactam and EDTA 

(86) PCT/IN2005/000382 (87) WO2006/059344 

(51) IPC2011.01:A61K31/546,46; A61K9/00; A61P31/04 

(71) VENUS REMEDIES LIMITED 

(72) Chaudhary, Manu; 



(31) 04DEL 2411 (32) 2 Dec 2004 (33) IN 

(74) A.P.T. PATENT AND TRADE MARK ATTORNEYS, 383 Goodwood 

Road, Westbourne Park, SA 5041, Australia 

(57) Disclosed is a pharmaceutical composition for combating betalactamase 

mediated antibiotic resistance, said pharmaceutical composition 

comprising a beta-lactam antibiotic, wherein said beta-lactam antibiotic 

is ceftriaxone or a pharmaceutically acceptable salt thereof, which 

is ceftriaxone sodium;a beta-lactamase inhibitor, wherein said betalactamase 

inhibitor is sulbactam or a pharmaceutically acceptable salt 

thereof, which is sulbactam sodium; wherein said beta-lactam antibiotic 

and said beta-lactamase inhibitors are present in a weight ratios of 1:4 to 

4:1 along with EDTA or a pharmaceutically acceptable salt thereof. 

(21) 555287 (22) 28 Nov 2005 

(54) Solid formulations of liquid biologically active agents such as propofol 

(86) PCT/CA2005/001790 (87) WO2006/056064 

(51) IPC2011.01:A61K31/47,05,08; A61K47/30; A61K9/10,14 

(71) LABOPHARM EUROPE LIMITED; LABOPHARM (BARBADOS) LIM- 

ITED; LABOPHARM INC. 

(72) Ravenelle, Francois; Gori, Sandra; Lessard, David; Luo, Laibin; Le 

Garrec, Dorothee; Smith, Damon; 

(31) 04 631755 (32) 29 Nov 2004 (33) US 



(57) Disclosed is a solid product suitable for reconstitution to an essentially 

clear, stable aqueous solution, comprising an intimate mixture of 

at least one amphiphilic copolymer which includes a hydrophilic part that 

comprises at least one member selected from the group consisting of 

poly(N-vinylpyrrolidone), poly(N-2-hydroxypropylmethacrylamide), poly(2ethyl-2oxazoline), 

poly(glycidol), poly(2-hydroxyethylmethacrylate), 

poly(vinylalcohol), polymethacrylic acid derivatives, poly(vinylpyridinium), 

poly((ammoniumalkyl)methacrylate), poly((aminoalkyl)methacrylate) and 

combinations and derivatives thereof, and at least one liquid biologically 

active agent such as propofol loaded within said amphiphilic copolymer, 

in such a manner that said liquid biologically active agent is intimately 

associated with said amphiphilic copolymer in a substantially solid product; 

The aqueous solution which is produced by reconstituting the solid 

contains the biologically active agent as stable nanodispersions or micelles 

and is substantially free of organic solvent. Also disclosed is an 

apparatus and a process for preparing the solid product comprising forming 

an aqueous solution of at least one linear, branched or star-shaped 

amphiphilic copolymer, under conditions to achieve micelle or 

nanodispersion formation; adding the liquid biologically active agent to 

the solution to form a second mixture; and treating said second mixture 

under conditions effective to remove water, while forming a substantially 

solid product. 

(21) 555399 (22) 29 Nov 2005 

(54) Residential fire sprinkler with heat responsive trigger and deflective 

tines with slots 

(86) PCT/US2005/042816 (87) WO2006/060287 

(51) IPC2011.01:A62C37/08,14; B05B1/26 

(71) TYCO FIRE PRODUCTS LP 

(72) Rogers, Kenneth W.; Fesseden, Mark E.; Silva, Jr., Manuel R.; 

(31) 04 000128 (32) 1 Dec 2004 (33) US 



(57) A residential fire sprinkler comprises a body defining a passageway 

26 between an inlet 26A and an outlet 26B along a longitudinal axis with 

the outlet closer to an area to be protected than the inlet, the passageway 

having a rated K-factor of at least 6, the body including a portion 

having ¾ inch or greater NPT threads formed thereon, a closure positioned 

proximate the outlet opening so as to occlude the passageway 

26, a heat responsive trigger 36 that retains the closure to occlude the 

passageway 26, at least one frame arm 14 being coupled to the body 

and a deflector coupled to the at least one frame arm 14 and spaced 

from the outlet opening so that when the trigger is actuated, the deflector 

provides adequate fluid distribution for the protection of a dwelling unit, 

the deflector including a first surface that faces the outlet and a second 

surface spaced apart from the first surface, a plurality of tines that extends 

away from the longitudinal axis, the plurality of tines being disposed 

generally about the longitudinal axis and two slots formed through 

the first and second surfaces, each slot including two generally parallel 

walls between a first end and a second end to define an opening extending 

along a first axis generally perpendicular to a plane defined by the 

longitudinal axis and the at least one frame arm, the two walls of the slot 

converging towards each other at the first end and the second end to 

define a close-ended slot 40 having a generally polygonal perimeter. 

(21) 555406 (22) 2 Dec 2005 

(54) Cytotoxic agents comprising new taxanes 

(86) PCT/EP2005/014177 (87) WO2006/061258 

(51) IPC2011.01:C07D493/06; A61K39/395; A61P35/00; C07K16/30 

(71) AVENTIS PHARMA S.A. 

(72) Miller, Michael L.; Chari, Ravi V. J.; Baloglu, Erkan; Commercon, Alain; 

(31) 04 04292898 (32) 7 Dec 2004 (33) EP 





(57) Disclosed are Taxane compounds having the following formula (I) 

wherein R1 is a linker group comprising a disulfide group, or is an aryl or 

heterocyclic radical, alkyl alkenyl or alkynyl, cycloalkyl or cycloalkenyl, - 

OR2 or a carbamate formed from any of said, alkenyl or alkynyl, cycloalkyl 

or cycloalkenyl, or aryl or heterocyclyl; R2 is an alkyl, alkenyl or alkynyl, 

cycloalkyl or cycloalkenyl, aryl or heterocyclic; R3 is a linker group comprising 

a disulfide group, or is an aryl or heterocyclic, alkyl, alkenyl or 

alkynyl, cycloalkyl or cycloalkenyl; R4 is a linker group comprising a 

disulfide group, H, or is a hydroxy, an alkoxy, an alkenyloxy, an alkanoyloxy, 

aroyloxy, alkenoyloxy, alkynoyloxy, cycloalkanoyloxy, alkoxyacetyl, 

alkylthioacetyl, alkyloxycarbonyloxy, cycloalkyloxy, cycloalkenyloxy, 

carbamoyloxy, alkylcarbamoyloxy, or dialkylcarbamoyloxy, a heterocyclic 

or aryl ether, ester or carbamate, or alkyl or alkenyl ester or ether or a 

carbamate of the formula -OCOX, wherein X is a nitrogen-containing 

heterocycle or a carbamate of the formula –OCONR9R10, wherein R9 

and R10 are the same or different and are H, alkyl or aryl; R8 or R7 is H; 

Ra is H; R7 or R8 and R form a bond (cyclic ether); Ra = aryl or heterocyclic 

radical; and wherein R, or R3 or R4 represents said linking group. Also 

disclosed is a cytotoxic agent comprising said taxane and a cell binding 

agent e.g. an antibody. 

(21) 555470 (22) 17 Nov 2005 

(54) Rasagiline orally disintegrating compositions 

(86) PCT/US2005/041882 (87) WO2006/057912 

(51) IPC2011.01:A61K31/135 

(71) TEVA PHARMACEUTICAL INDUSTRIES, LTD. 

(72) Patashnik, Shulamit; Licht, Daniella; Gilbert, Adrian; 

(31) 04 630918 (32) 24 Nov 2004 (33) US 

(31) 04 997785 (32) 24 Nov 2004 (33) US 



(57) Disclosed is a solid pharmaceutical composition comprising rasagiline 

or a pharmaceutical acceptable salt of rasagiline, and particles having a 

non-filamentous microstructure of at least two sugar alcohols. 

(21) 555634 (22) 30 Nov 2005 

(54) Adjustable bracket for securing vessel to surface with flexible straps 

and slidable portions in receiving track 

(86) PCT/AU2005/001797 (87) WO2006/058366 

(51) IPC2011.01:F16M13/02; A62C13/78; A62B25/00; F17C13/08 

(71) Wilroof Products (WA) Pty Ltd 

(72) Larmont, James; 

(31) 04 906814 (32) 30 Nov 2004 (33) AU 

(74) P L BERRY & ASSOCIATES, AEQ Building, 61 Cambridge Terrace, 

Christchurch 8013, New Zealand 

(57) An adjustable bracket (10) for securing a vessel to a surface includes 

slidable portions (12) and receiving track (14) mounted on the surface. 

Each slidable portion (12) includes a track engaging portion (16) positioned 

within track (14), an outwardly extending portion (18) and a flexible 

member (34) attached to engaging portion (32). In use, slidable portions 

(12) are positioned adjacent opposing sides of the vessel and flexible 

members (34) are fastened around the vessel such that tension in 

flexible members (34) causes slidable portions (12) to be held in place 

upon track (14) by friction. The vessel may be a portable fire extinguisher 

or oxygen tank and the surface might be a wall. 

(21) 555721 (22) 22 Dec 2005 

(54) Fused pyrazole derivatives and uses thereof in methods of treatment 

of metabolic-related disorders 

(86) PCT/US2005/046599 (87) WO06/069242 

(51) IPC2011.01:C07D231/54; A61K31/4155,416; A61P9/10; C07D403/ 

04 

(71) Arena Pharmaceuticals, Inc. 

(72) Boatman, Douglas P; Schrader, Thomas O; Semple, Graeme; Skinner, 

Philip J; Jung, Jae-Kyu; 

(31) 04 638668 (32) 23 Dec 2004 (33) US 

(31) 05 676521 (32) 29 Apr 2005 (33) US 



(57) Disclosed herein are fused pyrazole derivatives of Formula (Ia), and 

pharmaceutically acceptable salts thereof wherein substituents are as 

defined within the specification. Such compounds exhibit useful pharmacological 

properties, for example, as agonists for the RUP25 receptor. 

Also disclosed are pharmaceutical compositions containing said compounds 

and methods of using the compounds and compositions of the 

invention in the treatment of metabolic-related disorders, including 

dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, 

type 2 diabetes, Syndrome-X and the like. The use of the compounds of 

Formula (Ia) in combination with other active agents such as those belonging 

to the class of á-glucosidase inhibitors, aldose reductase inhibitors, 

biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, 

fibrates, LDL catabolism enhancers, angiotensin converting enzyme 

(ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, 

and the like are further disclosed. 

(21) 555813 (22) 2 Dec 2005 

(54) Wall construction method using tilt-up wall panel with lengthwise extending 

rib supported on a structure with rebate 

(86) PCT/AU2005/001835 (87) WO2006/058390 

(51) IPC2011.01:E04B2/08,82,94 

(71) BLUESCOPE STEEL LIMITED 

(72) Kralic, John; Contouris, Samuel; 

(31) 04 906945 (32) 3 Dec 2004 (33) AU 



(57) A method of constructing a wall on a wall support structure having 

rebate is disclosed. A tilt-up wall panel (3) that is used in the method 



includes a composite slab having a profiled decking sheet (5) with at 

least one lengthwise extending rib (9). Concrete is casted on the profiled 

decking sheet (5). Firstly, a tilt-up wall panel (3) is positioned so that that 

the panel (3) rests on a horizontal surface of the wall support structure 

and extends vertically upwardly with the rib(s) (9) forming an internal 

face of the wall. Then, the wall panel (3) and wall support structures are 

connected together with at least one connecting means via the engagement 

of the connection means with a rib(s) (9) of the wall panel (3). 


(21) 556050 (22) 6 Dec 2005 

(54) Sleeved container package with V shaped opening feature and a 

plastic carrier with acontainer holding portion of interconnected stretchable 

loops 

(86) PCT/IB2005/054087 (87) WO2006/067651 

(51) IPC2011.01:B65D71/50,12,28,34,06 


(72) Marco, Leslie S; 

(31) 04 021263 (32) 23 Dec 2004 (33) US 

(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, 

Victoria 3000, Australia 

(57) A package 10 for containers 16 such as beverage bottles and cans 

includes a plastic carrier 20 with an array 50 of interconnected, stretchable 

loops, with one loop being provided for surrounding each container 

16. A sleeve 14 surrounds the group 18 of containers 16 held by the 

carrier 20. The sleeve 14 includes two parting lines 50, 52 with edges 

positioned to open the edges of the sleeve, and a tear-initiating breach 

60 placed substantially between two of the carrier loops and at the intersection 

of the parting lines 50, 52. The tear-initiating breach 60 comprises 

perforations in the sleeve arranged in a ‘V’ configuration. The arrangement 

gives the container package an easy and convenient opening 

feature. 

(21) 556150 (22) 30 Dec 2005 

(54) 18-methyl-19-NOR-17-pregn-4-en-21,17 carbolactones and pharmaceutical 

preparations comprising the same 

(86) PCT/EP2005/014205 (87) WO2006/072467 

(51) IPC2011.01:C07J53/00; A61K31/585; A61P5/34 

(71) BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 

(72) Borden, Steffen; Bohlmann, Rolf; Bittler, Dieter; Kuenzer, Hermann; 

Esperling, Peter; Muhn, Hans-Peter; Fritzemeier, Karl-Heinrich; Fuhrmann, 

Ulrike; Prelle, Katja; 

(31) 04 0463864 (32) 30 Dec 2004 (33) DE 


(57) Disclosed herein are 18-methyl-19-nor-17-pregn-4-en-21,17carbolactones 

of general formula (I), wherein the substituents are as 

defined in the specification. Said compounds have gestagenic and 

antimineralocorticoid activity and are suitable for the production of pharmaceutical 

preparations, for example, for oral contraception and the treatment 

of pre-, peri- and post-menopausal pain. 

(21) 556210 (22) 19 Dec 2005 

(54) Tool having an integral wireless system for remotely ordering replacement 

consumables 

(86) PCT/IB2005/054322 (87) WO2006/077473 

(51) IPC2011.01:B25B33/00; G06Q10/00 


(72) Panasik, Cheryl L; 

(31) 05 040978 (32) 21 Jan 2005 (33) US 



(57) A wireless system for a host power tool 10 having an integral system 

for ordering replacement consumables from an inventory order interface 

comprises a processing unit 18, a location provider 14 and a remote 

connector 16. The location provider 14 is configured to selectively provide 

the location of the host tool 10 to the processing unit 18, while the 

remote connector 16 is configured to establish a remote connection between 

the processing unit 18 and the inventory order interface of the 

supplier of the replacement consumables. A customer identification card 

having order information is selectively connected to the host tool 10. 

When the card is connected, the information is read by and transmitted 

from the host tool 10 to the inventory order interface through the remote 

connector 16. The processing unit 18 is configured to interface location 

information from the location provider 14 payment information and order 

information from the customer identification card, through the remote 

connector 16, to place an order for the replacement consumables of the 

host tool 10 at the inventory order interface. The system simplifies the 

ordering of replacement consumables like fasteners for the host power 

tool. 



(21) 556245 (22) 5 Jan 2006 

(54) Composition for treating wood, method for treatment of wood and 

wood product 

(86) PCT/FI2006/050012 (87) WO2006/072672 

(51) IPC2011.01:B27K3/50; A01N37/06,10,02 

(71) BIO-TEHO OY 

(72) Aitta, Eero; Seppi, Pekka; Kukkonen, Jari; Nissinen, Timo; 

(31) 05 050023 (32) 10 Jan 2005 (33) FI 

(74) P L BERRY & ASSOCIATES, AEQ Building, 61 Cambridge Terrace, 

Christchurch 8013, New Zealand 

(57) Disclosed is a method for the treatment of wood, in which a treatment 

composition and wood are brought into a contact with each other and the 

treatment composition contains formate salt characterized in that the 

treatment composition used is a composition which contains 1) the formate 

salt together with 2) sorbate salt and/or benzoate salt dissolved in 

an aqueous liquid carrier. Also disclosed is a wood material treated by 

said method. 

(21) 556312 (22) 25 Jan 2006 

(54) Container with two packs joined by straps in a Jacob’s Ladder arrangement 

(86) PCT/GB2006/000245 (87) WO2006/079799 

(51) IPC2011.01:B65D5/00; B65D21/02; B65D5/42; B65D71/02; B65D85/ 

10 

(71) British American Tobacco (Investments) Ltd 

(72) Bray, Andrew Jonathan; Tearle, Alan Douglas; 

(31) 05 0501733 (32) 27 Jan 2005 (33) GB 

(74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Australia 

(57) A package comprises first and second packs Pl, P2 each capable of 

containing items. Each pack has a first face Fl, Fl' bound by a first edge 

El, El' and a second edge E2, E2'. The first and second packs Pl, P2 are 

connected by first and second straps Sl, S2. In a first position of the 

packs the first faces Fl, Fl' of each pack face each other with the first 

edges El, El' of the first and second packs adjacent each other and the 

second edges El, E2' of the first and second packs adjacent each other. 

The first and second straps Sl, S2 extend across the first faces Fl, Fl' of 

the packs, the first strap Sl is hinged relative to the first pack at the first 

edge El of the first pack and hinged relative to the second pack at the 

second edge E2' of the second pack, and the second strap S2 is hinged 

relative to the second pack P2 at the first edge El' of the second pack 

and hinged relative to the first pack at the second edge of the first pack. 

When connected together by the straps Sl, S2, the first and second packs 

Pl, P2 are moveable, one relative to the other between at least the first 

position, a second position in which the second pack P2 is rotated relative 

to the first pack Pl about the first edge El and a third position in which 

the second pack P2 is rotated relative to the first pack Pl about the second 

edge E2'. 

(21) 556318 (22) 4 Jan 2006 

(54) N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as 

vanilloid TRPV1 receptor ligands 

(86) PCT/FR2006/000008 (87) WO2006/072736 

(51) IPC2011.01:C07D209/42; A61K31/33; A61P29/00; C07D401/12; 

C07D403/12; C07D405/12; C07D413/12; C07D417/12 

(71) sanofi-aventis 

(72) Dubois, Laurent; Evanno, Yannick; Malanda, Andre; 

(31) 05 0550068 (32) 7 Jan 2005 (33) FR 



(57) Disclosed are N-(heteroaryl)-1H-indole-2-carboxamide-based compounds 

of formula (I) wherein W is a fused bicyclic group and the remaining 

substituents are as defined in the specification, a process for 

preparing compounds of formula (I) and their agonist or antagonist effects 

on the TRPV1 receptor. Also disclosed is their use in treating diseases 

such as pain and inflammation, urological disorders, gynaecological 

disorders, gastrointestinal disorders, respiratory disorders, psoriasis, 

pruritus, dermal, ocular or mucous irritation, herpes and zona. 

(21) 556478 (22) 31 Jan 2006 

(54) DR5 antibodies and uses thereof 

(86) PCT/US2006/003577 (87) WO2006/083971 

(51) IPC2011.01:C07K16/28 

(71) GENENTECH, INC. 

(72) Adams, Camellia W; 

(31) 05 649550 (32) 2 Feb 2005 (33) US 

(31) 06 344564 (32) 30 Jan 2006 (33) US 



(57) Provided is an anti-DRS antibody comprising mutations in the heavy 

and light chain of full-length antibody 16E2, or a fragment thereof, wherein: 

said antibody or antibody fragment has a greater affinity for DRS than 

full-length antibody 16E2 and is capable of activating or stimulating 

apoptosis in cancer cells; and the mutations comprise: (i) a set of heavy 

chain mutations selected from the group consisting of (i) NS3Q, L102Y; 

(ii) M34L, N53Q, L102Y; (iii) N53Y, L102Y;(iv) M34L, N53Y, L102Y; (v) 

G33A, N53Q, L102Y; (vi) M34L, N53Y, L102Y; (vii) G33A, N53Q, L102Y; 

(viii) G33A, N53Y, L102Y; (ix) T28A, N53Q, L102Y; and (x) T28A, NS3Y, 

L102Y; and (ii) a set of light chain mutations selected from the group 

consisting of (i) Q24S, G50K, K51D, H95bY; (ii) Q24S, K51A, D92S, 

S93Y; and (iii) Q24S, K51A, R91A in the amino acid sequence. The antibodies 

can be used to treat cancer. 

(21) 556499 (22) 3 Feb 2006 

(54) Methods and materials with trans-clomiphene for the treatment of 

male infertility 

(86) PCT/US2006/003882 (87) WO2006/084153 

(51) IPC2011.01:A61K31/137 

(71) REPROS THERAPEUTICS INC. 

(72) Podolski, Joseph; 

(31) 05 650018 (32) 4 Feb 2005 (33) US 



(57) Disclosed is the use of a composition comprising an effective amount 

of trans-clomiphene or a pharmaceutically acceptable sale tor solvate 

thereof and optionally one or more pharmaceutically acceptable diluents, 

adjuvants, carriers or excipients in the manufacture of a medicament for 

treating infertility in a male with secondary hypogonadism wherein the 

composition is characterized by the following: a)the ratio of transchlomiphene 

to cis-clomiphene is greater than 71/29; or b) the composition 

comprises 0% to 29% w/w of cis-clomiphene and 100% to 71% transclomiphene. 



(21) 556546 (22) 6 Jan 2006 

(54) Compounds for inflammation and immune-related uses 

(86) PCT/US2006/000296 (87) WO2006/083477 

(51) IPC2011.01:A61K31/537,455,433,415; C07D213/02; A61K31/44 

(71) SYNTA PHARMACEUTICALS CORP. 

(72) Sun, Lijun; Chen, Shoujun; Xia, Zhi Qiang; Jiang, Jun; Xie, Yu; Zhang, 

Junyi; 

(31) 05 642179 (32) 7 Jan 2005 (33) US 

(31) 05 707845 (32) 12 Aug 2005 (33) US 



(57) Disclosed is a compound of formula (I), wherein L is a linker selected 

from the group of a covalent bond, -NRCH2-, -CH2NR-, -C(O)-, -NR- 

C(O)-, -C(O)-NR-, OC(O)-, C(O)O-, C(S)-, -NR-C(S)- or –C(S)-NR-, and 

the other substituents are disclosed within the specification, or a 

pharmaceutically acceptable salt thereof. Also disclosed is a method of 

inhibiting immune cell activation, inhibiting cytokine production or modulating 

an ion channel in a cell in vitro, comprising administering to the cell 

the said compound. Use of the said compound for the manufacture of a 

medicament for inhibiting immune cell activation, inhibiting cytokine production 

or modulating an ion channel in a cell is also disclosed. 

(21) 556620 (22) 15 Feb 2006 

(54) Mechanically operated nail advancement systems for nail arrays disposed 

within nailing tool magazines 

(86) PCT/US2006/005194 (87) WO2006/091433 

(51) IPC2011.01:B25C1/00; B25F5/00; B25C1/18 


(72) Porth, Chris H; Moeller, Larry M; Walthall, Barry C; Henry, Clayton D; 

(31) 05 060864 (32) 18 Feb 2005 (33) US 



(57) A fastener advancement system for example advancing the nail in 

the magazine of a nail gun using electromechanically operated mechanism 

is disclosed. The system comprises a driving means consisting of 

multi-lever and linkage (136) that are operatively connected to the blade 

member (126) of the fastener driving tool for advancing a leading fastener 

of a collated strip of fasteners into the driver blade channel of the 

fastener-driving tool. The system is characterised by the means for separating 

the leading fastener of the collated strip of fasteners that is movable 

in response to the rearward movement of the driving means. The 

system uses push type; pull type and rotary solenoid actuating members 

for moving the fastener-advancement feed pawl or claw member. Since 

the system is electromechanically operated it eliminates the need of any 

exhaust gases that would otherwise be required in the combustion powered 

fastener advancement system. 

(21) 556623 (22) 8 Feb 2006 

(54) A beehive lid which avoids propolis around the lids opening 

(86) PCT/GR2006/000006 (87) WO2006/085124 

(51) IPC2011.01:A01K47/00; A01K53/00 

(71) Ioannis Katsampis 

(72) Katsampis, Ioannis; 

(31) 05 0100057 (32) 9 Feb 2005 (33) GR 

(74) Acacia Law, 16 Brasenose Place, Tawa, Wellington, 5028, New Zealand 

(57) A beehive lid is disclosed. The lid includes a top cover that opens 

using a connecting mechanism (1), there are containers (8) under the 

top cover (10) for placement of liquid, and a surface (24, 25) attached to 

the sidewalls (2) of the lid. The surface has an opening (9) that is covered 

by a removable cover (48). One side (26) of the surface of the lid is 

inclined coming down into the containers leaving a gap between its end 

and the bottom (30) of the container (8). The liquids are transferred through 

the gap inside the body of the lid (99) to a space (7). The space is defined 

by walls having stripes to help the bees to climb up easily, and 

prevent immediate contact with the top (10) of the lid so they do not glue 

it with "propolis". This gives immediate access to the liquids in the containers 

(8) without having any contact with the bees and gives the ability 

to open the removable cover (48) to place anything inside or take anything 

out. On the top of the lid (10) there are shutters (11) that open and 

are adjustable to help the bees overcome any extreme weather conditions. 

When the shutters are closed, they cover the air intake holes. All 

the above are done without taking the lid (99) off and without smoking 

the bees, this avoids transferring the toxic substances of the smoke to 

the bees' products. 



(21) 556716 (22) 8 Feb 2005 

(54) Site-specific serine recombinases from Mycobacterium tuberculosis 

phage phiRv1 and M. smegmatis phage Bxb1and methods of their use 

(86) PCT/US2005/003851 (87) WO2006/083253 

(51) IPC2011.01:C12N15/85; C07H21/04 

(71) Intrexon Corporation 

(72) Padidam, Malla; 

(31) 05 49552 (32) 2 Feb 2005 (33) US 



(57) A method for obtaining site-specific recombination in an isolated 

eukaryotic cell comprising: 

- Providing an isolated eukaryotic cell that comprises a first recombination 

site and a second recombination site; 

- Contacting the first and second recombination site with a prokaryotic 

recombinase polypeptide resulting in recombination between the two sites; 

-The first recombination site is either a phage genomic recombination attachment 

site (attP) or a bacterial genomic recombination attachment 

site (attB) and the second recombination is either attP or attB, provided 

that when the first recombination site is attP the second recombination 

site is attB or vice versa; 

- The recombinase is a Mycobacterium tuberculosis phage recombinase 

or a M. smegmatis phage recombinase in particular the recombinases 

are phiRv1 or Bxb1 recombinase. 

The method also encompasses the use of pseudo attP and attB recombination 

sites as well as a third and fourth, and a fifth and sixth recombination 

site. 


(21) 556774 (22) 3 Jan 2006 

(54) Syrup composition comprising dexibuprofen as an active ingredient 

and method for the preparation thereof 

(86) PCT/KR2006/000016 (87) WO2006/073257 

(51) IPC2011.01:A61K9/08 

(71) HANMI PHARM. CO., LTD. 

(72) Woo, Jong Soo; Yi, Hong Gi; Jin, Ju Nam; 

(31) 05 0000222 (32) 3 Jan 2005 (33) KR 



(57) Disclosed is a glycerin-free dexibuprofen syrup composition comprising: 

0.1 to 10 w/v percent of dexibuprofen ((S)-ibuprofen) having an average 

particle size ranging from 10 to 300 microns; 0.01 to 40 w/v percent 

of a viscosity controlling agent selected from the group consisting of 

D-sorbitol solution, agar, sodium alginate, povidone, polyethylene glycol, 

hydroxyethylene cellulose and a mixture thereof; 0.1 to 80 w/v percent of 

a sweetener selected from the group consisting of sugar, high fructose, 

stevioside, dipotassium glycirhyzinate and a mixture thereof; 0.01 to 10 

w/v percent of a suspending agent; 0.01 to 5 w/v percent of an emulsifier; 

and 0.01 to 5 w/v percent of a pH controlling agent, said composition 

having a viscosity ranging from 500 to 3,000 cPs and pH ranging from 

3.0 to 6.0. Also disclosed is a method to prepare said compostion. 

(21) 560283 (22) 18 Jan 2006 

(54) Rod-shaped light and light holder for marking a pylon 

(86) PCT/EP2006/000394 (87) WO2006/077084 

(51) IPC2011.01:F21S8/00; F03D11/00; F21V21/04; F21V33/00; F21V21/ 

02 

(71) Aloys Wobben 

(72) Wobben, Aloys; 

(31) 05 05002650 (32) 19 Jan 2005 (33) DE 

(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza 

Offices, Woden Town Square, Woden, ACT 2606, Australia 

(57) A rod-shaped light 10 for a pylon comprises a substantially cylindrical 

rod-shaped holder at the first end of which lighting means and at the 

second end of which lighting means connections 15 are arranged. The 

rod-shaped light 10 is adapted to be fitted by means of the rod-shaped 

holder from the inside through a bore in the pylon wall 11 so that the 

lighting means radiate into the surrounding area of the pylon. 

(21) 560314 (22) 15 Feb 2006 

(54) Live attenuated rotavirus vaccine for oral administration 

(86) PCT/EP2006/001442 (87) WO2006/087205 

(51) IPC2011.01:A61K39/15; A61P1/00 

(71) GLAXOSMITHKLINE BIOLOGICALS S.A. 

(72) Vande Velde, Vincent; 

(31) 05 0503337 (32) 17 Feb 2005 (33) GB 


(57) A liquid rotavirus immunogenic composition suitable for oral administration 

to a human infant, comprising a rotavirus antigen, a sugar and a 

carboxylate. The composition has a pH of between pH 5.0 and pH 8.0 

and comprises less than 1 mM phosphate and the carboxylate is derived 

from a dicarboxylic acid with a pKa > 4. Suitable carboxylates are adipate, 

malate, succinate, malonate, glutarate, maleate, fumarate and tartarate. 

The composition is used as a vaccine for infants to prevent or treat gastroenteritis. 

(21) 560320 (22) 25 Jan 2006 

(54) Quinoxaline derivatives as antitumor agents 

(86) PCT/US2006/002717 (87) WO2006/081331 

(51) IPC2011.01:A61K31/495; C07D239/90; A61P35/00; C07D405/12; 

C07D409/12; G01N33/50,68 

(71) Prolexys Pharmaceuticals Inc.; Whitehead Institute for Biomedical 

Research; The Trustees of Columbia University in the City of New York 

(72) Becklin, Robert R; Chepanoske, Cindy Lou; Pelter, John M; Ql, 

Longwu; Robbins, Paul B; Sahasrabudhe, Sudhir R; Selliah, Robert; 

Simmons, Keith; Stockwell, Brent R; Venkat, Raj Gopal; Von Rechenberg, 

Moritz; Zhen, Eugene; 

(31) 05 647303 (32) 25 Jan 2005 (33) US 

(31) 06 762221 (32) 24 Jan 2006 (33) US 


(57) Disclosed are quinoxaline compounds of formula (I), or 

pharmaceutically acceptable salts thereof, wherein W is a piperidine or a 

piperazine moiety and the rest of the substituents are disclosed within 

the specification. Also disclosed is the use of the said compound in the 

manufacture of a medicament for treating cancer in a mammal. 



(21) 560398 (22) 17 Feb 2006 

(54) Microwaveable film or sheet suitable for vacuum skin packaging applications 

and peelable microwaveable vacuum skin package obtained 

therewith 

(86) PCT/EP2006/001491 (87) WO2006/094617 

(51) IPC2011.01:B32B27/32; B65D75/30; C08L23/08 

(71) CRYOVAC, INC. 

(72) Riccio, Marina; Della Bianca, Serena; 

(31) 05101749 (32) 7 Mar 2005 (33) EP 

(31) 05108515 (32) 16 Sep 2005 (33) EP 



(57) The disclosure relates to a multi-layer film or sheet suitable for use in 

vacuum skin packaging (VSP) applications that has an outer layer comprising 

a blend of from about 8 to about 30 wt. % of modified polypropylene, 

from 0 to about 20 wt. % of polybutene and the complement to 100 wt. % 

of ionomer, wherein said modified polypropylene is a polypropylene that 

has been modified by grafting thereon an unsaturated carboxylic acid or 

a derivative thereof. The disclosure also relates to a peelable VSP package 

where one of the webs has an outer sealing layer comprising a blend 

of from about 8 to 30 wt. % of modified polypropylene that has been 

modified by grafting thereon an unsaturated carboxylic acid or a derivative 

thereof, from 0 to about 20 wt. % of polybutene and the complement 

to 100 wt. % of ionomer and the other web comprises an outer sealing 

layer having an ethylene homo- or copolymer-based surface, wherein 

said outer sealing layers are sealed to each other in one or more selected 

areas with a seal strength of from about 2.0 to about 4.0 N/25.4 

mm. 

(21) 560568 (22) 9 Dec 2005 

(54) Particulate compositions comprising phosphatidyl choline, diacyl glycerol 

or tocopherol, and a non-ionic stabilising amphiphile 

(86) PCT/GB2005/004745 (87) WO2006/077362 

(51) IPC2011.01:A61K9/127 

(71) CAMURUS AB 

(72) Johnsson, Markus; Tiberg, Fredrik; 

(31) 05 0501364 (32) 21 Jan 2005 (33) GB 

(31) 05 0507812 (32) 18 Apr 2005 (33) GB 



(57) Disclosed is a particulate composition comprising: 

a) 5 to 50% of at least one phosphatidyl choline component b) 20 to 85% 

of at least one diacyl glycerol component, at least one tocopherol,or mixtures 

thereof, andc) 1 to 40% of at least one non-ionic stabilising 

amphiphile consisting essentially of surfactants having a molecular weight 

below 8000 amu,wherein all parts are by weight relative to the sum of the 

weights of a+b+c and wherein the composition comprises particles of at 

least one non-lamellar phase structure or forms particles of at least one 

non-lamellar phase structure when contacted with an aqueous fluid. 

(21) 560613 (22) 17 Jan 2006 

(54) Water treatment with sand between aggregate layers, and distribution 

of water evenly at inlet 

(86) PCT/AU2006/000056 (87) WO2006/074529 

(51) IPC2011.01:B01D24/00,02,10,12,20; C02F1/00; E03F1/00; E03F5/ 

00,14; B01D24/22 

(71) H2O World Wide Water Solutions Pty Ltd 

(72) Venville, Kevin John; 

(31) 05 900172 (32) 17 Jan 2005 (33) AU 

(31) 05 900228 (32) 20 Jan 2005 (33) AU 

(31) 05 905595 (32) 11 Oct 2005 (33) AU 

(74) H2O World Wide Water Solutions Pty Ltd, c/- H20 Pureplus Pty Ltd, 

Unit 2, No. 8 Riverland Drive, Loganholme, Queensland 4129, Australia 

(57) A sand filter apparatus (10) for treating water includes a filter retention 

vessel (16) having an outlet (18) from which filtrate can be supplied. 

An inlet arrangement (not shown fully) is in fluid communication with the 

filter retention vessel and is connectable to a supply of waste water. A 

filter is interposed between the inlet arrangement and the outlet. The 

filter includes two layers of aggregate (12) and a layer of sand (26) interposed 

between the two layers of aggregate. The sand is at least one of, 

or a mixture of, granite-based sand and substantially pure silica based 

sand. A distribution system (not shown) is connected to the inlet arrangement 

so that waste water from the inlet to the filter is distributed substantially 

evenly into the upper aggregate layer. 

(21) 560699 (22) 31 Aug 2006 

(54) Gravity gradiometer for measuring diagonal components of the gradient 

tensor 

(86) PCT/AU2006/001276 (87) WO2007/038825 

(51) IPC2011.01:G01V7/16 

(71) Technological Resources Pty Limited 

(72) Van Kann, Frank Joachim; Winterflood, John; Mann, Anthony Gordon; 

(31) 05 905524 (32) 6 Oct 2005 (33) AU 

(31) 05 906669 (32) 29 Nov 2005 (33) AU 

(31) 06 900193 (32) 13 Jan 2006 (33) AU 



(57) Disclosed is a system for measuring a gravity gradient tensor. The 

system comprises of: a gravity gradient sensor (40) with a pair of transversely 

arranged masses (41, 42) for use in a gravity gradiometer for 

measuring components of a gravity gradient tensor; a calibration sensor 

for sensing, at room temperature prior to cryogenic operation of the gravity 

gradiometer, whether one of the pair of masses associated with the 

calibration sensor is balanced; and an adjusting mechanism for adjusting 

the balance of the masses at room temperature prior to cryogenic 

operation of the gravity gradiometer. The calibration sensor comprises a 

resonant circuit having an inductor, and a capacitor which has a first 

plate formed by a surface of one of the masses and a second plate spaced 

from that surface of one of the masses; and an oscillator for receiving a 

signal from the resonant circuit and for producing an output signal indicative 

of the spacing between the first plate and the second plate. In 

use the calibration sensor produces a signal indicative of the balance of 

the one of the pair of masses associated with the calibration sensor. 



(21) 560700 (22) 31 Aug 2006 

(54) Gravity Gradiometer with chevron shaped mass having a non-zero 

quadruple moment 

(86) PCT/AU2006/001272 (87) WO2007/038821 

(51) IPC2011.01:G01V7/16 


(72) Van Kann, Frank Joachim; Winterflood, John; 

(31) 05 905524 (32) 6 Oct 2005 (33) AU 

(31) 05 906669 (32) 29 Nov 2005 (33) AU 

(31) 06 900193 (32) 13 Jan 2006 (33) AU 



(57) Disclosed is a gravity gradiometer for measuring components of a 

gravitational gradient tensor. The gradiometer comprises: a first housing 

(45); a first mass (41) forming one part of a pair of masses; and a first 

flexure web (59) located on a peripheral edge of the first mass. The 

flexure web pivotally connects the first mass with the first housing for 

movement there between in response to differences in a gravitational 

field so that signals can be produced indicative of components of the 

gravitational gradient tensor. The first mass has a non-zero quadruple 

moment with a centre of mass located at the flexure web and the first 

mass is chevron-shaped with first and second arms extending from the 

centre of mass. 

(21) 560701 (22) 31 Aug 2006 

(54) Gravity Gradiometer with a mounting having a three part mount connected 

by flexure webs 

(86) PCT/AU2006/001273 (87) WO2007/038822 

(51) IPC2011.01:G01V7/16 



(31) 05 905524 (32) 6 Oct 2005 (33) AU 

(31) 05 906669 (32) 29 Nov 2005 (33) AU 

(31) 06 900193 (32) 13 Jan 2006 (33) AU 




gravity gradient tensor. The gradiometer comprises: a sensor (41, 42) for 

measuring the components of the gravity gradient tensor; and a mounting 

(5) for providing rotation about three substantially orthogonal axes, 

and for supporting the sensor. The sensor comprises a first mass (41) 

and a second mass (42) supported within respective first and second 

housings for movements relative to the housings in response to the gravitational 

field. The mounting comprises: a first mount (10); a second mount; 

and a first flexure web (33) for pivotally coupling the first and second 

mounts for pivotal movement about a first axis. The second mount has a 

first part (25), a second part (26) and a third part (27). The first part 

connects to the second part by a second flexure web (37) for pivotally 

coupling the first part to the second part for pivotal movement about a 

second axis orthogonal to the first axis. The third part is coupled to the 

second part by a third flexure web (35) for pivotally coupling the third part 

to the second part for pivotal movement about a third axis orthogonal to 

the first and second axes. 

(21) 560702 (22) 31 Aug 2006 

(54) Gravity Gradiometer with a mounting having a second mount with 

connectors which pass through cutouts in a first mount 

(86) PCT/AU2006/001271 (87) WO2007/038820 

(51) IPC2011.01:G01V7/16 



(31) 05 905524 (32) 6 Oct 2005 (33) AU 

(31) 05 906669 (32) 29 Nov 2005 (33) AU 

(31) 06 900193 (32) 13 Jan 2006 (33) AU 




gravitational gradient tensor. The gradiometer comprises a sensor (40) 

for measuring the components of the gradient tensor and a mounting for 

supporting the sensor. The mounting comprises; a first mount, a second 

mount, and connectors. The first mount (10) has a base, a cylindrical 

hub protruding from the base, a peripheral wall (14) disposed around 

and spaced from the hub and provided with a plurality of circumferentially 

spaced cutouts (16), and a central core coaxial with the hub and 

attached to the hub by a first flexure web to provide for relative rotation 

between the core and base about a first axis. The second mount fits 

within the peripheral wall of the first mount and has first, second and 

third parts. The first and second parts connect via a second flexure web 

for relative rotation about a second axis orthogonal to the first axis. The 

second and third parts connect by a third flexure web for relative rotation 

about a third axis orthogonal to the first and second axes. The connectors 

(13) extend outwardly from the first part of the second mount through 

the cutouts in the peripheral wall of the first mount for connecting the 

mounting to an external platform. The third part of the second mount is 

attached to the core of the first mount and the sensor is connected to the 

base of the first mount. Hence the sensor is rotatable with the base of 

the first mount about all three orthogonal axes. 



(21) 560836 (22) 19 Jan 2006 

(54) Food preservation systems including a multi phase bacterial inhibition 

food pad 

(86) PCT/US2006/001977 (87) WO2006/078868 

(51) IPC2011.01:A23B4/20; B65D81/28; A23B4/14; B65D81/26 

(71) Paper Pak Industries 

(72) Etchells, Marc D; Versteylen, Sayandro; 

(31) 05 645856 (32) 21 Jan 2005 (33) US 



(57) An absorbent, bacterial inhibition food pad comprises two or more 

layers 32, 34 of absorbent or superabsorbent tissue that can absorb up 

to 50 grams of a liquid purge from a food product. The absorbent media/ 

material includes a CO2 generating system that modifies the atmosphere 

in a food package that includes the food pad, and one or more bacterial 

inhibitors that may possess bacteriostatic and/or bactericidal properties. 

The CO2 generating system has a bacteriostatic effect on bacteria on 

the surface of the food product, while the bacterial inhibitors have a bacteriostatic 

effect on bacteria in the liquid purge. The food pad enhances 

the shelf life, food safety, and appearance of a food product. 


(21) 560849 (22) 6 Feb 2006 

(54) Compounds comprising linked heteroaryl moieties and their use as 

novel umami flavor modifiers, tastants and taste enhancers for comestible 

compositions 

(86) PCT/US2006/003956 (87) WO2006/084186 

(51) IPC2011.01:A23L1/231,226; C07D401/12; C07D405/14; C07D403/ 

14; C07D407/14; C07D409/12 

(71) SENOMYX, INC. 

(72) Tachdjian, Catherine; Lebl-Rinnova, Marketa; Wallace, David; 

(31) 05 650029 (32) 4 Feb 2005 (33) US 



(57) Disclosed is a compound of Formula (IA) or a comestibly acceptable 

salt thereof, wherein n', n", hAr1 and hAr2 is defined in the specification. 

Also disclosed is a composition comprising said compound and a method 

for modulating savory taste comprising said compound. 

(21) 560881 (22) 13 Mar 2006 

(54) Throwing and catching apparatus comprising at least one scoop element 

with flexible ribs 

(86) PCT/GB2006/000898 (87) WO2006/100435 

(51) IPC2011.01:A63B59/02 

(71) ROBERT GEORGE ELDRIDGE 

(72) Eldridge, Robert George; 

(31) 05 0505951 (32) 23 Mar 2005 (33) GB 



(57) An apparatus (10) for throwing and catching a ball is disclosed. The 

apparatus (10) comprises an elongate shaft member (11) and at least 

one scoop element (14). The scoop element (14) includes at least one 

flexible member comprising a plurality of flexible ribs that extend perpendicular 

to a longitudinal axis associated with the scoop element (14). 

The resilient feature of ribs allows absorption of energy from the impact 

of a ball so that this energy is not transferred to the ball which could 

otherwise bounce out of the scoop element (14). 

(21) 560914 (22) 7 Apr 2006 

(54) Cellulose solutions in ionic liquids based upon imidazolium cations 

(86) PCT/EP2006/061422 (87) WO2007/057235 

(51) IPC2011.01:C08B1/00; C08L1/02; C07D233/58 

(71) BASF Aktiengesellschaft 

(72) Maase, Matthias; Stegmann, Veit; 

(31) 05 05017715 (32) 15 Apr 2005 (33) DE 



(57) Disclosed is a solution comprising cellulose and an ionic liquid comprising 

anions and cations as solvent, wherein the cations comprise at 

least one atom selected from the group consisting of nitrogen, oxygen, 

sulfur and phosphorus which is present in protonated form, and wherein 

the ionic liquid comprises at least one imidazolium cation of formula (IVe) 

and oligomers comprising this structure, where the radical R is hydrogen; 

and the radicals R1 to R4 are each, independently of one another, 

hydrogen, or unbranched or branched C1-C18 alkyl which is unsubstituted. 



(21) 560964 (22) 10 Apr 2006 

(54) 1H-Quinazoline-2,4-diones and their use as AMPA-receptor ligands 

(86) PCT/EP2006/003251 (87) WO2006/108591 

(51) IPC2011.01:C07D239/96; A61K31/517; A61P25/08,18; C07D207/32; 

C07D231/12; C07D237/08; C07D249/06; C07D307/16,54; C07D309/12; 

C07D401/04; C07D403/04; C07D405/04; C07D413/04 


(72) Allgeier, Hans; Auberson, Yves; Floersheim, Philipp; Guibourdenche, 

Christel; Froestl, Wolfgang; Kallen, Jorg; Mattes, Henri; Nozulak, Joachim; 

Orain, David; Renaud, Johanne; Carcache, David; Koller, Manuel; 

(31) 05 0507298 (32) 11 Apr 2005 (33) GB 



(57) Disclosed are 1H-quinazoline-2,4-diones of formula (I) wherein R1 

represents CF3 or iso-propyl and R2 represents an optionally substituted 

heterocyclyl, such as N-[7-Isopropyl-6-(2-methyl-2H-pyrazol-3-yl)- 

2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methanesulfonamide 

or a salt thereof. Also disclosed is the use of the 

compounds for the treatment of conditions mediated by the AMPA receptor 

such as epilepsy and schizophrenia. 


(21) 560979 (22) 6 Feb 2006 

(54) Selective direction of air in roof space out of or into the building 

(86) PCT/AU2006/000146 (87) WO2006/081630 

(51) IPC2011.01:E04B7/18; E04D13/18,17; F24F7/02 

(71) Terrance Robert Oaten 

(72) Oaten, Terrance Robert; 

(31) 05 900509 (32) 4 Feb 2005 (33) AU 



(57) A roof assembly for a building which includes a roof, a roof space 2 in 

heat exchange relationship with a section 8 of the roof, a chamber 3 

placed on the roof and fans 15 for causing airflow within the roof space 

2. The chamber has one or more first openings 5 that allow airflow from 

within the roof space to outside the building to cool the building, and one 

or more second openings 7 that allow air flow from the roof space 2 to a 

living space of the building. Airflow is controlled by selectively opening 

and closing the first and second openings. 

(21) 561062 (22) 8 Mar 2006 

(54) Rechargeable battery and method for its operation 

(86) PCT/EP2006/002130 (87) WO2006/094785 

(51) IPC2011.01:H02J7/00 

(71) AXEL MUNTERMANN 

(72) Muntermann, Axel; 

(31) 05 05011081 (32) 8 Mar 2005 (33) DE 



(57) A rechargeable battery, a method for operation of a rechargeable 

battery, and a rechargeable battery arrangement, is disclosed. The rechargeable 

battery is provided for operation with an external voltage, 

which is applied at least at times to the output of the rechargeable battery, 

and is below the output voltage of the rechargeable battery when in 

its fully charged state. The rechargeable battery comprises: (a) at least 

one chargeable electrochemical cell; (b) an electrical connection to the 

output of the rechargeable-battery for inputting and/or outputting electrical 

energy; (c) a housing which surrounds the at least one chargeable 

electrochemical cell; and (d) a control circuit for controlling the charging 

process of the rechargeable battery and/or the production of the rechargeable-battery 

voltage at the output of the rechargeable battery. The control 

circuit is adapted to disconnect the rechargeable battery voltage from 

the output of the rechargeable battery at cyclic time intervals in order to 

check whether the external voltage is applied to the output of the rechargeable 

battery. 


(21) 561117 (22) 16 Mar 2006 

(54) Working platform for interior of tower such as wind power tower, with 

scissors carrier structure and overlapping plates 

(86) PCT/EP2006/060785 (87) WO2006/097505 

(51) IPC2011.01:E04G1/36 

(71) Aloys Wobben 

(72) Wobben, Aloys; 

(31) 05 05012497 (32) 16 Mar 2005 (33) DE 



(57) The disclosure relates to a working platform to be used inside a towertype 

building. The aim is to design a working platform, which can be 

used when the top section of the tower is closed by a structure. For this 

purpose, the inventive working platform consists of a bearing structure in 

the form of scissors lattice frame and a platform placed thereon. Said 

bearing structure in the form of scissors lattice frame enables the inventive 

working platform to be adapted to various internal diameters of the 

tower-type building, thereby covering the entire tower cross section. The 

bearing structure in the form of scissors lattice frame also makes it possible 

to release the working platform from the tower wall and to fix it in 

the other part of the tower having the different cross section. 



(21) 561145 (22) 1 Feb 2006 

(54) Pyrazolylaminopyridine derivatives useful as kinase inhibitors 

(86) PCT/GB2006/000334 (87) WO2006/082392 

(51) IPC2011.01:C07D401/14; A61K31/4439; A61P35/00; C07D401/12; 

C07D405/14; C07D409/14; C07D413/14 

(71) ASTRAZENECA AB 

(72) Davies, Audrey; Lamb, Michelle; Lyne, Paul; Mohr, Peter; Wang, Bin; 

Wang, Tao; Yu, Dingwei; 

(31) 05 653329 (32) 16 Feb 2005 (33) US 

(31) 05 721633 (32) 29 Sep 2005 (33) US 

(31) 05 650053 (32) 4 Feb 2005 (33) US 



(57) Disclosed is a compound of formula (I) wherein one of X1, X2, X3 and 

X4 is =N-, the other three are independently selected from =CR8, =CR9and 

=CR10-, A is a direct bond or optionally substituted C1-2alkylene, 

Ring C is carbocyclyl or heterocyclyl, and wherein the rest of the 

substituents are disclosed within the specification. 

Also disclosed is a process for preparing a compound of formula (I). Also 

disclosed is the use of a compound of formula (I) in the manufacture of a 

medicament for use in the inhibition of Trk activity, for the treatment or 

prophylaxis of cancer or for use in the production of an anti-proliferative 

effect. 

(21) 561232 (22) 20 Jun 2006 

(54) An attachment plate of an spinal disc comprising v-shaped self-tapping 

fixing ribs 

(86) PCT/EP2006/005910 (87) WO2006/136373 

(51) IPC2011.01:A61F2/44 

(71) CERVITECH, INC. 

(72) Keller, Arnold; 

(31) 05 05013517 (32) 22 Jun 2005 (33) EP 



(57) An attachment plate forming part of an intervertebral prosthesis that 

includes two attachment plates is disclosed. The attachment plate comprises 

an attachment surface with fixing projections. The attachment 

surface is configured for attachment to an adjacent vertebral body, which 

has a base surface configured to bear on a endplate of the adjacent 

vertebral body. The fixing projections rise from the base surface wherein 

the fixing projections are arranged symmetrically about a medial plane in 

at least two rows with an interspace opening between the rows. The 

rows extend outwardly and obliquely in a V-shape with respect to an 

implantation direction. The fixing projections are configured with a first 

limit surface formed by a lateral-facing side surface, a second limit surface 

formed by a medial-facing side surface, a third limit surface formed 

by a steep ventral-facing surface, and a fourth limit surface formed by an 

inclined dorsal facing surface. The fixing projections are self tapping and 

configured to penetrate into the endplate of the adjacent vertebral body. 

(21) 561237 (22) 24 Mar 2006 

(54) 8-Phenyl-7,8-dihydropyrido[2,3-d]pyrimidin-7-ones and their use as 

pharmaceuticals 

(86) PCT/US2006/010855 (87) WO2006/104915 

(51) IPC2011.01:A61K31/519,5365; C07D471/04; C07D487/04; C07D413/ 

14 

(71) GLAXO GROUP LIMITED 

(72) Boehm, Jeffrey C.; Callahan, James Francis; Cooper, Anthony William 

James; Livia, Stefano; Nevins, Neysa; Wan, Zehong; Norton, Beth A; 

(31) 05 665315 (32) 25 Mar 2005 (33) US 



(57) Disclosed are the compounds: 

3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-4-yI]-5-fluoro-4-methyl-N-(1methylethyl)benzamide;N-cyclopropyl-3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3d]pyrimidin-4-yl]-5-fluoro-4-methylbenzamide, 

and 3-{8-(2,6difluorophenyl)-2-[(1H-imidazol-2-ylmethyl)amino]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-4-yI}-4-methyl-N-1,3-thiazol-2-yIbenzamide. 

Also more generally disclosed are compounds of the pictured formula where 

the substituents are as described in the specification. Also disclosed are 

the use of the compounds in medicaments. 




(21) 561323 (22) 10 Feb 2006 

(54) Acetic acid production methods incorporating at least one metal salt 

as a catalyst stabilizer 

(86) PCT/US2006/004772 (87) WO2006/091397 

(51) IPC2011.01:C07C51/12; C07C53/08 

(71) Celanese International Corporation 

(72) Torrence, G. Paul; 

(31) 05 67265 (32) 24 Feb 2005 (33) US 



(57) A process for the production of acetic acid, by a catalytic carbonylation 

reaction, comprising reacting methanol in a reaction mixture, in the presence 

of carbon monoxide and a rhodium-based catalyst system comprising: 

(i) rhodium in a concentration of at least 300 ppm; 

(ii) a halogen promoter selected from hydrogen iodide and an organic 

iodide; (iii) an iodide salt co-promoter in the form of a soluble salt of alkali 

metal or alkaline earth metal or quaternary ammonium or phosphonium 

salt at a concentration that generates an iodide ion concentration of greater 

than 3 wt.% of the reaction mixture; and (iv) a metal salt stabilizer selected 

from the group consisting of ruthenium salts, tin salts, and mixtures 

thereof; wherein the reaction mixture comprises from 0.1 wt.% to 

14 wt.% water, and wherein the ruthenium salts, tin salts, and mixtures 

thereof are present in the reaction mixture in a molar ratio of combined 

ruthenium and tin to rhodium of from 0.1:1 to 20:1. 

(21) 561327 (22) 7 Feb 2006 

(54) Lighting system having magnetically attached plates 

(86) PCT/GB2006/050030 (87) WO2006/085117 

(51) IPC2011.01:F21V21/35,096; F21V23/06 

(71) COHDA DESIGN LIMITED 

(72) Liddle, Richard; 

(31) 05 0502725 (32) 10 Feb 2005 (33) GB 



(57) Disclosed is a movable lighting element using magnetic plates. The 

lighting element (1) comprises at least one light (3), means for delivering 

electricity to each light (12, 13), a pair of spaced apart plates (2, 2’), at 

least one magnet (4) located between the plates, and biasing means (8) 

for biasing the plates apart. The magnet is attached to a first plate (2) of 

the pair of plates and movable relative to a second (2’) of the pair of 

plates. The first plate is adapted to move towards the second plate against 

a biasing force generated by the biasing means, when a magnet having 

a polarity opposing that of the magnet attached to the first plate is presented 

up to and aligned therewith. 

(21) 561373 (22) 27 Feb 2006 

(54) Composite secondary carpet backing, method of manufacture thereof, 

and carpet made therefrom 

(86) PCT/US2006/006831 (87) WO2006/093861 

(51) IPC2011.01:B32B33/00; D04H1/48; D04H13/00; A47G27/00,02 

(71) PROPEX FABRICS INC 

(72) Gardner, Hugh C; Baker, Thomas L; Moon, Richard C; White, Robert 

J; Haire, James E; Galpin, Charles W.; 

(31) 05 657042 (32) 28 Feb 2005 (33) US 



(57) A carpet 700 consisting of a primary backing 705, face yarn consisting 

of a plurality of filaments tufted through the primary backing, and a 

binder layer 710 adhering a stitched side of the primary backing 705 to a 

secondary backing 300, the secondary backing 300 consisting of a woven 

fabric layer 405 having a flat weave which comprises at least one of 

a plain, satin, and twill weave construction of tape yarns in a warp direction 

interwoven with multifilament yarns in a filling direction, the woven 

fabric layer 405 having an open area of about 15% or less, the multifilament 

yarns having a thickness that is at least three times the thickness of 

warp tapes such that gaps are formed at crossover regions formed by 

the multifilament yarns and warp tapes, and a fibrous layer 510, where 

the fibrous layer 510 weighs between about 0.5 osy (0.169 gsm) and 

about 10 osy (3.39 gsm), and where at least a portion of the fibers 410 

have penetrated through the woven fabric layer 405 and extend outward 

from a side thereof and wherein the secondary backing 300 has an air 

permeability of greater than about 220 cfm/sq ft (67 m3/min/m2). 

(21) 561407 (22) 15 Mar 2006 

(54) Sequestering agent for micronutrient fertilisers 

(86) PCT/AU2006/000334 (87) WO2006/096912 

(51) IPC2011.01:C05G3/00; C05D9/02 

(71) ADELAIDE RESEARCH AND INNOVATION PTY LTD; COMMON- 

WEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION 

(72) McLaughlin, Mike; Stacey, Samuel; Lombi, Enzo; 

(31) 2005 901235 (32) 15 Mar 2005 (33) AU 

(74) COLLISON & CO, 117 King William Street, Adelaide, South Australia 


(57) Disclosed is a method of increasing the uptake of micronutrients by a 

plant which comprises applying to an area of a plant, or soil/substrate 

surrounding the plant, an effective amount of a plant fertiliser composition 

comprising a surfactant for forming coordinate bonds with the 

micronutrients, the surfactant transporting the micronutrients across a 

membrane of the plant and releasing the micronutrients for use by the 

plant wherein the surfactant is a rhamnolipid with the general formula 

(III), wherein the substituents are as defined in the specification. 

(21) 561438 (22) 24 Mar 2006 

(54) Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5d]pyrimidin-2-[1H]-one 

compounds, pharmaceutical compositions, and use 

in the manufacture of medicines 

(86) PCT/US2006/010792 (87) WO2006/104889 



(51) IPC2011.01:C07D475/00; C07D239/47; C07D243/08; C07D413/ 

12,14; A61K31/519,535,55,5513 

(71) Glaxo Group Limited 

(72) Callahan, James Francis; Wan, Zehong; Yan, Hongxing; 

(31) 05 665347 (32) 25 Mar 2005 (33) US 



(57) Disclosed are the following three compounds: 

3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide;3-[8-(2,6-difluorophenyl)-2-(4-methyl-1,4'-bipiperidin-1'-yl)-7-oxo-5,6,7,8tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1methylethyl)benzamide; 

and 3-{8-(2,6-difluorophenyl)-2-[4-(4-methyl-1piperazinyl)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5d]pyrimidin-4-yI}-4-methyl-N-(1-methyl 

ethyl)benzamide, and salts thereof. 

Also more generally disclosed are compound of the pictured formulas, 

where the substituents and variables are as defined in the specification. 

Also disclosed is the use of the above compound to treat CSBP/RK/p38 

kinase mediated diseases such as asthma, adult respiratory distress 

syndrome, chronic pulmonary inflammatory disease, and chronic obstructive 

pulmonary disease (COPD). 


(21) 561541 (22) 15 Mar 2006 

(54) Compositions of ethylene/alpha-olefin multi-block interpolymer suitable 

for films 

(86) PCT/US2006/009408 (87) WO2006/101930 

(51) IPC2011.01:C08F297/08; C08F2/38; C08F4/646 

(71) DOW GLOBAL TECHNOLOGIES INC. 

(72) Cheung, Yunwa Wilson; Demirors, Mehmet; Jain, Pradeep; Fuchs, 

David Winn; Cham, Pak-meng; 

(31) 2005 008917 (32) 17 Mar 2005 (33) US 

(31) 05 718198 (32) 16 Sep 2005 (33) US 



(57) Disclosed is a film (for use a stretchwrap packaging of fresh food for 

example) which comprises at least one ethylene/a-olefin interpolymer 

prepared using a chain shuttling agent in the polymerization, wherein the 

ethylene/a-olefin interpolymer is a multi-block interpolymer comprising 

at least 50 mole percent ethylene, has a polydispersity (Mw/Mn) from 

about 1.7 to about 3.5 and which also has the specific physical characteristics 

as defined herein. 

(21) 561552 (22) 22 Feb 2006 

(54) Low distortion interlayer for multiple layer glass panels 

(86) PCT/US2006/006357 (87) WO2006/091707 

(51) IPC2011.01:B32B17/10; B29D7/01 

(71) Solutia Inc. 

(72) Yacavone, Vincent; 

(31) 05 061778 (32) 22 Feb 2005 (33) US 



(57) A polymer sheet, comprising: poly(vinyl butyral); and, a plasticizer, 

wherein said polymer sheet has a surface with a waviness index of less 

than 20,000 square micrometers, an Rz value of at least 20 micrometers, 

and a permanence of between 10 and 95 percent is disclosed. 

The disclosure also relates to a method of producing a multiple layer 

interlayer, comprising the steps of: forming a first polymer sheet comprising 

poly(vinyl butyral) and a plasticizer, wherein said first polymer 

sheet has a first surface and a second surface and wherein said first 

surface has a waviness index of less than 20,000 square micrometers, 

an Rz value of at least 20 micrometers, and a permanence of between 

10 and 95; disposing a layer of polymer film in contact with said first 

surface of said first polymer sheet to form a stack; and, laminating said 

stack. 

(21) 561649 (22) 28 Mar 2006 

(54) Methods, compositions, and formulations for preventing or reducing 

adverse effects in a patient 

(86) PCT/US2006/011422 (87) WO2006/105167 

(51) IPC2011.01:A61K31/70,7056 

(71) PERICOR THERAPEUTICS, INC. 

(72) Mangano, Dennis T; 

(31) 05 666071 (32) 28 Mar 2005 (33) US 



(57) Disclosed is a use of 5-amino-1-beta-D-(5-benzylamino-5-deoxy-1beta-D-ribofuranosyl)imidazole-4-carboxamide,5-amino-1-(5-amino-5deoxy-beta-D-ribofuranosyl)imidazole-4-N-[(4chlorophenyl)methyl]carboxamide, 

or a salt thereof in the manufacture 

of a medicament for reducing the incidence of mortality in patients in 

need thereof, wherein said patients have decreased left ventricular function 

having an ejection fraction that is less than 30%, the medicament is 

also suitable for treating a patient with decreased left ventricular function 

having an ejection fraction that is less than 30%. 

(21) 561664 (22) 24 Feb 2006 

(54) Trans carotenoids, their synthesis, formulation and uses 

(86) PCT/US2006/006422 (87) WO2006/104610 

(51) IPC2011.01:C07C59/185 

(71) Diffusion Pharmaceuticals LLC 

(72) Gainer John L; Lanz, Marc; 

(31) 05 655422 (32) 24 Feb 2005 (33) US 

(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001, 

Australia 

(57) Disclosed is a pharmaceutical composition comprising: 

(i) a bipolar trans carotenoid salt having the formula: 

YZ-TCRO-ZY 

where: 

Y = a cation which can be the same or different, Z = a polar group which 

can be the same or different and which is associated with the cation, and 

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon 

double bonds and single bonds, and having pendant groups X, 

wherein the pendant groups X, which can be the same or different, are a 

linear or branched hydrocarbon group having 10 or less carbon atoms, 

or a halogen, and (ii) a cyclodextrin.These compositions are useful in 

improving diffusivity of oxygen between red blood cells and body tissues 

in mammals including humans, and are suitable for the treatment of cancer 

selected from the group consisting of glioblastomas, squamous cell 

carcinomas, melanomas, lymphomas, sarcomas, sarcoids, osteosarcomas, 

skin cancer, breast cancer, head and neck cancer, gynecological 

cancer, urological and male genital cancer, bladder cancer, prostate cancer, 

bone cancer, cancers of the endocrine glands, cancers of the alimentary 

canal, cancers of the major digestive glands/organs, CNS cancer, 

and lung cancer. 

(21) 561677 (22) 3 Apr 2006 

(54) (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8yl)ethyl]propionamide, 

and its use for treating depression and anxiety neurosis 

(86) PCT/JP2006/307047 (87) WO2006/107019 

(51) IPC2011.01:C07D307/77; A61K31/343; A61K45/00; A61P25/ 

20,22,24,28; A61P43/00 

(71) Takeda Pharmaceutical Company Limited 

(72) Hirai, Keisuke; Miyamoto, Masaomi; 

(31) 2005 107674 (32) 4 Apr 2005(33) JP 



(57) Disclosed is a pharmaceutical composition for prevention or treatment 

of depression or anxiety disorders, which comprises synergistically 

effective amounts of (S)-N-[2-(1, 6,7, 8-tetrahydro-2H-indeno[5, 4-b] furan- 



8-yl)ethyl]propionarnide in combination with one or more drugs selected 

from other antidepressants and antianxiety drugs, consisting of SSRI 

and benzodiazepine antianxiety drugs, such as Fluoxetine, Sertraline, 

Paroxetine, Diazepam, Alprazolam and Oxazolam. 

(21) 561843 (22) 27 Apr 2005 

(54) Adding a production additive to an aqueous dispersion of calcined 

gypsum with the ratio of viscosity between the two is between 10:1 to 2:1 

(86) PCT/US2005/014504 (87) WO2006/115497 

(51) IPC2011.01:C04B11/00 


(72) Wittbold, James R; Song, W David; 



(57) Disclosed is a method of introducing a production additive to a postmixer 

aqueous dispersion of calcined gypsum. The method comprises 

the steps of: forming an aqueous dispersion of calcined gypsum in a 

mixer chamber; discharging the aqueous dispersion into a discharge 

apparatus; introducing the production additive into the aqueous dispersion 

within the discharge apparatus. The ratio of the viscosity of the production 

additive to the aqueous dispersion is between about 10:1 to about 

2:1. 

(21) 561849 (22) 29 Mar 2006 

(54) A manual vascular compression device with a rigid convex bottom 

pad 

(86) PCT/US2006/011395 (87) WO2006/105153 

(51) IPC2011.01:A61B17/00,08; A61D1/00; A61B17/03 

(71) MARINE POLYMER TECHNOLOGIES, INC. 

(72) Finkielsztein, Sergio; Finkielsztein, Marco; Vournakis, John N; 

(31) 05 92369 (32) 29 Mar 2005 (33) US 



(57) A vascular compression apparatus for applying pressure to tissue in 

proximity to a puncture site and a blood vessel, comprises a handle 14, 

a shaft 12 extending generally perpendicularly from the handle 14, and a 

rigid pad 11 having a top side 19 and a convex bottom side 18, which 

makes contact with the body surface. The device is configured to allow 

the user to rock the convex pad 11 proximally and distally. 

(21) 562130 (22) 7 Mar 2006 

(54) Optical phase conjugation laser diode with retro-reflecting elements 

(86) PCT/US2006/007817 (87) WO2007/027196 

(51) IPC2011.01:H01S3/13 

(71) OPC Laser Systems L.L.P. 

(72) Henrichs, Joseph Reid; 

(31) 05 74342 (32) 7 Mar 2005 (33) US 



(57) Disclosed is an optical phase conjugating laser diode. The diode includes 

a first reflector (168), a second reflector (165), and a gain-medium 

(160, 161, 162) sandwiched between the first and second reflectors. 

The second reflector is used to provide for a partial reflection and 

laser-emission output, and the gain medium is used to provide for a stimulated-emission 

and amplification. The first reflector comprises a phase- 

conjugating array, the array comprising a plurality of retro-reflecting elements. 

The first reflector is used to provide for an optical phase conjugation. 

(21) 562226 (22) 13 Mar 2006 

(54) Broadband land mobile antenna 

(86) PCT/IL2006/000324 (87) WO2006/097919 

(51) IPC2011.01:H04B1/02 

(71) Galtronics Ltd. 

(72) Babitsky, Gennady; Martiskainen, Matti; 

(31) 05 661795 (32) 14 Mar 2005 (33) US 

(74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market 

Street, Sydney, New South Wales 2000, Australia 

(57) Disclosed is a monopole antenna. The antenna includes a helical 

radiating element (126) including a first longitudinal portion having a first 

winding pitch (128) and a second longitudinal portion having a second 

winding pitch (130). The antenna also includes a cylindrical radiating 

element (134) generally coaxial with the helical radiating element and 

extending along at least most of the first longitudinal portion. 

(21) 562237 (22) 5 Oct 2007 (23) 6 Oct 2008 

(54) Proliferation signature and prognosis for gastrointestinal cancer 

(51) IPC2011.01:C12Q1/68 

(71) PACIFIC EDGE BIOTECHNOLOGY LTD 

(72) Anjomshoaa, Ahmad; Reeve, Anthony Edmund; Lin, Yu-Hsin; Black, 

Michael A; 



(57) Provided is a method of predicting the likelihood of long-term survival 

of a gastrointestinal cancer patient without the recurrence of 

gastrointestinal cancer, comprising determining the expression level of 

one or more prognostic RNA transcripts or their expression products in a 

gastrointestinal sample obtained from the patient, normalized against 

the expression level of all RNA transcripts or their products in the 

gastrointestinal cancer tissue sample, or of a reference set of RNA transcripts 

or their expression products; wherein the prognostic RNA transcript 

or expression product comprises the transcript of replication factor 

(activator 1) 4 (RFC4); and establishing likelihood of long-term survival 

without gastrointestinal cancer recurrence wherein increased expression 

of the one or more prognostic RNA transcripts or their expression products 

indicates an increased likelihood of long-term survival without 

gastrointestinal cancer recurrence. 




(21) 562254 (22) 8 Mar 2006 

(54) Exterior sheathing weather barrier construction and method of manufacture 

(86) PCT/IB2006/002341 (87) WO2007/004066 

(51) IPC2011.01:E04C2/04; B28B19/00 

(71) BPB Limited 

(72) Hauber, Robert J; Hennis, Mark E; Fahey, Michael P; Boydston, Gerald 

D; 

(31) 05 78518 (32) 11 Mar 2005 (33) US 



(57) A gypsum board panel comprises two facing main surfaces, at least 

one machine edge surface 295 with three dimensional features, at least 

one bull edge surface, and an outer gypsum layer 295 to which a polymer 

additive has been added. An adhesive material 385 which can form 

chemical cross-linking, co-polymer bonds with said polymer additive with 

the polymer additive in the outer gypsum layer is disposed on the machine 

edge surface. 

(21) 562363 (22) 18 Apr 2006 

(54) Process for the production of animal feed and ethanol and novel animal 

feed 

(86) PCT/US2006/014505 (87) WO2006/113683 

(51) IPC2011.01:A23K1/00; A23K3/00; B02B5/00; C12P7/06,08 

(71) ARCHER-DANIELS-MIDLAND COMPANY 

(72) Abbas, Charles; Binder, Thomas P; Beery, Kyle E; Cecava, Michael 

J; Holzgraefe, David P; Solheim, Leif P; Doane, Perry H; 

(31) 05 672779 (32) 19 Apr 2005 (33) US 



(57) Disclosed herein is a method for the production of ethanol and a 

modified animal feed. The method replaces the starch in known cornbased 

animal feed with biomass fiber treated to make it more digestible 

by animals. The process involves removing the pericarp from corn kernels 

to obtain a pericarp enriched fraction; contacting at least one of the 

pericarp enriched fraction and a lignocellulosic by-product of agricultural 

processing with a fiber hydrolyzing agent to at least partially hydrolyze 

lignocellulosic fibres and obtain a treated fiber fraction; removing the 

germ from said corn kernels, resulting in a starch and a protein; separating 

said protein from said starch; liquefying and saccharifying and fermenting 

said starch to produce a fermented starch broth; recovering 

ethanol and distillers dried grains from the fermented starch broth; and 

combining the treated fiber fraction with the distillers dried grains to form 

a modified distiller’s dried grain product. The modified animal feed may 

optionally include energy materials such as animal and vegetable fats, 

vegetable soapstocks, or glycerin, and combinations thereof. 

(21) 562409 (22) 10 May 2006 

(54) Use of barusiban in assisted reproduction 

(86) PCT/PL2006/000029 (87) WO2006/121362 

(51) IPC2011.01:A61K31/404,4025,4439,452,4545,4709,495,501,5513; 

A61K38/12; A61K45/06; A61P15/06 

(71) Ferring International Center SA. 

(72) Kuczynski, Waldemar; Pierzynski, Piotr; 

(31) 05 374954 (32) 10 May 2005 (33) PL 

(31) 05 376607 (32) 12 Aug 2005 (33) PL 

(31) 05 733916 (32) 4 Nov 2005 (33) US 



(57) Disclosed is the use of barusiban for the manufacture of a medicament 

for an improved uterine receptivity in assisted reproduction. 

(21) 562456 (22) 31 May 2006 

(54) Method of producing haploid and doubled haploid plant embryos 

(86) PCT/EP2006/005238 (87) WO2006/128707 

(51) IPC2011.01:A01H1/02; A01H5/00; A01H1/08; A01H5/10 

(71) Rijk Zwaan Zaadteelt en Zaadhandel B.V. 

(72) Dirks, Robert Helene Ghislain; Angenent, Gerrit Cornelis; Lelivelt, 

Cecilia Lucia Clara; Custers, Johannes Bernardus Maria; 

(31) 05 05076264 (32) 31 May 2005 (33) EP 



(57) Provided is a method for producing haploid plant embryos, comprising 

the steps of: a) providing microspores or pollen that are transformed 

with a nucleic acid to comprise cell division inducing molecules; b) pollinating 

an embryo sac cell, of the plant of which the haploid embryo is to 

be made with the transformed microspores or pollen; c) allowing the transformed 

microspores or pollen to discharge the cell division inducing molecules 

in or in the vicinity of the embryo sac cell, to trigger division thereof 

to obtain a haploid plant embryo. Doubled haploid plants can also be 

produced by a similar method. 

(21) 562535 (22) 15 Mar 2006 

(54) Thermal conduction during alkaline extraction 

(86) PCT/EP2006/002344 (87) WO2006/108481 

(51) IPC2011.01:C13D1/08; A23F3/18; A23F5/26; C13D1/02 

(71) Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt 

(72) Arnold, Jochen; Frenzel, Stefan; Michelberger, Thomas; 

(31) 05 05017446 (32) 15 Apr 2005 (33) DE 



(57) Disclosed is a process for extracting biological material, selected from 

sugar beet, chicory and sugar can from sugar beet cossettes or sugar 

beets in an extraction system, wherein the temperature of the biological 

material in the extraction system is increased throughout the course of 

the extraction from material feed to material discharge. 

(21) 562592 (22) 27 Apr 2006 

(54) Long-chain quaternary ammonium compounds as wood treatment 

agents 

(86) PCT/US2006/016134 (87) WO2006/118980 

(51) IPC2011.01:B27K3/15; B32B21/04; B32B23/04,06 

(71) Viance, LLC 

(72) Jin, Lehong; Preston, Alan F; Archer, Kevin J; Cui, Futong; Zahora, 

Andrew R; Walcheski, Paul J; 

(31) 05 121632 (32) 4 May 2005 (33) US 



(57) Disclosed is a composition comprising a wood preservative agent 

and a long-chain quaternary ammonium compound of formula (I), wherein 

R3 and R4 of the compound of formula (I) are long chain alkyl moieties 

having from 16-50 carbon atoms, unsubstituted or substituted with one 

or more N, O, S, or a halogen atoms. Also disclosed is a method of 

treating wood, comprising impregnating wood with the said composition. 



(21) 562595 (22) 27 Apr 2006 

(54) Substituted amide derivatives as protein kinase inhibitors 

(86) PCT/US2006/016344 (87) WO2006/116713 

(51) IPC2011.01:C07D401/14; A61K31/435,495; A61P35/00; C07D401/ 

12; C07D403/12; C07D405/14; C07D409/14; C07D413/12,14; C07D417/ 

14; C07D487/04; C07D495/04 

(71) AMGEN INC. 

(72) Kim, Tae-Seong; Bauer, David; Bellon, Steven; Boezio, Alessandro; 

Booker, Shon; Choquette, Deborah; D’Amico, Derin C; D’Angelo, Noel; 

Dominguez, Celia; Fellows, Ingrid M; Germain, Julie; Graceffa, Russell; 

Harmange, Jean-Christophe; Hirai, Satoko; La, Daniel; Lee, Matthew; 

Norman, Mark H; Potashman, Michele; Roveto, Philip; Siegmund, Aaron 

C; Xi, Ning; Yang, Kevin; Liu, Longbin; 

(31) 05 675805 (32) 27 Apr 2005 (33) US 



(57) Disclosed are substituted amide derivatives as protein kinase inhibitors 

and which are effective for prophylaxis and treatment of diseases, 

such as HGF mediated diseases. The disclosure encompasses compounds, 

analogs, enantiomer, diastereomer, solvate, N-oxide thereof and 

pharmaceutically acceptable salts thereof, pharmaceutical compositions 

and methods for prophylaxis and treatment of diseases and other maladies 

or conditions involving, cancer and the like. The disclosure also 

relates to processes for making such compounds as well as to intermediates 

useful in such processes. These compounds may be represented 

by formula (II), wherein the variables are as defined in the specification. 

(21) 562623 (22) 28 Apr 2006 

(54) Method to transform bulk material 

(86) PCT/US2006/016319 (87) WO2006/119044 

(51) IPC2011.01:B02C19/00 

(71) GTL Energy Ltd. 

(72) French, Robert R; Reeves, Robert A; 

(31) 05 676621 (32) 29 Apr 2005 (33) US 



(57) Disclosed is a method of removing void spaces and vapors present in 

carbonaceous materials including the steps of: 

Comminuting a carbonaceous material to form a crushed material of reduced 

particle size; 

Compacting the crushed material in a counter-rotating roll compaction 

machine produce a compact; Separating vapors from the compact to 

form a dried carbonaceous product. 


(21) 562777 (22) 3 May 2006 

(54) A float with a damping means and keel 

(86) PCT/IE2006/000044 (87) WO2006/117767 

(51) IPC2011.01:A01K61/00; B63B22/16,18 

(71) Rodicon Limited; John Francis Concannon 

(72) Concannon, John Francis; 

(31) 05 0273 (32) 4 May 2005 (33) IE 

(31) 06 0215 (32) 20 Mar 2006 (33) IE 



(57) A float 1 comprises a hollow shell 5 having a front end 19 and a rear 

end 20, the hollow shell defining an airtight hollow interior region and a 

first major horizontal plane 8 that in use extends through the hollow shell 

5 at its maximum horizontal cross-sectional area, a damping projection 

12 extending completely around and laterally outwardly from the hollow 

shell 5 that dampens the buoyant movement of the hollow shell 5 in 

water in a generally vertical direction with the damping projection 12 

defining a second plane 14 parallel to the first major plane 8 defined by 

the hollow shell, and a keel 18 extending downwardly from the hollow 

shell 5 that minimises the rolling movement of the hollow shell 5. The 

keel 18 extends along the hollow shell 5 and terminates at the damping 

projection 12 adjacent to the front and rear ends of the hollow shell 5, 

and defines a corresponding keel plane 9 that extends perpendicularly 

to the second horizontal plane 14 defined by the damping projection 12. 


(21) 562967 (22) 9 May 2006 

(54) Breath actuated drug delivery system with nasal delivery 

(86) PCT/US2006/018252 (87) WO2007/001650 

(51) IPC2011.01:A61M15/00 

(71) KOS LIFE SCIENCES, INC. 

(72) Williams, Robert; Ruckdeschel, Thomas; Khare, Matthew; Deaton, 

Daniel; 

(31) 05 160493 (32) 27 Jun 2005 (33) US 



(57) A nasal drug delivery system comprises a container 110 containing a 

substance to be delivered into the nasal passages of a user, a nasal 

shaft 108 extending from the drug delivery system for placement in or 

around the nose of user and in fluid communication with a valve of the 

container, the valve comprising a vertical lumen 132 and an angled lumen 

134, an oral shaft 106 extending from the drug delivery system for 

placement in the mouth of a user, and a pressure activated diaphragm 

120 trigger means. Upon application of pressure to the oral shaft the 

diaphragm trigger means releases a predetermined amount of the substance 

from the container 110 to the nasal shaft 108. The pressure activated 

diaphragm trigger means comprises a follower assembly 114, a 

follower 116, and a cam 118. 



(21) 562968 (22) 7 Apr 2006 

(54) Breath actuated nasal drug delivery system 

(86) PCT/US2006/012949 (87) WO2007/001585 

(51) IPC2011.01:A61M15/00 

(71) KOS LIFE SCIENCES, INC. 

(72) Williams, Robert; Ruckdeschel, Thomas; Khare, Matthew; Deaton, 

Daniel; 

(31) 05 160493 (32) 27 Jun 2005 (33) US 



(57) A nasal drug delivery system comprises a container containing a substance 

to be delivered into the nasal passages of a user, a nasal shaft 

extending from the drug delivery system for placement in or around the 

nose of user and in fluid communication with a valve of the container, the 

valve comprising a vertical lumen 132 and an angled lumen 134, an oral 

shaft extending from the drug delivery system for placement in the mouth 

of a user, and a pressure activated diaphragm trigger means. Upon application 

of pressure to the oral shaft the diaphragm trigger means releases 

a predetermined amount of the substance from the container to 

the nasal shaft . 

(21) 562969 (22) 13 Jun 2006 

(54) Modifiers for gypsum slurries and method of using them 

(86) PCT/US2006/022936 (87) WO2006/138277 

(51) IPC2011.01:C04B28/14; B32B1/04; C04B11/00 


(72) Lettkeman, Dennis M; Shake, Michael P; Liu, Qingxia; Wilson, John 

W; Randall, Brian; Blackburn, David R; 

(31) 05 152317 (32) 14 Jun 2005 (33) US 

(31) 06 450068 (32) 9 Jun 2006 (33) US 



(57) Disclosed herein is a gypsum slurry that includes water, calcium sulphate 

hemihydrate, a polycarboxylate dispersant and a modifier which is 

a phosphonate. The modifier is chemically configured to improve the 

efficacy of the polycarboxylate dispersant. 

(21) 563047 (22) 5 Apr 2006 

(54) Modal interval processor 

(86) PCT/US2006/012547 (87) WO2006/107996 

(51) IPC2011.01:G06F7/38 

(71) Sunfish Studio, Inc. 

(72) Hayes, Nathan T; 

(31) 05 668539 (32) 5 Apr 2005(33) US 

(31) 05 722107 (32) 30 Sep 2005 (33) US 

(31) 05 722103 (32) 30 Sep 2005 (33) US 

(31) 05 723216 (32) 3 Oct 2005 (33) US 

(31) 05 723059 (32) 3 Oct 2005 (33) US 

(31) 05 723249 (32) 3 Oct 2005 (33) US 



(57) A logic circuit for computing first and second modal interval (MI) result 

values is disclosed. The values are of at least first and second different 

MI functions responsive to respectively, first and second values of a selector 

signal. The computing is based on at least one MI operand value 

encoded in an operand signal. Each MI value comprises first and second 

multi-bit set theoretical numbers (STN) and the STNs define first and 

second end points of a range of real numbers. The logic circuit further 

encodes one of the universal and existential quantification values. 

The logic circuit includes at least first and second arithmetic functional 

units (AFUs) each connected to receive the operand signal. The AFUs 

perform an arithmetic operation using as the arguments therefor, each 

MI operand value encoded in the operand signal, and respectively provide 

the first and second MI result values in first and second result signals. 

The logic circuit also includes a multiplexer having a selector input 

receiving the selector signal having a multibit output port for providing an 

output signal encoding a MI result value, and having at least first and 

second multi-bit input ports. The first and second input ports are connected 

to receive respectively the first and second result signals provided 

as the operand signals by the first and second AFUs, and each 

input port is associated with a single selector signal value. The multiplexer 

supplies, encoded in an output signal provided by the output port, 

the MI result value provided at the input port thereof associated with the 

current selector signal value. The logic circuit also includes a result register 

for storing each MI result value, connected to receive the values 

respectively provided by the multiplexer output port. 


(21) 563073 (22) 2 May 2006 

(54) Interactive large scale touch surface system 

(86) PCT/CA2006/000706 (87) WO2006/116869 

(51) IPC2011.01:G06F3/01,041,042,048 

(71) SMART TECHNOLOGIES INC 

(72) Hill, Douglas; Beckie, Niel; Van Ieperen, Taco; Vdovine, Serguei; 

Sirotich, Roberto; Fletcher, Mark; Tallman, Scott; Williams, Marilyn; Bill, 

Shane Edward; Goodman, Shannon Patricia; 

(31) 05 118626 (32) 2 May 2005 (33) US 



(57) A method of facilitating user interaction with an image displayed on a 

touch surface of a large scale touch system is disclosed. 

Images of the touch surface are captured with sets of camera devices 

positioned in series along the length of the touch surface. Each set of 

camera devices comprises at least two laterally spaced camera devices 

having overlapping fields of view oriented to look generally across the 

touch surface. The captured images are processed to detect user interaction 

with the touch surface. 

A scaled version of at least a portion of the displayed image is displayed 

on the touch surface at a user accessible location in response to an 

associated input gesture made at an arbitrary location on the touch surface. 

The scaled version is displayed adjacent the location of the input 

gesture. Coordinates of the displayed scaled version to the corresponding 

coordinate portion of the displayed image are mapped so that user 

interactions with the displayed scaled version are translated to interactions 

with the displayed image. 



A writing input region can be further displayed on the touch surface adjacent 

a user accessible location in response to an associated input gesture 

made at an arbitrary location on the touch surface. 

The writing input into the writing input region via pointer interaction with 

the touch surface is detected and the detected writing input is displayed 

as text in a text display region on the touch surface at a location spaced 

from the writing input region. The position of at least one of the writing 

input region and the text display region on the touch surface is changed 

in response to user interaction with the touch surface. 

At least one portion of the displayed image can be reproduced on the 

touch surface at a user accessible location in response to an associated 

input gesture made at an arbitrary location on the touch surface and 

coordinates of the reproduced portion to the corresponding coordinate 

portion of the displayed image are mapped so that user interactions with 

the reproduced portion are translated to interactions with the corresponding 

portion of the displayed image. 

(21) 563119 (22) 4 Apr 2006 

(54) Self expanding flexible stent comprising a helical strut member and 

multiple helical elements 

(86) PCT/US2006/012579 (87) WO2006/108010 

(51) IPC2011.01:A61F2/06,90,82 

(71) Flexible Stenting Solutions, Inc. 

(72) Burpee, Janet; Beach, Bradley; 

(31) 05 667613 (32) 4 Apr 2005(33) US 

(31) 05 250226 (32) 14 Oct 2005 (33) US 

(31) 04 397987 (32) 4 Apr 2006(33) US 

(74) FISHER ADAMS KELLY, Level 29, 12 Creek Street, Brisbane, Queensland 


(57) A self expanding flexible stent 10 comprises a helical strut member 

12 helically wound about an axis of the stent 10, the helical strut member 

12 comprising several helical strut elements 12, and several helical 

elements 16 helically wound about the axis of the stent 10 in the same 

direction of the helical strut member 12 with the helical elements 16 

extending between and interconnecting points on subsequent windings 

of the helical strut member 12 , where the helical elements 16 are elongated 

elements 16 both in the compressed state and deployed state. 

The distance between at least some adjacent helical elements 16 in the 

compressed state varies along the length of the adjacent helical elements 

16 and is in a range from zero and about the maximum distance 

between adjacent helical elements 16 in the deployed state. The stent 

10 in the compressed state is longer than in the deployed state, and in 

the deployed state the elongated elements 16 are substantially parallel 

and the helical strut member 12 and the helical strut elements 16 define 

a cylinder having a constant diameter. 


(21) 563123 (22) 2 May 2006 

(54) Acrylate and methacrylate-based sdhesive formulations for metal 

bonding applications 

(86) PCT/US2006/017290 (87) WO2006/119469 

(51) IPC2011.01:C09J4/00 


(72) Wang, Xiaobin; Doe, Daniel K; Savory, Patricia M; Lambert, Kenneth 

A; 

(31) 05 120789 (32) 3 May 2005 (33) US 



(57) Disclosed is an adhesive formulation, including: an activator part comprising 

an initiator; and an adhesive part comprising: 

an acrylate monomer or a methacrylate monomer, or a combination 

thereof;and a chelating agent solution wherein at least a portion of a 

solvent of the chelating solution is water, the chelating agent solution 

comprising at least 1 percent by weight of the adhesive part; and 

a combination of at least two toughening agents, wherein the combination 

comprises: at least one toughening agent having a glass transition 

temperature of at least one domain in the range of -25 Deg C to -50 Deg 

C (-13 Deg F to -58 Deg F); and at least one other toughening agent 

having a glass transition temperature of at least one domain lower than - 

50 Deg C (-58 Deg F). 


(21) 563202 (22) 13 Jul 2006 

(54) Thiophene compounds and thrombopoietin receptor activators 

(86) PCT/JP2006/314317 (87) WO2007/010954 

(51) IPC2011.01:C07D333/32; C07D409/12 

(71) Nissan Chemical Industries, Ltd. 

(72) Miyaji, Katsuaki; Yanagihara, Kazufumi; Shigeta, Yukihiro; Iwamoto, 

Shunsuke; Horikawa, Masato; Owada, Shingo; Nakano, Satoshi; Ota, 

Hirofumi; Ishiwata, Norihisa; Hirokawa, Yukata; 

(31) 05 206822 (32) 15 Jul 2005 (33) JP 

(31) 05 206823 (32) 15 Jul 2005 (33) JP 

(31) 06 083770 (32) 24 Mar 2006 (33) JP 

(31) 06 083771 (32) 24 Mar 2006 (33) JP 

(31) 06 115569 (32) 19 Apr 2006 (33) JP 



(57) A 3-hydroxythiophene-3-yl hydrazide represented by the formula (I): 

wherein R1 is a phenyl group. R2 is a hydrogen atom or an alkyl group, 

R3 is a phenyl group, a pyridyl group or a thienyl group and R4 is a 

hydrogen atom or an alkyl group, a tautomer, prodrug or pharmaceutically 

acceptable salt of the compound or a solvate thereof. Also disclosed is 

the use of said hydrazide for increasing platelets. 



(21) 563252 (22) 14 Apr 2006 

(54) Containment pen comprising panels having mesh material between 

struts 

(86) PCT/US2006/014404 (87) WO2006/113619 

(51) IPC2011.01:A01K63/00 

(71) OCEAN FARM TECHNOLOGIES INC. 

(72) Cartwright, Paul; Page, Stephen H; 

(31) 05 671861 (32) 14 Apr 2005 (33) US 



(57) Disclosed is a finfish aquaculture containment pen (10) in a polyhedral 

structure. The pen comprises: a plurality of panels (12) that when 

joined together form the majority of the exterior surface of the containment 

pen; a plurality of compression-bearing struts extending along the 

boundaries between panels; and a plurality of hubs at which some of the 

struts and the comers of some of the panels abut each other. The panels 

each comprise tension-bearing mesh material forming the exterior surface 

of the containment pen, and the mesh material is attached to the 

struts along the lengths of the struts. 

(21) 563267 (22) 26 Apr 2006 

(54) Vacuum vessel for treatment of oils 

(86) PCT/SE2006/000502 (87) WO2006/118517 

(51) IPC2011.01:C11B3/14; B01D3/34; C11B3/16 

(71) ALFA LAVAL CORPORATE AB 

(72) Gullov-Rasmussen, Bjarne; 

(31) 05 0501008 (32) 29 Apr 2005 (33) SE 


(57) A vacuum vessel for continuous or semi-continuous treatment of oils 

in connection with deodorization comprises spaces 12 through which oil 

to be treated is brought to pass and means to heat or cool the oil in the 

form of U-tubes. There are perforated pipes 26 arranged at the bottom of 

the spaces to lead stripping gas into the oil. The vessel has a connection 

to a vacuum source (7). The spaces in the vessel are arranged such that 

the oil to be treated in the vessel flows through the same by gravity. The 

heating or cooling medium passing the U-tubes is arranged to be pumped 

there through. The U-tubes for heating or cooling medium are arranged 

in such a way in the spaces that the flow of oil is counter-current to the 

flow of heating or cooling medium all through the vessel and a number of 

U-tubes are arranged in groups, parallel and in rows above each other in 

the spaces. 

(21) 563315 (22) 2 May 2006 

(54) A device that can be used for bracing the pelvic region of a patient 

(86) PCT/AU2006/000573 (87) WO2006/116811 

(51) IPC2011.01:A61F5/01; A61G1/013,044 

(71) Martin Richardson 

(72) Richardson, Martin; 

(31) 05 902215 (32) 2 May 2005 (33) AU 



(57) A device that can be used for bracing the pelvic region of a patient is 

disclosed. The device includes a plurality of bracing elements. One or 

more of the bracing elements include first and second straps and an 

attachment means. The first strap is detachably connected to the second 

strap at a first point of interconnection. The interconnection can be 

moved along the second strap so that the combined length of the first 

and second straps can be altered. This alteration allows adjustment of 

the length of the bracing element that can be wrapped at least in part 

around or about the pelvic region of a patient. The attachment means, in 

use, can detachably interconnect the second strap directly or indirectly 

to the first strap so that the bracing element forms a closed loop that can 

at least partially be wrapped around or about the patient. The attachment 

means detachably interconnects the first and second straps at a second 

point of interconnection. The second interconnection can be moved along 

the first strap to further adjust the length of the bracing element can be 

wrapped at least in part around the pelvic region of a patient. 

(21) 563332 (22) 22 May 2006 

(54) Wall assembly using corrugated panels snapped in place to a supporting 

rail on the floor or ceiling by a plug 

(86) PCT/AU2006/000674 (87) WO2006/122375 

(51) IPC2011.01:E04B1/66; E04B2/72; E04F19/00 

(71) Steel Storage Holdings Pty Ltd 

(72) Perrin, Jonathon Gilbert Francis; Ryan, Gerard Michael; 

(31) 05 902629 (32) 20 May 2005 (33) AU 

(74) WYNNES - PATENT AND TRADE MARK ATTORNEYS, Level 3, 

Waterfront Place, 1 Eagle Street, Brisbane, QLD 4121, Australia 

(57) A securing cap (43) used in the wall (40) of a building is disclosed. 

The cap (43) fills the gap in a single space formed between two adjacent 

corrugations (44) in the wall (40) and a floor or ceiling mounting (42). The 

cap (43) has a cover portion and one or more legs extending downwardly 

from the cover portion. The cap also has one or more protrusions to 

engage with the corrugated wall (40) and the floor or ceiling mounting 

(42). The protrusions snap fit into openings in the wall (40) and engage a 

lip on the floor or ceiling mounting (42) to enclose the single space and 

facilitate fixing of the wall (40) to the floor or ceiling mounting (42). 



(21) 563361 (22) 31 May 2006 

(54) HCV protease inhibitors in combination with food 

(86) PCT/US2006/021115 (87) WO2006/130686 

(51) IPC2011.01:C07K5/08; A61K31/40; A61P31/12 

(71) Schering Corporation 

(72) Zhang, Jenny; Gupta, Samir K; 

(31) 05 686925 (32) 2 Jun 2005 (33) US 



(57) Disclosed herein is the use of compounds which are useful for treating 

a wide variety of diseases or disorders associated with hepatitis C 

virus ("HCV") by inhibiting HCV protease (ie HCV NS3/NS41 serine protease). 

The compounds are administered concurrently with the consumption 

of food, or up to 90 minutes after the consumption of food, or 

up to 30 minutes before the consumption of food to enhance absorption 

of the compounds in the gastrointestinal tract and increase the 

bioavailability of the compounds. 

(21) 563365 (22) 31 May 2006 

(54) Combination of HCV protease inhibitors with a surfactant 

(86) PCT/US2006/021003 (87) WO2006/130628 

(51) IPC2011.01:A61K31/454; A61K38/05,06; A61P31/14 

(71) Schering Corporation 

(72) Malcolm, Bruce A; Bradley, Prudence K; Pavlovsky, Anastasia; Cho, 

Wing-Kee Philip; Qiu, Zhihui; 

(31) 05 686945 (32) 2 Jun 2005 (33) US 



(57) Disclosed is a formulation for treating HCV infection comprising sodium 

lauryl sulphate and a compound of formula Ia, 1b, or IC. The said 

formulation is in the form of a capsule, a tablet, a gel, a suppository, a 

powder or a fluid. The use of the said formulation for the manufacture of 

a medicament for the treatment of HCV infection is also disclosed. 

(21) 563416 (22) 18 May 2006 

(54) Electrostatic separation of mineral products with foreign particles being 

triboelectrically charged 

(86) PCT/EP2006/062425 (87) WO2006/122967 

(51) IPC2011.01:B03C7/00; B02C23/08; B03C3/15 

(71) OMYA GMBH 

(72) Mangelberger, Thomas; Tavakkoli, Bahman; 

(31) 05 05023950 (32) 20 May 2005 (33) DE 



(57) A method for manufacturing dispersed mineral products by grinding 

the mineral raw material, sizing the same in a flow classifier, sorting the 

same in dispersion in air, and eliminating the dispersion air. The method 

includes triboelectrically charging the dispersed mineral particles of the 

particle-air dispersion during the sizing process and directing the charged 

particles through an electrostatic separation chamber in order to separate 

the foreign particles from the valuable particles. 

(21) 563446 (22) 2 Jun 2006 

(54) Combination of pyrimidylaminobenzamide compounds and imatinib 

for treating or preventing proliferative diseases 

(86) PCT/US2006/021307 (87) WO2006/132930 

(51) IPC2011.01:A61K31/506; A61P35/00 


(72) Alland, Leila; Manley, Paul W; Mestan, Juergen; 

(31) 05 687758 (32) 3 Jun 2005 (33) US 





(57) Disclosed is the use of a combination of 4-Methyl-3-[[4-(3-pyridinyl)- 

2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3- 

(trifluoromethyl)phenyl] benzamide, or a pharmaceutically acceptable salts 

thereof, of the formula (II); and imatinib for the formula (III) or 

pharmaceutically acceptable salts thereof, for the preparation of a medicament 

for the treatment of gastrointestinal stromal tumours. 

(21) 563455 (22) 16 May 2006 

(54) Post-transcriptional regulation of gene expression in plants using a 

destablising sequence selected from a 3’SAUR terminator, a DST element, 

an ATTTA motif, an ATTTAA motif or a combination of ATTTA and 

ATTTAA motifs 

(86) PCT/US2006/018736 (87) WO2006/124777 

(51) IPC2011.01:C12N15/82 

(71) MONSANTO TECHNOLOGY LLC 

(72) Thai, Kwan Y; Wang, Qi; Dabrowski, John P; Ulmasov, Tim N; House, 

Ida M; 

(31) 05 682471 (32) 19 May 2005 (33) US 



(57) Disclosed is a method to post-transcriptionally decrease message 

stability of an exogenous gene of interest in a seed of a crop plant. The 

method comprises expressing said exogenous gene in a seed tissue, 

wherein said gene comprises a destabilising sequence in the 3’ 

untranslated region, whereby message stability of said gene of interest 

is post-transcriptionally decreased in the seed. The destabilising sequence 

of the disclosed method comprises a 3’SAUR terminator, a DST element, 

an ATTTA motif, an ATTTAA motif or a combination of ATTTA and 

ATTTAA motifs. 

(21) 563508 (22) 18 Oct 2007 

(54) A panel with interlocking members 

(86) PCT/AU2007/001590 (87) WO2008/046154 

(51) IPC2011.01:E06B9/01; E04F11/18; E06B7/082; E04C2/42; E04H17/ 

14 

(71) ALAN BROWNBILL; Danielle Tiffany Brownbill 

(72) Brownbill, Alan; 

(31) 06 230672 (32) 18 Oct 2006 (33) AU 


Australia 

(57) Disclosed is a panel including a) a plurality of first members (11) 

disposed in a first direction, b) at least one second member (12) disposed 

in a second direction provided with i) a longitudinal opening extending 

at least partially through the at least one second member; ii) a 

one or more lateral openings intersecting the longitudinal opening to re- 

ceive at least a portion of respective first members, and iii) at least one 

locking member provided adjacent each lateral opening to abut a first 

member forced into the lateral opening, to lock the first member relative 

to the second member through application of compressive force to the 

first member. 

(21) 563564 (22) 31 May 2006 

(54) Phosphatidylserine enriched milk fractons for the formulation of functional 

foods 

(86) PCT/DK2006/000303 (87) WO2006/128465 

(51) IPC2011.01:A23L2/00; A23C9/00; A23G1/00; A23J7/00; A23L1/29 

(71) ARLA FOODS AMBA 

(72) Burling, Hans; Andersson, Ingemar; Schneider, Michael; 

(31) 05 685527 (32) 31 May 2005 (33) US 



(57) Provided is a process for the preparation of a phosphatidylserine (PS) 

source derived from bovine milk, containing at least 0.2% 

phosphatidylserine calculated on the weight of total lipids, by performing 

the steps of: centrifuging cream for butter oil production to a cream containing 

about 80 % of fat; breaking the resulting emulsion by high shearing 

to obtain a butter milk together with a butter oil; collecting the butter 

milk; separating fat from the butter milk to give butter milk containing 

about 70-80% phospholipids in the total lipids in the butter milk; treating 

the fat-separated butter milk by ultrafiltration to provide a concentrate; 

and spray-drying the resulting concentrate. Further provided are products 

produced by the process. 


(21) 563606 (22) 21 Nov 2007 (23) 21 Nov 2008 

(54) An expanded food product comprising hominy 

(51) IPC2011.01:A23L1/10 

(71) CORSON GRAIN LIMITED 



(72) Hardacre, Allan Keith; 



(57) Provided is an expanded food product comprising about 49-94.3% w/ 

w hominy and about 5-60% w/w dairy protein isolate(s). The dairy protein 

isolates can be selected from lactic casein, MPC 85, MPC70, WPC392, 

WP1894, Alatel 825 or a mixture thereof and can be included in breakfast 

cereals and snack food. 

(21) 563644 (22) 28 Apr 2006 

(54) A system with a shielded electrical cable with an armour that is exposed 

when entering an apparatus 

(86) PCT/GB2006/001549 (87) WO2006/114636 

(51) IPC2011.01:H04B3/56; H02G15/00,10 

(71) Manx Electricity Authority 

(72) Mcghee, Stephen; Jones, Alfred; Patrick, Matthew William; 

(31) 05 0508673 (32) 28 Apr 2005 (33) GB 



(57) Disclosed is an electrical system for data transmission over an electricity 

distribution network. The system comprises of an electrical apparatus 

and a shielded electrical cable (3) connected to the apparatus, the 

cable having a core, a metallic sheath (35) around the core and surrounding 

armour (36). The armour is disengaged from around the metallic 

sheath at a location where the sheath enters the apparatus and is 

connected to and supported relative to the apparatus by means of a 

coupling such that a portion of the sheath is exposed between the location 

and the armour. The coupling comprises a first end arranged to receive 

the armour and a second end spaced from, but connected to, the 

first end, which second end being mounted to a part of the apparatus. 


(21) 563658 (22) 26 Apr 2006 

(54) Treatment station for a water drainage conduit with sediment collection 

(86) PCT/GB2006/001522 (87) WO2006/114621 

(51) IPC2011.01:E03F1/00; E03F5/14,16 

(71) THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH; 

Iain Alexander Stewart Robinson 

(72) Cunningham, Colin John; Robinson, Iain Alexander Stewart; 

(31) 05 0508483 (32) 27 Apr 2005 (33) GB 


(57) Disclosed is a treatment station for a water drainage conduit (8). The 

station comprises; a chamber (1) having inlet (10) and outlet (6) means 

in fluid communication with upstream and downstream sections of the 

conduit and a sediment collection portion (14). Water enters the chamber 

via the inlet means collecting in the sediment collection portion until 

it reaches a level in the chamber such that it flows out of the outlet means. 

The chamber is provided with a filter means mount for releasably mount- 

ing a filter means (22) above the sediment collection portion for the upwards 

flowing filtration of water passing through the chamber to remove 

organic contaminants. The treatment station is further provided with access 

means (46) for removal and replacement of said filter means and 

the removal of solid material deposited in the sediment collection portion. 

The treatment station further comprises a preliminary sediment collection 

chamber (40), upstream of the chamber with the sediment collection 

portion and filter means mount. 

(21) 563785 (22) 3 May 2006 

(54) Mutation in OAS1 genes 

(86) PCT/US2006/016983 (87) WO2006/119363 

(51) IPC2011.01:C12N9/12; A61K38/16; C12Q1/68 

(71) Illumigen Biosciences, Inc. 

(72) Iadonato, Shawn P; Magness, Charles L; Scherer, Christina A; Fellin, 

P, Campion; Hagen, Tory; Olson, Amy; 

(31) 05 677680 (32) 4 May 2005 (33) US 



(57) Provided is an oligoadenylate synthetase 1 protein comprising a 

polypeptide having a specified amino acid sequence with at least one 

amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 

69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 

142, 160, 161, 162, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 

279, 282, 284, 288, 289, 292, 295, 314, 315 and 335. Further provided 

are corresponding antisense and RNAi molecules, ribozymes and antibodies. 

The compositions are useful in treating viral diseases. 


(21) 563787 (22) 9 May 2006 

(54) Apparatus and method for displaying vinyl records 

(86) PCT/GB2006/001705 (87) WO2006/120436 

(51) IPC2011.01:A47G1/06; A47F7/14; G11B33/04 

(71) MEMORY BOX UK LIMITED 

(72) Heeps, Andrew Nicholas; 

(31) 05 0509446 (32) 9 May 2005 (33) GB 



(57) Display apparatus 2 comprises first and second parts pivotally mounted 

to each other, where the first part comprises a window 6 through which 

the item to be displayed can be viewed and the second part comprises 

means 36, 38, 40, 42 for mounting the display apparatus 2 to a wall. A 

catch that limits the relative rotation of the two parts is included in one 

part. One part further comprises means for pressing an item located 

between the two parts against the other part. 



(21) 563829 (22) 26 May 2006 

(54) Device, system, and method for epithelium protection during cornea 

reshaping 

(86) PCT/US2006/020563 (87) WO2006/128038 

(51) IPC2011.01:A61B18/18; A61F9/007,008,009,01,013 

(71) NTK Enterprises, Inc. 

(72) Berry, Michael J; Woodward, Benjamin W; 

(31) 05 684749 (32) 26 May 2005 (33) US 

(31) 05 695175 (32) 29 Jun 2005 (33) US 

(31) 06 440794 (32) 25 May 2006 (33) US 



(57) A system 100 comprises a light source 106 operable to generate light 

energy 218 for a cornea reshaping procedure, and a device 102 operable 

to be attached to an eye 104 having a cornea 204. The device 102 

includes a window 210 operable to contact at least a portion of the cornea 

204 and to substantially or completely flatten at least part of the 

contacted surface of the cornea. The window 210 is substantially transparent 

to the light energy 218 that irradiates the cornea 204 during the 

cornea reshaping procedure, and is also operable to cool at least a portion 

of a corneal epithelium in the cornea 204 during the cornea reshaping 

procedure 

(21) 563863 (22) 2 Jun 2006 

(54) Agent for regeneration and/or protection of nerves 

(86) PCT/JP2006/311084 (87) WO2006/129788 

(51) IPC2011.01:A61K45/00; A61K31/426,427; A61K47/40; A61P19/08; 

A61P25/00; A61P43/00; A61P9/00; C07D277/20,56; C07D417/12 

(71) ONO PHARMACEUTICAL CO., LTD. 

(72) Ohmoto, Kazuyuki; Kinoshita, Akihiro; Matsuya, Hidekazu; 

(31) 05 164458 (32) 3 Jun 2005 (33) JP 



(57) The disclosure relates to an compound of formula (I-3) which is an 

agent for regeneration and/or protection of nerves. More particularly, it 

relates to an agent for regeneration and/or protection of nerves comprising 

an EP2 agonist which may have an EP3 agonistic effect. The compound 

of formula (I-3) is therefore useful as a therapeutic agent for a 

disease of the peripheral nervous system, such as a lower or upper motor 

neuron disease, a nerve root disease, plexopathy, thoracic outlet compression 

syndrome, peripheral neuropathy, neurofibromatosis and neu- 

romuscular transmission disease. An EP2 agonist which has an EP3 

agonistic effect is a safe and effective agent for the regeneration and/or 

protection of nerves which has little influence on the circulatory system. 

(21) 563867 (22) 8 May 2006 

(54) Non-pneumatic vehicle tyre with embedded compound-curve springs 

(86) PCT/US2006/017893 (87) WO2006/122107 

(51) IPC2011.01:B60C7/14 

(71) New Tech Tire LLC 

(72) Moon, Michael; Corn, Morris; 

(31) 05 123808 (32) 6 May 2005 (33) US 



(57) A non-pneumatic tyre (30) for a vehicle featuring a body of elastic 

material and having a circumferentially-extending crown portion featuring 

a running surface and circumferentially-extending sidewalls joined to 

the crown portion. The side walls terminate in circumferentially-extending 

beads which are adapted to engage the rim of a vehicle wheel. A 

number of radially-extending and circumferentially-spaced compoundcurve 

springs (32) made of a composite material are at least partially 

embedded within the crown portion and the sidewalls. The curved springs 

have ends terminating within the beads of the tyre body. A circumferentially-extending 

belt constructed of a high-strength and low stretch material 

is positioned radially outside of the compound-curve springs. The 

springs have sidewalls that are generally S-shaped. 

(21) 563871 (22) 20 May 2006 

(54) Stabile active ingredient complex of salts of the o-acetylsalicylic acid 

with basic amino acids and glycine 

(86) PCT/EP2006/004799 (87) WO2006/128600 

(51) IPC2011.01:C07C69/86; A61K31/198,60; A61P11/06; A61P9/00 

(71) Bayer Schering Pharma Aktiengesellschaft 

(72) Franckowiak, Gerhard; Hayauchi, Yukata; Ledwoch, Wolfram; 

Schweinheim, Eberhard; 

(31) 05 05025283 (32) 2 Jun 2005 (33) DE 


(57) Disclosed is an active compound complex consisting of a salt of oacetylsalicylic 

acid with a basic amino acid and glycine wherein the compound 

complex has a particle size distribution having a mean particle 

size of less than 100 micrometers. 



Also disclosed is the process for making the complex by rapidly combining 

o-acetylsalicylic acid and a basic amino acid in water or a watermiscible 

organic solvent at a temperature less than or equal to 40 degrees 

C to form a homogeneous mixture, cooling the homogeneous mixture 

to a temperature of from -5 to 10 degrees C, adding thereafter cooled 

acetone and a cooled suspension of glycine, stirring for at least one hour 

and isolating the crystals wherein during crystallization the temperature 

is not higher than 5 degrees C. 

Further disclosed is a solid product containing the active complex, a pharmaceutical 

composition comprising the active complex and the use of 

the active complex to prepare a medicament for the treatment of arthritis, 

neuralgia, myalgia, migraine, myocardial infarction, stroke, ischemic 

heart disease, angina pectoris, bypass operations, PTCA and stent implantation. 

(21) 563883 (22) 13 May 2006 

(54) Oil suspension concentrate comprising dioxazine pyridylsulfonylureas 

(86) PCT/EP2006/004521 (87) WO2006/131187 

(51) IPC2011.01:A01N47/36; A01N25/04 

(71) Bayer CropScience AG 

(72) Sixl, Frank; Schmidt, Annika; 

(31) 05 05012120 (32) 4 Jun 2005 (33) EP 


(57) Disclosed herein is an oil suspension concentrate comprising a) one 

or more herbicidally active compounds from the group of the dioxazine 

pyridylsulfonylureas in suspended form, b) one or more organic solvents, 

and c) non-ionic emulsifiers and dispersants. Said oil suspension concentrate 

is suitable for use in the crop protection sector. 

(21) 563979 (22) 23 May 2006 

(54) Solid compositions and methods for treating middle-of-the night insomnia 

(86) PCT/US2006/020502 (87) WO2006/128022 

(51) IPC2011.01:A61K31/415; A61K9/20 

(71) Transcept Pharmaceuticals, Inc. 

(72) Singh, Nikhilesh; Pather, Sathasivan Indiran; 

(31) 05 684842 (32) 25 May 2005 (33) US 

(31) 05 741673 (32) 1 Dec 2005 (33) US 

(31) 06 788340 (32) 31 Mar 2006 (33) US 

(31) 06 788249 (32) 31 Mar 2006 (33) US 



(57) Disclosed is the use of zolpidem or a salt thereof for the manufacture 

of a medicament for use in the treatment of a subject who characteristically 

awakens from sleep, has difficulty returning to sleep, and wishes to 

resume sleep for less than 5 hours, and wherein the medicament comprises 

less than 5 mg of zolpidem or a pharmaceutically acceptable salt 

thereof. 

(21) 564015 (22) 31 May 2006 

(54) Bag with leak resistant features 

(86) PCT/US2006/020759 (87) WO2006/135562 

(51) IPC2011.01:B64F1/02 

(71) The Glad Products Company 

(72) Broering, Shaun T; Isakson, Cathy Lynn; Waldron, Matthew William; 

Mack-Robles, Nancy; O’Hara, Michael Scott; Hnat, Matthew Richard; Hird, 

Bryn; 

(31) 05 689249 (32) 10 Jun 2005 (33) US 

(74) Pizzeys Patent and Trade Mark Attorneys, Level 14, ANZ Centre, 324 

Queen Street, Brisbane, Queensland 4000, Australia 

(57) A leak resistant bag is disclosed. The bag comprises a first pliable 

sidewall, a second pliable sidewall, and an absorbent-adhesive mixture. 

The second pliable sidewall overlies and joins to the first sidewall along 

a closed bottom edge to provide an interior volume. The interior volume 

accessible via an opening disposed between the first and second 

sidewalls. The absorbent-adhesive mixture comprises an absorbent agent 

and an adhesive. The absorbent-adhesive mixture is located on both the 

first and second sidewalls along the closed bottom edge. 

(21) 564097 (22) 9 Jun 2006 

(54) Dried and/or microencapsulated saccharomyces cerevisiae cells with 

a high content of (S)-(+)-S-adenosyl-L-methionine, process for their preparation, 

and compositions containing said cells 

(86) PCT/EP2006/005521 (87) WO2006/131382 

(51) IPC2011.01:C12N1/18,04; A61K36/064 

(71) GNOSIS S.P.A. 

(72) Benedetti, Alberto; Sivieri, Lino; 

(31) 05 05425413 (32) 9 Jun 2005 (33) EP 



(57) Disclosed is a pharmaceutical composition (such as a tablet, a 

gastroresistant tablet or a capsule) containing: (a) dried and/or 

microencapsulated Saccharomyces cerevisiae cells wherein (R)-(+)-(S)adenosyl-L-methionine 

is in a quantity lower than or equal to 10% of (S)- 

(+)-S-adenosyl-L-methionine, said (S)-(+)-adenosyl-L-methionine being 

in the form of a free base obtainable from strains of Saccharomyces 

cerevisiae having a (S)-(+)-S-adenosyl-L-methionine productivity of 2.0- 

6.0% w/dry w at the end of fermentation and 7-20% w/dry w at the end of 

an enrichment stage, and (b) suitable excipients, in dried form or in 

microencapsulated form. 

(21) 564108 (22) 19 May 2006 

(54) Tire fire suppression and vehicle with same 

(86) PCT/US2006/019479 (87) WO2006/130363 

(51) IPC2011.01:A62C3/07 

(71) Kidde Technologies Incorporated 

(72) Hodges, Steven Edward; Simpson, Gregory Deane; 

(31) 05 141881 (32) 31 May 2005 (33) US 



(57) A fire suppression apparatus 10 comprises a fire suppressant container 

16, at least one temperature sensor 94 positioned away from the 

container 16 for sensing an elevated temperature condition at a location, 

at least one nozzle 98 positioned away from the container 16 for directing 

the suppressant toward the location, and an actuator 20 for connecting 

the container 16 to the nozzle 98 for the suppressant to be dispersed 

from the nozzle 98. The actuator 20 comprises a chamber 74 that is 

sealed from the container, and containing gas at a pressure that is greater 

than the ambient air pressure. The chamber 74 has a normally closed 

discharge port to atmosphere, which is connected to the temperature 

sensor 94 such that the discharge port will open when the sensor 94 is 

exposed to the elevated temperature and the gas will be discharged. 

The resultant drop in gas pressure in the chamber 74 will cause the 

actuator to release the suppressant from the container 16 to the nozzle 

98. The apparatus 10 provides a simple, rugged automatic fire suppression 

system. 


(21) 564141 (22) 24 Mar 2006 

(54) Two way communication system for monitoring an analyte 

(86) PCT/US2006/011090 (87) WO2006/121510 

(51) IPC2011.01:A61B5/00 

(71) Theranos, Inc. 



(72) Holmes, Elizabeth A; Roy, Shaunak; Howard, John; Gibbons, Ian; 

Wang, Chengwang; Kemp, Tim; Todd, Chris; Oral, Ron; Fenton, Jeff; Qi, 

Shize Daniel; Zeng, Shulin; 

(31) 05 678801 (32) 9 May 2005 (33) US 

(31) 05 705489 (32) 5 Aug 2005 (33) US 

(31) 05 717192 (32) 16 Sep 2005 (33) US 

(31) 05 721097 (32) 28 Sep 2005 (33) US 



(57) A two-way communication system for monitoring an analyte in a body 

fluid sample, comprises a reader assembly, an external device configured 

to transmit a protocol to the reader assembly, and a fluidic device 

configured to be inserted in the reader assembly, where the fluidic device 

comprises a sample collection unit configured to collect a body fluid 

sample that contains the analyte, an assay assembly containing reactants 

that react with the body fluid sample to carry out the test required 

by the protocol transmitted from the external device and produce a signal 

that indicates the presence of the analyte in the sample, and an identifier 

that is configured to provide the identity of the fluidic device and 

also to request the transmission of the protocol. The reader assembly is 

configured for two-way communication with the external device, and comprises 

a programmable processor configured to receive the protocol from 

the external device, where the protocol in turn effects a reaction in the 

assay assembly for generating the signal, and where the reader assembly 

further comprises a detection assembly for detecting the signal, and 

a communication assembly for transmitting the signal to the external 

device. The system allows remote assessment of a patient’s physiological 

condition 


(21) 564146 (22) 24 May 2006 

(54) Stable and selective formation of Hoogsteen-type triplexes and 

duplexes using twisted intercalating nucleic acids (TINA) and process for 

the preparation of TINA 

(86) PCT/DK2006/050022 (87) WO2006/125447 

(51) IPC2011.01:C12N15/11; C07H21/00 

(71) TINA Holding ApS 

(72) Filichev, Vyachelsav; Pedersen, Erik Bjerregaard; 

(31) 05 00762 (32) 25 May 2005 (33) DK 



(57) Provided is a flexible basestacking monomer with the general structure 

X – L - I1 – C - I2 wherein X is a backbone monomer unit of an 

oligonucleotide or an oligonucleotide analogue, or PNA, or PNA analogues, 

and wherein X comprises alkylenediol, L is a linker comprising 

an alkyl chain, an oxaalkyl chain, an azaalkyl chain, a thiaalkyl chain, 

carboxamide group, a thiocarboxamide group, a sulphonamide group or 

combinations thereof and comprises between 0-60 atoms, I1 is a 

monocyclic or a polycyclic aromatic ringsystem selected from the group 

consisting of benzene, naphthalene, azulene and bicyclic heteroaromatic 

ring systems, C is a conjugator selected from the group of alkyl of 1 to 12 

carbons, alkeny of 2 to 12 carbons, alkynyl of 2 to 25 carbons or diazo or 

combinations thereof with a length of no more than 25 carbons or/and 

nitrogen atoms, I2 is selected from the group of bicyclic aromatic 

ringsystems, tricyclic aromatic ringsystems, tetracyclic aromatic 

ringsystems, pentacyclic aromatic ringsystems and heteroaromatic analogues 

thereof and such compounds with substitutions thereof. The composition 

can be used as a medicament targeted to specific genes or 

RNAs depending on the sequence of the included oligonucleotide. 

(21) 564154 (22) 26 Sep 2006 

(54) A survey device 

(86) PCT/AU2006/001404 (87) WO2007/041756 

(51) IPC2011.01:G01C15/00; G01S5/02; G01V3/00; H04B7/14 

(71) Data Info Tech Pty Ltd 

(72) Bell, Alexander; Lott, Simon; Murray, Neil; 

(31) 05 726070 (32) 11 Oct 2005 (33) US 

(31) 05 905602 (32) 11 Oct 2005 (33) AU 



(57) A handheld survey device, includes an antenna for receiving at least 

one wireless signal; at least one interface for receiving environmental 

data from at least one interchangeable peripheral device that produces 

the environmental data; one or more processors for determining spatial 

data using the at least one wireless signal, and for producing collocated 

data by combining the spatial data and the environmental data; and an 

output device for wirelessly transmitting the collocated data. 

(21) 564192 (22) 28 Jun 2006 

(54) High performance resin for abrasive products 

(86) PCT/US2006/025133 (87) WO2007/005452 

(51) IPC2011.01:C08L61/06; B24D11/00; B24D3/28; C08L61/24,28 

(71) SAINT-GOBAIN ABRASIVES, INC. 

(72) Gaeta, Anthony C; Rice, William C; 

(31) 05 695233 (32) 29 Jun 2005 (33) US 



(57) Disclosed is an abrasive product comprising: (a) a plurality of abrasive 

particles; and (b) an aldehyde resin cured with a polythiol group 

selected from the group consisting of trimethylolpropane tri(3mercaptopropionate), 

trimethylolpropane tri(2-mercaptoacetate), pentaerythritol 

tetra(3-mercaptopropionate), pentaerythritol tetra(2mercaptoacetate), 

polyol-3-mercaptopropionates, polyol-2mercaptoacetates, 

polyester-3-mercaptopropionates, polyester-2mercaptoacetates, 

and ethoxylated trimethylolpropane tri(3mercaptopropionate), 

and a method of preparing the abrasive product 

and a method of abrading a work surface with the product. 

Also disclosed is a curable composition, comprising: (a) a formaldehyde 

resin; and (b) a polythiol group selected from the group consisting of 

trimethylolpropane tri(3-mercaptopropionate), trimethylolpropane tri(2mercaptoacetate), 

pentaerythritol tetra(3-mercaptopropionate), pentaerythritol 

tetra(2-mercaptoacetate), polyol-3-mercaptopropionates, polyol- 

2-mercaptoacetates, polyester-3-mercaptopropionates, polyester-2mercaptoacetates 

and ethoxylated trimethylolpropan tri-3mercaptopropionate, 

a method of crosslinking the formaldehyde resin 

composition and a crosslinked formaldehyde resin composition. 



(21) 564258 (22) 22 Jun 2006 

(54) Azaindazole compounds and methods of use 

(86) PCT/US2006/024313 (87) WO2007/002293 

(51) IPC2011.01:A61K31/496; C07D487/06 

(71) CHEMOCENTRYX, INC. 

(72) Zhang, Penglie; Pennell, Andrew M.K.; Wright, John J Kim; Chen, 

Wei; Leleti, Manmohan R; Li, Yandong; Li, Lianfa; Xu, Yuan; 

(31) 05 693525 (32) 22 Jun 2005 (33) US 



(57) Disclosed are azaindazole compounds and are represented by the 

formulas Ia and Ib. The compounds feature a pyrazole fused with a nitrogen 

containing heterocycle and an optionally substituted piperazinyl ring. 

The substituents are as disclosed in the description. 

Also disclosed is a pharmaceutical composition containing a compound of 

formula Ia or Ib and the use of a compound of formula Ia or Ib in the 

manufacture of a medicament for treating CCR 1 mediated disease especially 

inflammatory conditions and immunoregulatory disorders such 

as rheumatoid arthritis, multiple sclerosis, transplant rejection, restenosis, 

dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food 

allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus 

erythematosus, osteoarthritis, stroke, and encephalomyelitis. 

(21) 564284 (22) 23 Jun 2006 

(54) Baling and bale wrapping apparatus and methods 

(86) PCT/IE2006/000069 (87) WO2006/137046 

(51) IPC2011.01:A01F15/07,00 

(71) Welmount Limited 

(72) McHale, Padraic Christopher; Heaney, James John; O’Connor, Patrick 

Thomas; Sheridan, Gerard Patrick; Cummins, John Joseph; McHale, Martin 

William; McHale, Paul Gerard; 

(31) 05 0426 (32) 23 Jun 2005 (33) IE 



(57) Baling apparatus 1 for forming material into a cylindrical bale and for 

wrapping the bale wrapping material 64 comprises a a baler 16 defining 

a bale forming chamber defining a longitudinally extending main central 

axis, and within which the bale is formed, the baler 16 comprising at 

least two segments 21, 22 , at least one of which is moveable relative to 

the other between a bale forming state where the segments 21, 22 cooperate 

to form the bale forming chamber, and a discharge state with 

two of the segments 21, 22 defining a discharge opening from the bale 

forming chamber for accommodating discharge of the bale there from, a 

bale support located adjacent the baler 16 for receiving a bale discharged 

there from and for supporting the bale during wrapping, a first dispenser 

63 located to a first side of the discharge opening for dispensing the 

wrapping material 64 for circumferentially wrapping the bale and a holding 

means located to a second side of the discharge opening opposite to 

the first side thereof, the holding means being adapted to grip the wrapping 

material 64 extending from the first dispenser 63 with the wrapping 

material 64 extending across the discharge opening, so that when the 

bale is discharged from the bale forming chamber through the discharge 

opening onto the bale support, the wrapping material 64 is engaged by 

the circumferential surface of the bale, and is drawn from the first dispenser 

63 onto the bale to extend circumferentially partly around the 

circumferential surface of the bale. 

(21) 564339 (22) 26 Jun 2006 

(54) Quinoline derivatives as antibacterial agents 

(86) PCT/EP2006/063556 (87) WO2007/000436 

(51) IPC2011.01:A61K31/4353; A61P31/04; C07D215/22,227,36 

(71) Janssen Pharmaceutica N.V. 

(72) Andries, Koenraad Jozef Lodewijk Marcel; Koul, Anil; Guillemont, 

Jerome Emile Georges; Motte, Magali Madeleine Simone; 

(31) 05 05105769 (32) 28 Jun 2005 (33) EP 



(57) Disclosed is the use of a quinoline derivative compound of formula Ia 

or Ib in the manufacture of a medicament for the treatment of a bacterial 

infection. The substituents are as disclosed in the description. 

Also disclosed is a compound of formula Ia. 

Further disclosed is a combination of a compound of formula Ia and another 

antibacterial agent; a pharmaceutical composition containing a 

compound of formula Ia; and the use of the combination of composition 

to treat bacterial infection other than Mycobacterial infection. Particular 

bacterial infections are infection with Staphylococci, Enterococci or Streptococci 

especially the infection is an infection with methicillin resistant 

Staphylococcus aureus (MRSA), methicillin resistant coagulase negative 

staphylococci (MRCNS), penicillin resistant Streptococcus 

pneumoniae or multiple resistant Enterococcus faecium. 

(21) 564340 (22) 26 Jun 2006 


(86) PCT/EP2006/063552 (87) WO2007/000434 

(51) IPC2011.01:A61K31/4353; A61P31/04; C07D215/227,36 



Jerome Emile Georges; Motte, Magali Madeleine Simone; Lancois, David 

Francis Alain; 

(31) 05 05105755 (32) 28 Jun 2005 (33) EP 





(57) Disclosed is the use of quinoline compounds of formula (Ia) and (Ib) 

a N-oxide, tautomeric or a stereochemically isomeric form thereof, wherein 

the substituents are as defined in the specification, for the treatment of 

bacterial infections such as infection with Staphylococci, Enterococci or 

Streptococci. 

(21) 564376 (22) 15 Jun 2006 

(54) Method for the synthesis of anthocyanins 

(86) PCT/GB2006/002172 (87) WO2006/134352 

(51) IPC2011.01:C07H17/04; C07H15/18 

(71) Biosynth AS 

(72) Bakstad, Einar; 

(31) 05 0512206 (32) 15 Jun 2005 (33) GB 



(57) Disclosed is a method for preparing an Eastern portion of anthocyanin 

comprising reacting an alpha functionalised ketone starting material 

of general formula S-1, with a sugar anion of general formula XO-. 

Also disclosed is the compound of formula S-1, wherein LG is Br or I and 

R1, R2 and R3 each denote a benzyloxy, or R1 denotes H and R2 and 

R3 together denote diphenylmethylenedioxy. Also disclosed are compounds 

of formula (i), (ii) or (iii). 

(21) 564378 (22) 16 Jun 2006 

(54) Methods and systems for delivering foamed beverages from liquid 

concentrates through a dispenser machine 

(86) PCT/EP2006/005785 (87) WO2006/136329 

(51) IPC2011.01:A47J31/00,40 

(71) Nestec S.A. 

(72) Saggin, Raffaella; Leser, Martin; Bezelgues, Jean-Baptiste; Livings, 

Simon; Sher, Alexander A; 

(31) 05 156922 (32) 20 Jun 2005 (33) US 



(57) A method and system to deliver foamed beverages from liquid 

concentrate(s) through a dispenser machine is disclosed. In an embodiment, 

the method and system for improving foam quality by generating 

foam with the desired texture, stability and bubble size distribution comprises 

use of a low viscous liquid(s) to generate a primary foam, which is 

then stabilized by mixing it with liquid(s) of higher viscosity. To create 

high quality foam, different dosing protocols including two approaches 

such as delivery of foaming liquid concentrates at different concentration, 

or getting different concentration by varying water dosing times and/ 

or flow rates were used. Positive results were found for the dispensing 

systems using milk and other liquid concentrates at specific dispensing 

conditions (flow rates and times). 



(21) 564496 (22) 3 Jul 2006 

(54) An apparatus and process for conversion of biomass/waste into bioorganic 

soil enricher & conditioner and fuel 

(86) PCT/IN2006/000235 (87) WO2007/034504 

(51) IPC2011.01:C05F9/02; B01F7/04,12; C05F11/08; C05F9/04 

(71) Excel Industries Limited 

(72) Shroff, Ashwin Champraj; Jawdekar, Mohan Chintopant; 

(31) 05MU 823 (32) 5 Jul 2005 (33) IN 



(57) The disclosure relates to a device and a process for conversion of 

biodegradable waste into organic fertilizer and fuel for heating. The organic 

fertilizer produced by the disclosed method provides nutrients to 

plants and at the same time improves moisture retaining capacity of the 

soil, prevents erosion and leaching. Particularly disclosed is an apparatus 

for treating biomass/organic waste comprising a container incorporating 

a shaft at the axis, affixed on which are plough type blades and an 

opening preferably at the top side for feeding the material; a chopper 

assembly, at least the blades of the said chopper assembly inserted into 

the container; a discharge assembly preferably connected at the bottom 

side of the container; a door at the connecting junction of the container 

and the discharge assembly which can be opened and closed, the said 

door may be a part of the container or the discharge assembly. Also 

disclosed is a process for converting bio-degradable waste/biomass 

material into organic fertilizer comprising feeding the said material into 

the container of said apparatus and chopping the material; adding a microbial 

culture or substance obtained there from; optionally adding a 

moisture absorbing substance; running the motor for mixing, taking out 

the material preferably on the ground to make a heap and ensuring aerobic 

conditions until the material matures into an organic fertilizer. The 

bio-stabilised material produced using said apparatus can be converted 

into fuel by spreading the material in a suitable mould, pressing and cutting 

the material into pieces of suitable size; and drying the material. 

(21) 564689 (22) 23 May 2006 

(54) Novel piperidine carboxylic acid amide derivatives 

(86) PCT/IB2006/051641 (87) WO2006/129237 

(51) IPC2011.01:C07D471/08; A61K31/451; A61P9/00; C07D401/10,12; 

C07D211/78 

(71) Actelion Pharmaceuticals Ltd. 

(72) Bezencon, Olivier; Boss, Christoph; Bur, Daniel; Chen, Austin Chih- 

Yu; Corminboeuf, Olivier; Dube, Daniel; Fischli, Walter; Grisostomi, 

Corinna; Remen, Lubos; Richard-Bildstein, Sylvia; Sifferlen, Thierry; 

Therien, Michel; Weller, Thomas; 

(31) PCT/EP2005/0005732 (32) 27 May 2005 (33) EP 

(31) PCT/IB2006/050134 (32) 13 Jan 2006 (33) IB 



(57) Disclosed are piperidine carboxylic acid amide compounds of formula 

(I) wherein R1 is cycloalkyl and the remaining substitutents are as 

defined in specification. Also disclosed are pharmaceutical compositions 

containing said compounds and their use as rennin inhibitors and 

treating diseases such as cardiovascular events and renal insufficiency. 

(21) 564886 (22) 15 Aug 2006 

(54) Humidifier for CPAP device with tub base plate forced into engagement 

with heater plate by cradle retaining structure 

(86) PCT/AU2006/001170 (87) WO2007/019625 

(51) IPC2011.01:A61M16/16 

(71) RESMED LIMITED 

(72) SMITH, Ian Malcolm; SNOW, John Michael; LITHGOW, Perry David; 

KAO, Dan; 

(31) 05 707948 (32) 15 Aug 2005 (33) US 



(57) A CPAP device includes a humidifier including humidifier tub having a 

heat conducting base plate; and a cradle to support the humidifier tub in 

an operative position. The cradle may also support a flow generator in 

operative relation to the humidifier tub. The cradle includes a heater plate 

in communication with the heat conducting base plate of the humidifier 

tub in use. The cradle further includes a retaining mechanism to retain 

the humidifier tub in the cradle, the retaining mechanism being structured 

to force the base plate into engagement with the heater plate. The 

humidifier and/or flow generator may include various features to manage 

inadvertent back-spill of water from the humidifier to the flow generator. 


(21) 564908 (22) 7 Sep 2005 

(54) N-Phenyl-2-pyrimidine-amine derivatives and process for the preparation 

thereof 

(86) PCT/KR2005/002962 (87) WO2007/018325 

(51) IPC2011.01:C07D239/02; A61K31/425,44,4965,505; A61P35/00; 

C07D239/28; C07D401/02; C07D417/00 

(71) IL-YANG PHARM. CO., LTD 

(72) Kim, Dong-Yeon; Cho, Dae-Jin; Lee, Gong-Yeal; Kim, Hong-Youb; 

Woo, Seok-Hun; Kim, Yong-Seok; Lee, Sun-Ahe; Han, Byoung-Cheol; 

(31) 05 050071656 (32) 5 Aug 2005 (33) KR 



(57) Disclosed are N-phenyl-2-pyrimidine-amine derivatives of formula (1) 

wherein one of R4 or R5 must be a radical of formula (2). A process for 

preparing the said compounds is also disclosed. Also disclosed is the 

use of the said compound in a pharmaceutical composition for the manufacture 

of a medicament for the treatment of cancer. 



(21) 564954 (22) 14 Jun 2006 

(54) Method of treating or preventing benign prostatic hyperplasia using 

modified pore-forming proteins 

(86) PCT/CA2006/000971 (87) WO2006/133553 

(51) IPC2011.01:C07K14/195; A61K35/74; A61K38/16 

(71) Protox Therapeutics Incorporated 

(72) Buckley, James Thomas; 

(31) 05 690269 (32) 14 Jun 2005 (33) US 



(57) Provided is the use of a modified pore-forming protein for the preparation 

of a medicament for the treatment of benign prostatic hyperplasia 

(BPH), wherein said modified pore-forming protein is derived from a naturally-occurring 

pore-forming proaerolysin protein and comprising one or 

more prostate-selective modifications selected from: an activation sequence 

cleavable by a prostate-specific protease, and one or more prostate-specific 

targeting domains capable of selectively targeting prostate 

cells, wherein said modified pore-forming protein is capable of selectively 

killing prostate cells. Further provided is the use of the medicament 

for treating BPH in non-human animals. 

(21) 565001 (22) 9 Aug 2006 

(54) Improvements in and relating to wool treatment 

(86) PCT/GB2006/002955 (87) WO2007/017668 

(51) IPC2011.01:D06M13/46; D06M11/32,38,50 

(71) PERACHEM LIMITED 

(72) Lewis, David Malcolm; Hawkes, Jamie Anthony; 

(31) 05 0516392 (32) 10 Aug 2005 (33) GB 

(31) 05 0524371 (32) 30 Nov 2005 (33) GB 



(57) Disclosed is a method of treating a wool material, the method comprising 

the steps of: (a) contacting the wool material with a cationic surfactant; 

and (b) contacting the wool material with a nucleophile; wherein 

steps (a) and (b) are performed simultaneously at a pH of at least 8 

wherein the nucleophile is selected from hydrogen peroxide and its derivatives, 

the perhydroxy anion, the superoxide anion, a per-acid, a 

polyper-acid, an alkali metal hydroxide or ammonium hydroxide, the hydroxyl 

anion, hydroxylamine, an alkanolamine, an alcoholate, an amine, 

a phenol, thiocyanate or any mixture thereof; and wherein the method 

comprises a continuous process. Also disclosed is a wool material that 

is treated by the above method. 

(21) 565062 (22) 24 Jul 2006 

(54) Benzylpiperazine derivates and their use in treating conditions mediated 

by GPR38 receptors 

(86) PCT/EP2006/007390 (87) WO2007/012479 

(51) IPC2011.01:C07D401/10; A61K31/496; A61P1/08 

(71) Glaxo Group Limited 

(72) Johnson, Christopher Norbert; Macpherson, David Timothy; Stanway, 

Steven James; Stemp, Geoffrey; Thompson, Mervyn; Westaway, Susan 

Marie; 

(31) 05 0515381 (32) 26 Jul 2005 (33) GB 

(31) 06 0611469 (32) 9 Jun 2006 (33) GB 



(57) Disclosed is a compound including a piperidine and a piperazine as 

shown in formula (I), or a salt thereof, wherein A is phenyl or pyridine, 

and the other substituents are as defined in the specification. 

Also disclosed is the use of the compound to treat conditions mediated by 

GPR38 receptors, such as gastroesophageal reflux disorders, functional 

dyspepsia, irritable bowel syndrome, constipation, intestinal pseudo-obstruction, 

paralytic ileus following surgery or other manipulation, emesis, 

gastric stasis or hypomotility caused by various diseases such as diabetes 

and/ or by the administration of other drugs, Crohn's disease, colitis, 

cachexia associated with advanced diseases such as cancer and/or the 

treatment thereof, appetite/metabolism related cachexia, and incontinence. 

Also disclosed is a method to synthesise the compound, and intermediates 

useful in that method. 

(21) 565150 (22) 25 Jul 2006 

(54) Pyrazine derivatives useful as adenosine receptor antagonists 

(86) PCT/EP2006/007318 (87) WO2007/017096 

(51) IPC2011.01:C07D401/04,14; C07D413/14; A61K31/497; C07D403/ 

04; C07D417/04; A61K31/506; C07D405/14; C07D417/14; A61P11/06; 

C07D409/14; C07D487/04 

(71) LABORATORIOS ALMIRALL, S.A. 

(72) Vidal Juan, Bernat; Esteve Trias, Cristina; Soca Pueyo, Lidia; 

Eastwood, Paul Robert; 

(31) 05 0501876 (32) 29 Jul 2005 (33) ES 



(57) Disclosed is a secondary pyrazine amine of formula (I) wherein: A 

represents an aryl or heteroaryl group, B represents a nitrogen-containing 

heteroaryl group and R1 and R2 are defined in the specification and 

the pharmaceutically acceptable salts and N-oxides thereof. Also disclosed 

is a composition comprising said amine and the use of said amine 

in the treatment of a condition susceptible of being improved by antagonism 

with the A2B adenosine receptor for example, hypertension and 

inflammation. 

(21) 565162 (22) 19 Oct 2005 

(54) Catalyzed decomposing foam for encapsulating space-based kinectic 

objects 

(86) PCT/US2005/037586 (87) WO2007/001419 



(51) IPC2011.01:B64G1/00,22,64; F41H11/02; F42B12/56 

(71) Raytheon Company 

(72) Duden, Quenten E; Mense, Allan T; 

(31) 04 969724 (32) 20 Oct 2004 (33) US 



(57) Disclosed is a kinetic media payload of a weapon system which uses 

kinetic media to intercept a target, the payload being suitable for launching 

into space by a vehicle. The kinetic media payload comprises kinetic 

media which is at least partially surrounded by foam which decomposes 

in the presence of high energy electromagnetic radiation. 

(21) 565205 (22) 16 Jun 2006 

(54) Cell signalling genes from plants (Eucalyptus and Pinus species) and 

related methods 

(86) PCT/US2006/023561 (87) WO2006/138606 

(51) IPC2011.01:A01H5/00; A01H7/00; C12N15/82; C12N5/04; C12P21/ 

06; C12N1/20; C12N15/00; C07H21/02; C12N9/00; C07H21/04; A01H1/ 

00 

(71) ArborGen, LLC 

(72) Chang, Shujun; Connett, Marie B; Emerson, Sarah Jane; Forster, 

Richard L; Gause, Katrina; Havukkala, Ilkka; Higgins, Colleen; Kodrzycki, 

Robert John; 

(31) 05 691398 (32) 17 Jun 2005 (33) US 

(74) KNIGHTSBRIDGE PATENT ATTORNEYS, Level 14, 200 Queen 

Street, Melbourne, Victoria 3000, Australia 

(57) Disclosed is a polyphosphoinositide binding protein from Pinus Radiata. 

The protein is associated with plant cell signalling and can be 

used to control plant phenotype. 

(21) 565218 (22) 25 Jul 2006 

(54) Liquid natural gas processing for hydrocarbons heavier than methane 

(86) PCT/US2006/028822 (87) WO2007/014209 

(51) IPC2011.01:F25J3/02 

(71) HOWE-BAKER ENGINEERS, LTD 

(72) Schroeder, Scott; Reddick, Kenneth; Belhateche, Noureddine; 

(31) 05 188961 (32) 25 Jul 2005 (33) US 



(57) A process for the recovery of natural gas liquids (NGL) from liquefied 

natural gas (LNG) is disclosed. The LNG feed stream is subjected to a 

two stage separation process where the bottoms from the first stage 

separation containing C2+ hydrocarbons is split into two portions, with 

one portion being heated and used as a reflux during the second stage 

separation to recover the NGL product. Particularly disclosed is a process 

of recovering hydrocarbons heavier than methane from liquefied 

natural gas (LNG) comprising, a) pumping liquid, low pressure LNG to a 

pressure of greater than 100 psia; (b) directing the pressurized liquid 

LNG from step (a) to a cold box where it is heat exchanged to increase 

its temperature; (c) directing the heat exchanged pressurized liquid LNG 

from step b) to a separator where, in combination with a first and second 

reflux, a separator overhead is produced along with a separator bottoms; 

(d) pressurizing the separator bottoms and then splitting the pressurized 

separator bottoms into first and second portions; (e) directing 

the first portion of pressurized separator bottoms to a deethanizer as a 

reflux stream; (f) heating the second portion of pressurized separator 

bottoms by directing the second portion to the cold box; (g) directing the 

heated second portion of pressurized separator bottoms to the 

deethanizer; (h) removing hydrocarbons heavier than methane as 

deethanizer bottoms; (i) directing a deethanizer overhead as the second 

feed to the separator; (j) removing the separator overhead from the separator 

and compressing the separator overhead prior to introduction into 

the cold box and heat exchanging with the pressurized liquid LNG to 

produce a re-liquefied pressurized LNG; and (k) separating a portion of 

the re-liquefied pressurized LNG for use as the first reflux. 

(21) 565247 (22) 20 Jul 2006 

(54) Process for the production drospirenone utilising the metal-free oxidation 

of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes with TEMPO 

(86) PCT/EP2006/007287 (87) WO2007/009821 

(51) IPC2011.01:C07J53/00; C07J19/00; C07J21/00 

(71) BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 

(72) Seba, Hartmut; Seilz, Carsten; 

(31) 05 05090214 (32) 21 Jul 2005 (33) EP 

(31) 05 185984 (32) 21 Jul 2005 (33) US 


(57) Disclosed is a process for the production of a 3-oxo-pregnane-21,17carbolactone 

of formula II, comprising the reaction of a compound of 

formula I, with at least 3 molar equivalents of an organic or inorganic 

hypochlorite as oxidizing agent in the presence of catalytic amounts of a 

2,2,6,6-tetramethylpiperidine-N-oxide derivative (TEMPO) at a pH of at 

least 8.0, wherein R5 is hydrogen or hydroxy; R6a is hydrogen, or together 

with R7a a -CH2 group; R6b is hydrogen, or together with R7b a 

-CH2 group or a double bond; R7a is hydrogen, alkyl, alkoxycarbonyl, 

thioacyl or together with R6a a -CH2 group, R7b is hydrogen, or together 

with R6b a -CH2 group or a double bond; R9 is hydrogen or together with 

R11 is a double bond, or together with R11 is an epoxy group -O-; R10 is 

hydrogen, methyl, or ethyl; R11 is hydrogen, or together with R9 a double 

bond or together with R9 is an epoxy group -O-; R13 is hydrogen, methyl 

or ethyl; R15 is hydrogen, alkyl, or together with R16 a -CH2 group or a 

double bond; R16 is hydrogen, or together with R15 a -CH2 group or a 

double bond. Also disclosed is a process for the production of a 3-oxopregn-4-ene-21,17-carbolactone 

of formula III which comprises the elimination 

of water from a compound of formula II at a pH of less than 5, 

optionally in the presence of an acid. Further disclosed is the use and 

preparation of 6b,7b;15b,16b-dimethylene-3-oxo-17a-pregnan-5b-ol- 

21,17-carbolactone-dichloromethane hemisolvate of formula (IV). 



(21) 565504 (22) 2 Aug 2006 

(54) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained 

by indirect chemical conjugation 

(86) PCT/EP2006/007717 (87) WO2007/014784 

(51) IPC2011.01:A61K47/48 

(71) FIDIA FARMACEUTICI S.P.A. 

(72) Renier, Davide; Bettella, Fabio; 

(31) 05 PD A 0242 (32) 3 Aug 2005 (33) IT 



(57) Disclosed is a chemical-pharmaceutical conjugates of hyaluronic acid 

and/or its derivatives obtained through an indirect binding between the 

polysaccharide and an alkaloid drug with an antitumoral action, via a 

molecular spacer which forms an ester or amide bond with the carboxylic 

group of HA and/or its derivative. Also disclosed is a composition 

comprising said conjugate, the use of said conjugate in the preparation 

of pharmaceutical compositions for the treatment of cancer and a process 

for the preparation of the said conjugates. 

(21) 565553 (22) 11 Aug 2006 

(54) A device for capturing energy from a fluid flow having a lift generating 

element with a lunate surface adapted to drive the device in oscillatory 

motion 

(86) PCT/AU2006/001148 (87) WO2007/019607 

(51) IPC2011.01:E02B9/08; F03B13/18,26; F03D5/00 

(71) BioPower Systems Pty. Ltd. 

(72) Finnigan, Timothy Donegal; 

(31) 05 904358 (32) 12 Aug 2005 (33) AU 

(31) 06 904032 (32) 26 Jul 2006 (33) AU 



(57) A device for capturing energy from a fluid flow is disclosed. The device 

comprises a base, a longitudinal member, a lift generating element, 

and an energy transfer mechanism. The base is stationary and is mounted 

relative to the fluid flow. The member has a longitudinal axis, and is 

movably connected to the base. The lift generating element, connected 

to the member, has a leading edge and a trailing edge and a generally 

lunate surface extending therebetween. The lift generating element is 

movable relative to the direction of the fluid flow to vary a direction of lift 

produced by the lift generating element as fluid flows around it. The generating 

element drives the member in an oscillatory motion relative to the 

base. An energy transfer mechanism is attached to the member and is 

driven by the oscillation of the member. 


(21) 565714 (22) 16 Aug 2006 

(54) Dual gland air inversion and steam cure of cured in place liners 

(86) PCT/US2006/031927 (87) WO2007/022232 

(51) IPC2011.01:F16L55/165 

(71) INA ACQUISITION CORP.; INSITUFORM HOLDINGS (UK) LIMITED 

(72) Hirtz, Steve J; Driver, Franklin Thomas; Polivka, Richard C; Blasczyk, 

James H; Birchler, Neil; Costa, Kyle; 

(31) 05 708934 (32) 17 Aug 2005 (33) US 

(31) 06 504909 (32) 16 Aug 2006 (33) US 



(57) Installation of a flexible cured in place liner is disclosed by inverting 

the liner with air and curing the liner with steam introduced through a 

perforated lay flat hose without deflating the liner between the inversion 

and cure. The installation is performed with an apparatus having two 

independently operable glands with at least one fluid inlet port installed 

on the line downstream of the second gland liner. As the liner reaches 

the distal end of the conduit to be lined, it enters a sample and porting 

pipe with an exhaust pipe gland and exhaust pipe and it is pierced by a 

rigid porting tool. Steam is then introduced into the lay flat hose to cure 

the resin and is exhausted through an exhaust hose connected to a controllable 

exhaust pipe. After curing steam is replaced with air to cool the 

liner, the ends are cut to restore service through the host pipe. 

(21) 565726 (22) 23 Jun 2006 

(54) Low-temperature motor compressor unit with continuous ‘cold’ combustion 

at constant pressure and with active chamber 

(86) PCT/FR2006/001444 (87) WO2006/136728 

(51) IPC2011.01:F01B17/02; F02B29/04; F02G1/02,04; F02G3/02; F02G1/ 

00; F02G3/00 

(71) MDI Motor Development International S.A. 

(72) Negre, Guy; Negre, Cyril; 

(31) 05 0506437 (32) 24 Jun 2005 (33) FR 





(57) Low-temperature, continuous cold combustion, constant pressure, 

active chamber motor-compressor unit, operating with working compressed 

air or gas comprises a piston travel control device that momentarily 

stops a main engine piston 1 at its top dead centre position, as well 

as a variable volume active chamber fitted with the means to produce 

work during filling, joined to and in permanent contact with the space 

contained above the main engine piston by means of a passage 12, as 

well as an integrated or non-characterized compression device and a 

cold chamber 29 able to reduce to very low temperatures the atmospheric 

air or gas that supplies the input 28 of the compression device. 

The compression device then forces this low temperatures working compressed 

air or gas into an external work capacity or combustion chamber 

19 fitted with a constant pressure heating device 19A where the working 

compressed air or gas will increase in volume before the working compressed 

air or gas is transferred into an expansion device that includes 

an active chamber 13. When the main engine piston is stopped at the 

top dead centre position, the expansion chamber will be at its smallest 

volume. The compressed air or gas will increase its volume and thus 

produce work by pushing the pressure piston 14. The compressed air or 

gas contained in the expansion chamber then expands in the engine 

cylinder thus pushing the main engine piston 1 downwards along its travel 

and supplying work in turn. During the exhaust stroke the main engine 

piston 1 will travel upwards again reducing the variable volume of the 

expansion chamber to its lowest value to restart a complete work cycle. 

(21) 565727 (22) 12 Jun 2006 

(54) Multiple nozzle venturi system for watercraft 

(86) PCT/US2006/023026 (87) WO2007/005209 

(51) IPC2011.01:B63H5/16; B63H11/00; B63H5/00,07,15 

(71) Marine Propulsion Technologies, Inc, 

(72) Smith, Terrence L; Schultz, Wilderich C; 

(31) 05 696285 (32) 5 Jul 2005 (33) US 



(57) A multiple nozzle Venturi system 10A for watercraft comprises a first 

hemispherical component and a second hemispherical component, both 

the first hemispherical component and the second hemispherical component 

including a hemispherical structural ring 18 and two or more hemispherical 

nozzle rings 22, 24 the first hemispherical component and the 

second hemispherical component including two or more ring connecting 

fin struts 16 spanning, separating and integrated into the structural ring 

18 and the two or more nozzle rings 22, 24 the first hemispherical component 

and the second hemispherical component further including an 

upper mounting plate 26 and a lower mounting plate 31 spanning, separating 

and integrated into the structural ring 18 and the two or more nozzle 

rings 22, 24 and a skeg shield 32 including a T-shaped skid plate 36 

sandwiched between the lower mounting plate 31 of the first hemispherical 

component and the second hemispherical component including an 

upper portion and a lower portion where the lower portion is removably 

attachable to the lower mounting plate of both the first and second hemispherical 

components. The T-shaped skid plate 36 further includes a 

skeg lock 42 adjustable in construction to fit a skeg located on the lower 

portion of a watercraft motor, where the skeg lock 42 functions to stabi- 

lize the watercraft when in motion in reverse, and reinforces any fasteners 

used to attached the skeg shield 32, the T-shaped skid plate 36 and 

the lower mounting plate 31, and where the upper mounting plate 26, the 

lower mounting plate 31, the skeg shield 32, and the skeg lock 42, are 

fastened to the watercraft motor using steel fasteners. 

(21) 565729 (22) 27 Jul 2006 

(54) Axle spindle and wheel end assembly with inboard and outboard bearings 

immovably mounted on axle spindle 

(86) PCT/US2006/029205 (87) WO2007/030220 

(51) IPC2011.01:B60B27/00 

(71) Hendrickson International Corporation 

(72) White, Jay; 

(31) 05 713887 (32) 2 Sep 2005 (33) US 



(57) An axle for a heavy-duty vehicle extends transversely across the vehicle 

and includes a central portion. Each one of a pair of relatively short 

and lightweight axle spindles is connected to and extends outboardly 

from a respective end of the axle central portion. A wheel end assembly 

is rotatably mounted on each axle spindle. Each wheel end assembly 

includes spaced-apart inboard and outboard bearings that are immovably 

mounted on its respective axle spindle, and preferably are standard 

heavy-duty vehicle stock-type bearings. A relatively short and lightweight 

wheel hub is rotatably mounted on the bearings so that the wheel end 

assembly selectively accommodates a dual-wheel, standard-tire configuration 

and a single-wheel, wide-tire configuration, including a two-inch 

offset wheel. 

(21) 565798 (22) 13 Jul 2006 

(54) Wave protection structure, method for producing a toe element for a 

wave protection structure, and method for producing a wave protection 

structur 

(86) PCT/NL2006/000366 (87) WO2007/011208 

(51) IPC2011.01:E02B3/12,14 

(71) Koninklijke BAM Groep N.V 

(72) Van Den Berge, Arnoud; Reedijk, Jan Sebastiaan; Canto, Rolf Rainer; 

(31) 05 1029538 (32) 15 Jul 2005 (33) NL 





(57) Wave protection structure for a slope, where the slope merges into a 

bed at the location of a toe, is disclosed. The wave protection structure 

comprises a plurality of wave protection elements of the interlocking type 

and a plurality of toe elements. The wave protection elements are each 

provided with a plurality of projections, where the projections extend in a 

plurality of planes to form a three-dimensional structure for the dissipation 

of wave energy. Also, the wave protection elements may engage in 

spaces between the projections of one or more adjacent wave protection 

elements in such a manner that the freedom of movement of the 

wave protection elements is limited in three dimensions. The wave protection 

elements on the slope are provided in a substantially regular imaginary 

grid, with a horizontal grid spacing between the centres of gravity 

of the wave protection elements. The toe elements extend in a longitudinal 

direction of the toe in order to counteract displacement of the 

wave protection elements from the slope to the bed, and are of a shape 

which deviates from the shape of the wave protection elements. The 

centres of gravity of the toe elements, in the longitudinal direction of the 

toe, are provided at substantially the same horizontal grid spacing from 

one another as the wave protection elements. 

(21) 565873 (22) 8 Aug 2006 

(54) A storage racking beam with a horizontal loading capacity independent 

of its vertical loading capacity 

(86) PCT/AU2006/001126 (87) WO2007/016735 

(51) IPC2011.01:E04C3/07; E04G5/00; F16S3/02,06; A47B55/00; A47B47/ 

02; A47B96/14; B65G1/02 

(71) Dematic Pty Ltd 

(72) Clarke, Murray; Berry, Paul; Celati, Stephen; 

(31) 05 904257 (32) 8 Aug 2005 (33) AU 



(57) Disclosed is a storage rack beam (10) which includes top (12) and 

bottom (13) flanges and at least one web (14) that interconnects the 

flanges (12, 13). The web (14) includes at least one stiffening formation 

(16) arranged to stiffen an intermediate region of the web (14) along a 

substantial portion of its length so as to resist lateral impact loading applied 

to the beam (10). The beam (10) may take various forms, including 

first and second U-shaped sections in opposed abutting relationship, or 

formed as a closed S-shaped profile. The application also discloses a 

storage rack beam that has a vertical loading capacity and a horizontal 

loading capacity, where at least part of the horizontal loading capacity is 

independent of the vertical loading capacity applied to the beam. 

(21) 565910 (22) 1 Aug 2006 

(54) Optimizing the detection of tollable vehicles on toll roads 

(86) PCT/EP2006/064901 (87) WO2007/025826 

(51) IPC2011.01:G07B15/00; G08G1/017 

(71) SIEMENS AKTIENGESELLSCHAFT 

(72) Petroczi, Julius; 

(31) 05 041068 (32) 30 Aug 2005 (33) DE 



(57) Disclosed is a method for optimizing the detection of vehicles liable to 

pay tolls on toll roads of a road network. The method includes using a 

vehicle-mounted position determining unit connected to a vehicle external 

management unit. Toll roads are overlaid in an electronic image of 

the road network by detection zones (E), and the position determining 

unit, upon determining vehicle positions (PE) within the detection zones, 

determines toll-related data and sends the data to the management unit. 

Monitoring zones (K) are also provided in the image, and are assigned to 

and extend beyond their assigned detection zone. The position determining 

unit, upon determining journeys exclusively within the monitoring 

zone and outside the detection zone, sends position data (P-K-) of the 

journeys to the management unit. The management unit then performs a 

retrospective check of the position data (PK-) to determine whether the 

detection zone should be adjusted, and adjusts if necessary. 

(21) 565981 (22) 29 Aug 2006 

(54) Octagonal bulk bin constructed from a single blank with self-locking 

webbed bottom flats 

(86) PCT/US2006/033950 (87) WO2007/027836 

(51) IPC2011.01:B65D5/02,06,10,42 

(71) International Paper Company 

(72) Wisecarver, Mark; Quaintance, Benjamin; 

(31) 05 712236 (32) 29 Aug 2005 (33) US 



(57) An octagonal bulk bin (10) erected from a blank is disclosed. The bin 

(10) has sidewalls (11, 12), end walls (13, 14) and diagonal corner panels 

(15, 16, 17, 18) interposed between adjacent sidewalls and end walls. 

Major bottom flaps (22, 23) are joined to a bottom edge of the sidewalls. 

Bottom flaps are joined to the bottom edge of the walls and panels that 

inter connect to form the bottom of the bin (10). Anti-tear cuts are formed 

in the bottom flaps joined to the sidewalls (11, 12) and foldable web panels 

interconnect opposite edges of bottom the flaps joined to the end 

walls (13, 14). 



(21) 566004 (22) 29 Aug 2006 

(54) Indoor unit of air conditioner 

(86) PCT/JP2006/316998 (87) WO2007/026706 

(51) IPC2011.01:F24F13/28; B01D46/10; F24F13/00; F24F1/00; B01D46/ 

00 

(71) Toshiba Carrier Corporation 

(72) Ozawa, Tetsuro; Suzuki, Hideto; Sano, Mitsukuni; Mishima, Takechika; 

Okada, Kaku; Takeya, Nobuyuki; Hida, Yoshiyuki; Shibayama, Yoshiyuki; 

(31) 05 249735 (32) 30 Aug 2005 (33) JP 



(57) An indoor machine of an air conditioner, comprising a front air filter 

(5A) and an upper air filter (5B) installed to face a front suction port (4) 

and an upper suction port (6), a front suction frame (7A) holdingly supporting 

the front air filter (5A) movably in the direction of the upper suction 

port (6), an upper suction frame (7B) holdingly supporting the upper 

air filter (5B) movably in the direction of the front suction port (4), a front 

moving mechanism reciprocatingly moving the front air filter (5A), an 

upper moving mechanism reciprocatingly moving the upper air filter (5B), 

and a cleaning unit (Z) having a rotary brush removing dust from the 

front air filter (5A) and the upper air filter (5B) and a dust collection part 

collecting the dust. The front moving mechanism and the upper moving 

mechanism alternately move the front air filter (5A) and the upper air 

filter (5B) to the cleaning unit (Z) for cleaning. 

(21) 566012 (22) 31 Jul 2006 


(86) PCT/EP2006/064847 (87) WO2007/014934 

(51) IPC2011.01:A61K31/4709; A61P31/04; C07D413/06 



Jerome Emile Georges; Pasquier, Elisabeth Therese Jeanne; 

(31) 05 05107155 (32) 3 Aug 2005 (33) EP 



(57) Disclosed is the use of quinoline derivatives of formula (Ia) or (Ib) for 

the manufacture of a medicament for the treatment of a bacterial infection, 

wherein the substituents are defined within the specification, and 

provided that the bacterial infection is other than a Mycobacterial infection. 

Other quinoline derivatives which comprise a naphthalene group 

are also disclosed. The use of these derivatives in combination with other 

antibacterial agents, for the manufacture of a medicament for the treatment 

of a bacterial infection other than a Mycobacterial infection is also 

disclosed. 

(21) 566065 (22) 17 Jul 2006 

(54) Shin guard with bandage forming opening for calf muscle, and shield 

attached to bandage 

(86) PCT/EP2006/007005 (87) WO2007/014641 

(51) IPC2011.01:A63B71/12; A41D13/00,015; A41D31/00 

(71) SCHEFFER, Harald 

(72) Scheffer, Harald; 

(31) 05 036170 (32) 2 Aug 2005 (33) DE 

(74) McCABE & COMPANY, Level 6, Polo House, 267 Wakefield Street, 

Wellington, New Zealand 

(57) A shin pad in particular for footballers, comprises a rigid shield element 

3 which is to be positioned in front of the user's shin, and attach- 



ments for fastening the shield element on the user's lower leg 1, where 

the fastening attachments have a bandage 2 which at least partially surrounds 

the user's lower leg 1, and the shield element 3 has a detachable 

connection with the bandage 2 over a considerable part of its inner surface, 

which faces the user's shin, such that the forces acting on the 

shield element are distributed over the shield element such that the static 

frictional force between the bandage and the lower leg is not exceeded. 

The bandage 2 has an opening 5 which leaves the user's calf 4 free, so 

that the connection areas 6, 7 remain above and below the opening 5 

and at least partially surround the user's lower leg 1. The connection 

areas 6, 7 are positioned so near to the hollow of the user's knee and 

ankle, and are of such a length, that they do not impede activity of the 

user's calf muscle. 

(21) 566151 (22) 13 Sep 2006 

(54) Dispenser having a reservoir comprising a porous material 

(86) PCT/US2006/035368 (87) WO2007/033107 

(51) IPC2011.01:A01K11/00; A01K13/00; A01K27/00 

(71) Aircom Manufacturing, Inc. 

(72) Trompen, Mick A; Lyon, Gregory A; Meyer, Jeffery A; 

(31) 05 226478 (32) 14 Sep 2005 (33) US 


(57) A dispenser is disclosed. The dispenser comprises a shell having an 

opening; means for attaching the dispenser to an animal; a reservoir 

disposed in the shell comprising a porous material containing a liquid 

substance; and a wick having a first portion in direct contact with the 

porous material and a second portion positioned adjacent the opening. 

The wick is in fluid communication with the reservoir. The wick has a 

greater capillary attraction than the reservoir whereby during use of the 

dispenser the wick draws the liquid substance from the reservoir through 

the first portion of the wick and the second portion of the wick deposits 

the liquid substance on an animal upon contact. Substantially all payout 

of the liquid substance from the reservoir is delivered by wicking action 

of the wick and through the opening. 

(21) 566392 (22) 28 Aug 2006 

(54) Motion capture using primary and secondary markers 

(86) PCT/US2006/033715 (87) WO2007/025301 

(51) IPC2011.01:G06T7/20 

(71) SONY CORPORATION; SONY PICTURES ENTERTAINMENT INC. 

(72) Gordon, Demian; Hauck, Dennis J; 

(31) 05 711923 (32) 26 Aug 2005 (33) US 

(31) 05 711905 (32) 26 Aug 2005 (33) US 

(31) 06 467494 (32) 25 Aug 2006 (33) US 



(57) A system and a method for capturing the motion of a plurality of primary 

markers and at least one secondary marker are disclosed. The 

system comprises an apparatus, a plurality of primary markers coupled 

to a target and at least one secondary marker coupled to the target. 

The apparatus comprises means for capturing a plurality of primary marker 

data points by illuminating the plurality of primary markers; and capturing 

a response of the plurality of primary markers to the illumination. The 

plurality of primary markers includes a plurality of reflective markers, and 

the response includes a reflection of the illumination by the plurality of 

reflective markers. Each primary marker data point of the plurality of 

primary marker data points corresponds to one primary marker of the 

plurality of primary markers. The illumination is subject to periodic gating 

to generate on-states and off-states of the illumination and the reflection 

of the illumination is captured during an on-state of the illumination. 

The apparatus also comprises means for capturing at least one secondary 

marker signature, each secondary marker signature corresponding 

to and uniquely identifying each secondary marker of the at least one 

secondary marker. The at least one secondary marker signature is captured 

by capturing a unique attribute of the at least one secondary marker 

during an off-state of the illumination. 

The apparatus also comprises means for identifying the plurality of primary 

markers using the at least one secondary marker signature. 

The means for capturing a plurality of primary marker data points and the 

means for capturing at least one secondary marker signature comprise 

an image capture module configured to capture a plurality of primary 

marker data points and each primary marker data point corresponds to 

one primary marker of the plurality of primary markers. The image capture 

module also is configured to capture at least one secondary marker 

signature. The means for identifying the plurality of primary markers using 

the at least one secondary marker signature comprises a primary 

marker tracking module configured to identify the plurality of primary 

markers using the at least one secondary marker signature. 

(21) 566435 (22) 23 Oct 2006 

(54) A flexible knitting pin 

(86) PCT/IN2006/000417 (87) WO2007/049300 

(51) IPC2011.01:D04B3/02 

(71) T.A. Devagnanam 

(72) Devagnanam, T.A.; 

(31) 05 CH 1571 (32) 28 Oct 2005 (33) IN 




(57) A flexible knitting pin and a process for manufacturing the flexible 

knitting pin is disclosed. The knitting pin includes two relatively stiff shanks 

having first and second ends, where each shank is pointed at the first 

end and has a ferrule which holds a ball head screw at the second end. 

The second ends of the shanks are connected with each other by a 

flexible hollow connecting material comprising a joint. A brass adapter 

connects each shank with the flexible hollow connecting material for 

smooth transition. 

(21) 566437 (22) 12 Oct 2006 

(54) Cam tube bracket with tab pair engaging cam tube outer surface 

(86) PCT/US2006/040244 (87) WO2007/044928 

(51) IPC2011.01:F16D65/22,16,14 

(71) Hendrickson International Corporation 

(72) Pierce, Phillippi R; White, Jay D; Morris, Jeff; Gregg, Dane; 

(31) 05 725933 (32) 12 Oct 2005 (33) US 



(57) A cam shaft support/enclosure assembly for brake systems of heavyduty 

vehicles is mounted on a beam of an axle/suspension system and 

includes a cam tube (54') . A bracket for mounting the cam tube on the 

beam includes a pair of plates (82,84) that are mounted on the beam. 

Each one of the plates is formed with an opening for receiving the cam 

tube (54') and includes at least three tabs (90) , and preferably four tabs, 

that extend outwardly from each respective plate adjacent the opening 

and contact the outer surface of the cam tube (54') . Each tab includes a 

generally arched and optionally textured face for mating with an outer 

surface of the cam tube, which may also be optionally textured, so that 

when the plates are mounted the tabs engage the cam tube in a presstype 

fit, minimizing movement of the cam tube. 

(21) 566630 (22) 1 Aug 2006 

(54) A water heater where the flue and flue outlet pipe have a length relationship 

to control combustion of the pilot 

(86) PCT/AU2006/001085 (87) WO2007/030855 

(51) IPC2011.01:F24H9/18; F24D17/00; F24H1/24; F23J11/00; F23D14/ 

26 

(71) Dux Manufacturing Limited 

(72) Pussell, Patrick; 

(31) 05 905137 (32) 16 Sep 2005 (33) AU 



(57) A water heater (10) with flue proportions that control the combustion 

of the pilot light. The heater (10) has a tank (12), a burner (26) and a 

heated gas outlet duct (40). The tank (12) has a central flue (14) with an 

outlet (24) at the top (20) of the tank (12). The tank (12) in use is mounted 

with the flue (14) vertically. The burner (26) is located beneath the tank 

(12) and has an air inlet (32) and a pilot flame and is adapted to a burn a 

fuel to discharge heated gases up through the flue (14). The heated gas 

outlet duct (40) is of substantially unrestricted cross-section and has an 

upper, first end (42) in gas communication with the flue outlet (24) and a 

second, lower end (46) in gas communication with atmosphere. When 

only the pilot flame is burning, the heated gas outlet duct (40) is adapted 

to restrict the air drawn into the flue (14) via the air inlet (32) to the minimum 

amount required to maintain the pilot flame alight. This is achieved 

by the duct (40) having approximately the same cross sectional area of 

the flue (14) and having approximately 25% of the length of the flue (14) 

i.e. L2 = L1 x ~0.25. 

(21) 566756 (22) 22 Sep 2006 

(54) Safety needle assembly with spring axis spaced from needle assembly 

axis 

(86) PCT/US2006/037288 (87) WO2007/035924 

(51) IPC2011.01:A61M5/00; A61M25/06 

(71) TYCO HEALTHCARE GROUP LP 

(72) Jones, Scott; Clark, George; 

(31) 05 719762 (32) 22 Sep 2005 (33) US 



(57) A needle safety device is provided having a housing, a needle assembly 

movably mounted within the housing and a spring for biasing the 

needle assembly within the housing. The needle assembly is movable 

along a first axis and the spring is movable along the second axis different 

from the first. There is also provided a lens for enhancing visualization 

of the flow of fluid through the needle safety device. There is further 

provided a safety sheath for covering a needle of the needle assembly 

and restraining the needle assembly against movement due to the bias 

of the spring. 



(21) 566780 (22) 29 Jun 2006 

(54) Thermal energy system with solar collection and controller to predict 

operation and change flow rate 

(86) PCT/GB2006/002408 (87) WO2007/028938 

(51) IPC2011.01:F24D11/02; F24D19/10; F24J2/04,24 

(71) Endoenergy Systems Ltd 

(72) Virk, Gurvinder Singh; 

(31) 05 0518218 (32) 7 Sep 2005 (33) GB 



(57) Disclosed is a thermal energy system (3) for heating and/or cooling 

applications. The system has: solar collection means (10) for transferring 

heat energy to and/or from a heat transfer fluid; thermal upgrading 

means (44) for increasing the thermal energy within the system; and 

thermal storage means (48, 50). The collection means, upgrading means 

and storage means are connected so as to allow the transfer of heat 

there between via the heat transfer fluid. Control means are arranged to 

receive readings of operational variables from the thermal energy system 

and to process the operational variables using a system model so 

as to predict future operational variables for the system. The control means 

controls the flow of the heat transfer fluid around the system based on 

the predicted operational variables. The flow is controlled by controlling 

of operation of one or more pumps (36, 62, 70, 78, 80) or fans and one or 

more valves (40, 42, 54, 86), the valves being disposed between the 

solar collection means and the thermal storage means. 

(21) 566816 (22) 6 Oct 2006 

(54) Dispensing of restricted goods from an authorised vendor to an approved 

purchaser 

(86) PCT/AU2006/001458 (87) WO2007/041767 

(51) IPC2011.01:G07F7/08; G06Q50/00; G06Q90/00 

(71) Bluepoint International Pty Ltd 

(72) Allinson, John Clive; Boyd, Garry David; 

(31) 05 905515 (32) 7 Oct 2005 (33) AU 

(74) I P Strategies, 24 Christowel Street, Camberwell, Victoria 3124, Australia 

(57) A dispenser and a method of dispensing restricted goods by an authorized 

vendor to an approved purchaser is disclosed. The dispenser 

comprises: a cabinet containing an inventory storage system, a purchaser 

transaction module, a reject system and a control system where the inventory 

storage system includes product storage in rows and columns. 

The purchaser transaction module includes an audio communication link 

from the dispenser to the authorized vendor. A payment transaction system 

in the dispenser verifies payment for the product and a collection 

tray in the dispenser is locked until the vendor releases the product to 

the purchaser. The reject system securely removes product to a reject 

hopper at any time after the product is held by the product selection 

device but prior to the vendor releasing the product from the collection 

tray. The control system includes an identification device and a product 

selection device where the identification device enables the vendor to 

verify the purchaser's status as an approved purchaser. The product 

selection device enables verification that the product selected is correct 

and holds and carries the product from its storage location to one or 

more of a printing location, viewing location, and issue tray all located 

within the dispenser. A reject key enables the vendor to actuate the reject 

system and a release key unlocks the collection tray. 

(21) 566881 (22) 21 Sep 2006 

(54) Cover for a vent 

(86) PCT/AU2006/001386 (87) WO2007/033423 

(51) IPC2011.01:F24F13/28,06,068 

(71) Mariella Elizabeth Niveagh Rosso 

(72) Rosso, Mariella Elizabeth Niveagh; 

(31) 2005905215 (32) 21 Sep 2005 (33) AU 



(57) Disclosed is a cover for a vent of a ducted air system. The cover 

includes a filter for inhibiting traffic of particulate matter through said vent 

and a fastener for securing the cover around a portion of the vent shaped 

for insertion into a corresponding outlet of the ducted air system. The 

filter has a hollow receptacle that extends beyond the portion of the vent 

shaped for insertion into the outlet. The receptacle is shaped to accommodate 

a vent closure which is operable to move between open and 

closed conditions. When in an open condition the vent closure extends 

beyond the portion of the vent shaped for insertion into the corresponding 

outlet of the ducted air system. 

(21) 567102 (22) 2 Oct 2006 

(54) Optical device for led light sources 

(86) PCT/CH2006/000535 (87) WO2007/036064 

(51) IPC2011.01:G02B6/00,42 

(71) Radical Form Lighting Ltd. 

(72) Zweig, Frederic; Buhrer, Thomas; 

(31) 05 1581 (32) 30 Sep 2005 (33) CH 


(57) Disclosed is an optical device for the targeted reproduction of light 

emitted by LED light sources (6). The optical device comprises at least 

two component parts, a first optical component part (10) in the form of a 

solid waveguide and another component part for connection to the LED 

light source. In a system of Cartesian co-ordinates, the first optical component 

part (10) has a length in the y direction shorter than or equal to its 

length in the z direction and shorter than or equal to its length in the x 

direction. The first part comprises: first and second planar outer surfaces 

opposing in the x-z plane; third and fourth planar or nonplanar outer surfaces 

substantially opposing on the x-y plane; and fifth and sixth opposing 

outer surfaces curved in a convex manner with regard to the y-z 



plane. The third and fourth outer surfaces are square, and the fifth and 

sixth outer surfaces are curved such that the fourth outer surface has a 

length in the x·direction that is smaller than the length of the third outer 

surface. 

(21) 567195 (22) 12 Oct 2006 

(54) Method of operating a plurality of clean rooms 

(86) PCT/US2006/040068 (87) WO2007/050320 

(51) IPC2011.01:F24F3/16; F24F11/00 

(71) Charles W Spengler 

(72) Spengler, Charles W; 

(31) 05 258057 (32) 26 Oct 2005 (33) US 

(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zealand 

(57) A method of operating a plurality of clean rooms in a compound within 

a common area of an enclosed building is disclosed. Each clean room 

consists of a portable enclosure including a generally rectangular open 

frame covered on its top wall and sidewalls by a flexible, substantially air 

impermeable sheet material. Air supply blower means outside of and 

connected to the clean room provides filtered air into the room. An entrance 

means through a sidewall provides access to the clean room. The 

method comprises: (a) arranging the clean rooms in the compound consisting 

of two parallel spaced rows of clean rooms with an access corridor 

there between and with the entrances to the clean rooms of each row 

opening into the access corridor; (b) providing a plurality of blowers 

operably connected to each clean room for supplying clean filtered air 

into the respective clean rooms, and permitting air to escape from the 

clean room beneath the sidewalls thereof; (c) continuously operating the 

blowers to produce a clean air bubble consisting of a volume of air containing 

at least about 75% recirculated filtered air which has escaped 

from the clean rooms, and (d) arranging the clean rooms and the blowers 

in a pattern wherein the clean air bubble created by each blower 

overlaps the clean air bubble produced by at least two other blowers, 

whereby the entire compound of clean rooms is contained within the 

overlapping bubbles produced by the blowers. 

(21) 567232 (22) 10 Aug 2006 

(54) Body massager with a light source mounted on a massage formation 

(86) PCT/US2006/031051 (87) WO2007/032835 

(51) IPC2011.01:A61H7/00 

(71) FKA DISTRIBUTING CO. D/B/A HOMEDICS, INC. 

(72) Ferber, Roman; Wei, Huang Wen; 

(31) 05 223685 (32) 9 Sep 2005 (33) US 

(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zealand 

(57) Disclosed is a massage apparatus with illumination effects. The apparatus 

includes a housing (46); a massage formation (136’) provided 

on the housing for contacting a body part of a user; a massage mechanism 

oriented within the housing for imparting a massage effect to the 

massage formation for massaging the body part; and a light source (146) 

provided on the massage formation for conveying an illumination effect 

from the massage formation. The apparatus further includes: a carriage 

(52) oriented in the housing for limited translation in the housing, the 

massage formation provided on the carriage; a motor supported upon 

the carriage; and a shaft (110) mounted on the carriage and operably 

driven by the motor for rotation about an axis. The shaft has a pair of 

secondary shaft portions each canted relative to the shaft axis. The ap- 

paratus also has: a pair of massage brackets (124) each joumalled to 

one of the secondary shaft portions and engaging the carriage for limited 

rotation about the shaft axis such that rotation of the shaft oscillates the 

massage brackets relative to the carriage; a pair of massage arms (136’) 

each pivotally connected to one of the massage brackets; and a pair of 

massage rollers (138’, 140’) each pivotally connected to one of the massage 

arms. The massage rollers impart a rolling massage effect upon a 

desired body part of the user as the carriage is translated relative to the 

housing and for imparts a kneading massage effect upon the portion of 

the user's body as the massage brackets oscillate relative to the carriage. 

(21) 567257 (22) 20 Oct 2006 

(54) Method of cracking a crude product to produce additional crude products 

(86) PCT/US2006/040991 (87) WO2007/050450 

(51) IPC2011.01:C10G1/00,02; C10G11/00 

(71) SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. 

(72) Mo, Weijian; Nair, Vijay; Roes, Augustinus Wilhelmus Maria; 

(31) 05 729763 (32) 24 Oct 2005 (33) US 

(31) 06 794298 (32) 21 Apr 2006 (33) US 



(57) Disclosed is a method for producing a crude product, comprising: 

producing formation fluid from a subsurface in situ pyrolysis heat treatment 

process; separating the formation fluid to produce a liquid stream 

and a first gas stream, wherein the first gas stream comprises olefins; 

fractionating the liquid stream to produce one or more crude products, 

wherein at least one of the crude products has a boiling range distribution 

from 38 degrees Celsius and 343 degrees Celsius as determined by 

ASTM Method D5307; and catalytically cracking the crude product having 

the boiling range distribution from 38 degrees Celsius and 343 degrees 

Celsius by a fluidizable cracking catalyst comprising a molecular 

sieve having cracking activity dispersed in a porous, inorganic refractory 

oxide matrix or binder to produce one or more additional crude products 

comprising gasoline hydrocarbons having an octane number of at least 

70, wherein at least one of the additional crude products is a second gas 

stream, and the second gas stream has a boiling point of at most 38 

degrees Celsius at 0.101 Mpa and comprises hydrocarbons having a 

carbon number of at least 3. Also disclosed the product obtained by said 

method. 

(21) 567376 (22) 27 Oct 2006 

(54) Single or multiple stage blower and nested volute(s) and/or impeller(s) 

therefor 

(86) PCT/AU2006/001617 (87) WO2007/048206 

(51) IPC2011.01:A61M16/00; A61M1/00; F04B17/00; F04D29/60,66 

(71) ResMed Limited 

(72) Kenyon, Barton John; Reed, Nicholas Jerome; Wilson, Andrew; Smith, 

Ian Malcolm; 

(31) 05 730875 (32) 28 Oct 2005 (33) US 

(31) 06 775333 (32) 22 Feb 2006 (33) US 

(31) 06 841202 (32) 31 Aug 2006 (33) US 





(57) A single ended or double-ended blower comprising a blower motor 

assembly supporting opposed first (258) and second (260) shaft ends, 

the first (258) and second (260) shaft ends having respective first (244) 

and second (248) impellers attached thereto and enclosed within first 

(247) and second (251) volutes, respectively, wherein the first volute 

(247) is connected to an inlet (264) and the second volute (251) is connected 

to an outlet (276); and the blower motor assembly supported in a 

chassis enclosure; a radially outer inter-stage path between the first (247) 

and second (251) volute, wherein the second (251) volute is at least 

partially substantially concentrically nested with the radially outer interstage 

gas path. 


(21) 567401 (22) 11 Oct 2006 

(54) Ear tag for the identification of an animal, comprising a deformable 

element for accomodating a pin 

(86) PCT/EP2006/067264 (87) WO2007/042528 

(51) IPC2011.01:A01K11/00; G09F3/00 

(71) Allflex Europe SAS 

(72) Costantini, Anne; Hilpert, Jean-Jacques; 

(31) 0510448 (32) 13 Oct 2005 (33) FR 

(74) ELLIS TERRY, Level 12, 45 Johnston Street, Wellington 6011, New 

Zealand 

(57) An ear tag for the identification and tagging of animals is disclosed. 

The ear tag combines a receiving button and a pin by irreversible interlocking 

of the receiving button and pin. The button comprises a head 

inside of which is located a cavity for axial accommodation of a punch of 

the pin. The head is secured to a shell for holding the punch where the 

shell is equipped with an opening for inserting the punch inside the button 

toward the cavity. A holding shoulder holds the punch against the 

withdrawal of the punch from the button by stopping a shoulder that the 

punch comprises against the holding shoulder. An axial wall of the holding 

shell that delimits the opening is formed of an elastic material and is 

radially deformable to allow passage of the punch through the opening. 

At least one chamber is located between the head and the axial wall for 

the accommodation of the axial wall that is deformed under the action of 

the passage of the punch through the opening. 

(21) 567507 (22) 17 Oct 2006 

(54) Food holding cabinet with removable tray covers 

(86) PCT/US2006/040411 (87) WO2007/047597 

(51) IPC2011.01:A47J36/34; F24C15/16 

(71) MERCO/SAVORY LLC 

(72) Jones, Douglas S; 

(31) 05 727343 (32) 17 Oct 2005 (33) US 


(57) A food holding cabinet having a housing defining a heating chamber 

for holding a covered food tray in a tray location has a pair of elongated 

rigid rods mounted to the housing for suspending a food tray cover thereon 

in a position above the tray location. A front rod extends across the opening 

to the heating chamber and supports the front end of the tray cover 

and a rear rod supports the rear of the cover. When a food tray is inserted 

into the tray location, it lifts and supports the cover. When the tray 

is removed, the front rod prevents removal of the cover along with the 

underlying tray. The front rod is spring-loaded to be pulled away from the 

housing to facilitate removal of the cover. A tray cover is also provided. 


(21) 567538 (22) 19 Oct 2006 

(54) A slip type pipe joint 

(86) PCT/AU2006/001547 (87) WO2007/045033 

(51) IPC2011.01:F16L25/12; F16L27/12; F16L47/10 

(71) JTL Australia Pty Ltd 

(72) Phillipps, Guy Malcolm; 

(31) 05 905769 (32) 19 Oct 2005 (33) AU 



(57) A slip type pipe fitting for joining two spaced apart plastic pipe ends is 

disclosed. The fitting includes: a first insert (12) having an elongate pipe 

support portion (14), insertable into an internal bore of a first plastic pipe 

end (11), and a distal end (16) in use projecting outside the first pipe end 

(11) and having a first annular seal (17); an elongate hollow pipe connector 

(30) defining a bore (32) and having first and second connector ends, 

the inner bore (32) receiving the distal end (16) and first annular seal (17) 

of the first insert (12) for sliding movement and sealing therein; and a 

first compression joining assembly including a first end nut (42) for mechanically 

joining the first connector end (40) to the first pipe end (11) by 

a compression action sandwiching the first pipe end (11) between the 

first end annular member (42) and the pipe support portion (14) thereby 

locking the connector (30) with respect to the first pipe end (11). In use 

the support portion (14) extends into the first pipe end (11) an axial distance 

AL such that said locking can occur over a range of axial positions. 

(21) 567570 (22) 12 Oct 2006 

(54) Biphenyl derivatives as modulators of voltage gated ion channels 

(86) PCT/US2006/040156 (87) WO2007/047474 

(51) IPC2011.01:C07D275/02; A61K31/425; C07D417/10 

(71) Vertex Pharmaceuticals Incorporated 



(72) Martinborough, Esther; Lehsten, Danielle; Neubert, Timothy; Kawatkar, 

Aarti Sameer; Zimmermann, Nicole; Termin, Andreas; 

(31) 05 725686 (32) 12 Oct 2005 (33) US 


Australia 

(57) Disclosed is a biphenyl sulfamoyl compound of formula I: or a 

pharmaceutically acceptable salt thereof wherein: ring Z is a 5 membered 

ring having at least one ring heteroatom selected from O, S, N, and NH, 

z is 0 to 4; Q is a bond or is a alkylidine chain, or a spirocycloalkylene 

moeity; RQ is a aliphatic group, a monocyclic ring or a bicyclic ring system, 

RN and RM and Y are defined in the specification. Also disclosed is 

a composition comprising said compound, a method of inhibiting one or 

more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, 

NaV1.8, NaV1.9, or CaV2.2 activity in a biological sample comprising 

contacting said biological sample with said compound and the use of 

said compound in the manufacture of a medicament to treat a disease, 

disorder, or condition selected from acute, chronic, neuropathic, or inflammatory 

pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, 

herpetic neuralgia, general neuralgias, epilepsy or epileptic conditions, 

neurodegenerative disorders, psychiatric disorders such as anxiety 

and depression, myotonia, arrhythmia, movement disorders, neuroendocrine 

disorders, ataxia, multiple sclerosis, irritable bowel syndrome, 

incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, 

diabetic neuropathy, radicular pain, sciatica, back pain, head or neck 

pain, severe or intractable pain, nociceptive pain, breakthrough pain, 

postsurgical pain, stroke, bipolar disorders, and cancer pain. 

(21) 567733 (22) 26 Oct 2005 

(54) Upright shaft post capable of accommodating various containers 

(86) PCT/US2005/039397 (87) WO2007/067161 

(51) IPC2011.01:A47F3/14; A47G29/02; B25H3/02; A44B11/08,26; 

A47B49/00; A47F5/05 

(71) Steelworks Hardware, LLC 

(72) Nguy, Chanwa; Lin, Pei Ying; 



(57) A tool storage device is disclosed. The tool storage device comprises 

a hollow upright pivot shaft having two ends, a top end and a bottom end 

where the pivot shaft is end capped on the top and bottom ends, and a 

tool storage means coupled to the hollow upright pivot shaft. Each end 

cap has a coupling wall and a plughole formed in the coupling wall. A 

plurality of detachable connecting structures are provided, each having 

a plug rod attachable to each end cap through the plughole. A plurality of 

fastening structures comprise a base having a plurality of apertures for 

fastening to an upright support structure. Each fastening structure comprising 

a coupling unit detachably connectable to the connecting structure 

at the top and bottom ends of the capped hollow upright pivot shaft. 

(21) 568025 (22) 25 Apr 2006 

(54) Process for the preparation of fipronil, an insecticide, and related 

pyrazoles 

(86) PCT/IB2006/000999 (87) WO2007/122440 

(51) IPC2011.01:C07D231/44 

(71) Gharda Chemicals Limited 

(72) Gharda, Keki Hormusji; Malte, Ashokkumar Maganlai; Joseph, 

Pulinattu Cherian; Parkar, Sureshkumar Dattatraya; Sathe, Shekhar 

Vishwanath; Damania, Pragnesh Dalpatram; 



(57) Disclosed is a process for the preparation of 5-amino-1-phenyl-3cyano-4-trifluoromethyl 

sulphinyl pyrazoles as defined by Formula-I, 

wherein: R1 = trifluoromethyl or trifluoromethoxy, and R2 and R3 are 

individually hydrogen, chlorine or bromine, the process comprising the 

step of oxidizing a compound of Formula-II wherein: R1 = trifluoromethyl 

or trifluoromethoxy, R2 and R3 = individually hydrogen, chlorine or bromine, 

in a medium comprising at least one oxidizing agent and trichloro 

acetic acid, and/or the reactions product (s) of the at least one oxidizing 

agent and trichloro acetic acid, and at least one melting point depressant 

selected from monochloro acetic acid, dichloro acetic acid, methylene 

dichloride, ethylene dichloride, monochlorobenzene and a haloalkane. 

Also disclosed are 5-amino-1-phenyl-3-cyano-4-trifluoromethyl sulphinyl 

pyrazoles as defined by Formula-I obtained by said process. 

(21) 568165 (22) 8 Nov 2006 

(54) Carton with reinforced handle using a side end reinforcement flap 

(86) PCT/US2006/043340 (87) WO2007/056365 

(51) IPC2011.01:B65D5/46; B65D71/00 

(71) Graphic Packaging International, Inc. 

(72) Brand, Kirsten Laura; 

(31) 05 734504 (32) 8 Nov 2005 (33) US 



(57) Disclosed is a carton with a reinforced handle for containing a plurality 

of articles. The carton comprises: a plurality of panels (30, 40) that 

extend at least partially around an interior of the carton; at least two end 

flaps (12, 22, 32) respectively foldably attached to respective panels of 

the plurality of panels; and a handle (11) in the closed end of the carton 

having a handle opening (139) for grasping and carrying the carton. The 

plurality of panels comprises a top panel (30), a bottom panel, a first side 

panel, and a second side panel (40). The end flaps are overlapped with 

respect to one another and thereby at least partially form a closed end of 

the carton. The at least two end flaps comprising at least one side end 

flap (22, 42) foldably attached to one of the first side panel and the second 

side panel, and a top end flap (32, 56) foldably attached to the top 



panel. The at least one side end flap comprises a main panel (70, 72) for 

at least partially closing the closed end of the carton and a reinforcement 

panel (80, 82) foldably attached to the main panel and upwardly folded 

relative to the main panel to at least partially overlap the main panel, the 

reinforcement panel cooperating with the main panel to form the handle. 

(21) 568407 (22) 17 Nov 2006 

(54) Tightening means for anti-skid and traction enhancement devices 

(86) PCT/EP2006/068631 (87) WO2007/057450 

(51) IPC2011.01:B60C27/10 

(71) Emrah Bozkurt; Ender Bozkurt; Murat Yerlikaya 

(72) Bozkurt, Emrah; Bozkurt, Ender; Yerlikaya, Murat; 

(31) 05110988.2 (32) 18 Nov 2005 (33) EP 

(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New 

Zealand 

(57) A tightening system for use with anti-skid and traction enhancement 

devices for wheeled vehicles is disclosed. The system comprises sealed 

tightening mechanism which can clutch and ratchet the rotational movement 

applied by the user on a knob. The tightening system further comprises 

at least one connection assembly which is adapted to be pivotably 

and releasably attached to a proximal end of a surface contact member 

and which is adapted to be connected to the tightening mechanism. The 

tightening mechanism comprises a locking component which has a base 

plate, an inner sidewall and an outer sidewall standing perpendicular to 

said base plate. The inner sidewall recessed portion has a plurality of 

recesses which are adapted to engage with a peripheral projection of the 

upper clutch for holding the knob in place during locked and unlocked 

positions of the knob. The outer sidewall enters fully or partly, respectively 

in locked and unlocked positions of the knob, into a corresponding 

slot of said knob for sealing inner volume of the tightening mechanism 

from outside conditions. 

(21) 568430 (22) 21 Nov 2006 

(54) 4-oxadiazolyl-piperidine compounds and use thereof 

(86) PCT/EP2006/011150 (87) WO2007/057229 

(51) IPC2011.01:C07D413/04; A61K31/454; A61P25/00; C07D413/14 

(71) Purdue Pharma L.P. 

(72) Tafesse, Laykea; 

(31) 05 739107 (32) 21 Nov 2005 (33) US 



(57) Disclosed are 4-oxadiazolyl-piperidine compounds as depicted or a 

pharmaceutically acceptable salt thereof, wherein the substituents are 

as defined in the specification. Also disclosed are compositions comprising 

the 4-oxadiazolyl-piperidine compounds and their use in treating pain 

or diarrhea. 

(21) 568435 (22) 5 Dec 2006 

(54) Method and apparatus for processing of materials with bearings supporting 

rotating drum being sealed from heat and pressure added in interstitial 

space 

(86) PCT/US2006/061604 (87) WO2007/117313 

(51) IPC2011.01:A61L11/00; B03B3/00 

(71) Gordon Craig Boots; Robert D Bartlett; Ryan J Bright; Mark C Woodin 

(72) Boots, Gordon C; Bartlett, Robert D; Bright, Ryan J; Woodin, Mark C; 

(31) 05 742824 (32) 5 Dec 2005 (33) US 



(57) A treatment vessel has a drum 200 to which pressure and heat can be 

applied and rotationally supported within a shell via roller 400. The drum 

is supported by bearings 440, 490 which are sealed from pressure and 

heat added to the interstitial space between the drum and the shell. 

(21) 568512 (22) 16 Aug 2006 

(54) Non-peroxide preparation for whitening natural and manufactured teeth 

(86) PCT/US2006/031953 (87) WO2007/061468 

(51) IPC2011.01:A61Q11/00; A61K8/64,66 

(71) TOM’S OF MAINE 

(72) Bergeron, Chantal; 

(31) 05 281009 (32) 17 Nov 2005 (33) US 



(57) Disclosed is a peroxide-free method for whitening natural or manufactured 

teeth, the method comprising: 

(a) providing an actinidin-containing preparation; 

(b) formulating the actinidin-containing preparation of step (a) for application 

to natural or manufactured teeth; and 

(c) contacting the formulation of step (b) with natural or manufactured 

teeth in an amount and for a period of time sufficient to effect whitening 

of the natural or manufactured teeth; 

wherein the actinidin-containing preparation is formulated in: a whitening 

strip, a dentifrice, a mouthrinse, a mouthwash, chewing gum, a preparation 

for soaking manufactured teeth or a whitening tray.

Patent Abridgement 1 [3.1 MB PDF] - Intellectual Property Office of ...

Create successful ePaper yourself

Delete template?

Save as template?